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7New psychoactive substances (NPAS) and ‘legal highs’ 
have become a global phenomenon which is developing 
at an unprecedented pace. In 2011, 49 new psychoactive 
substances were officially notified for the first time in the 
European Union. This represents the largest number of 
substances ever reported in a single year, considerably up 
from 2010 (41 substances) and 2009 (24 substances). 
The speed at which new drugs appear on the market — 
which is reflected not only in the sheer number of substances, 
but also in their diversity and in how they are produced, 
distributed and marketed — challenges the established 
procedures for monitoring and calls for a re-evaluation of the 
information sources used and the ways in which we 
disseminate information to inform policy, practice and the 
general public. 
The EU mechanism to monitor new drugs — the early 
warning system (EWS) — as established by Council 
Decision 2005/387/JHA on the information exchange, risk 
assessment and control of new psychoactive substances (1) 
has been one of the innovative, successful and highly visible 
activities carried out by the EMCDDA during the last years. 
It allows the European Union institutions and Member States 
to rapidly exchange information and to act on new narcotic 
and psychotropic substances that appear on the European 
Union drug scene. It also provides the possibility of a risk 
assessment to be conducted and, if merited, the control of 
specific new psychoactive substances.
The European EWS on new psychoactive substances is a 
multidisciplinary network of 30 national early warning 
mechanisms (2) which collect, appraise and rapidly 
disseminate information on new drugs and products that 
contain them. It is implemented primarily by the EMCDDA 
and its partners in the Member States (the Reitox network), 
in cooperation with Europol, and with the active contribution 
of the European Medicines Agency (EMA) and the European 
Commission. The EWS builds on a variety of information 
sources such as health and care providers, law 
enforcement organisations, sources closer to drug users, 
media, the Internet, etc.
The considerable added value of the EWS is that it not only 
fulfils the requirements of Council Decision 2005/387/JHA, 
but is also an important part of the overall EU drug 
information system. The EWS has been successful in 
fulfilling its role as a low-cost mechanism to share information 
on new threats, and as a catalyst for action, when this has 
been merited. In the last years, the EWS has established itself 
as a real-time vehicle for the exchange of multidisciplinary 
information which is now extensively used by forensic 
science community, health and law enforcement professionals 
throughout Europe. Furthermore, the EWS is highly 
recognised among professionals outside the EU who are 
increasingly relying on it as an alert system on new 
psychoactive substances and to remain up to date.
 
Responding to the need to remain vigilant and react rapidly 
to new substances and products identified, the EWS has 
increased its operational capacity and expanded to include 
not only new forensic science and toxicological laboratories, 
but also a range of health and law enforcement professionals 
as well as independent researchers. Investment to allow 
better detection of new drugs by improving the capacity 
for investigative forensic and toxicology analysis and to 
increase the capacity to identify and monitor patterns and 
trends in their use linked to the EWS are therefore essential.
Council Decision 2005/387/JHA provides legally binding 
definitions of the substances it covers; however, there are 
other terms in common usage in this area and confusion 
is possible. For example, historically, new psychoactive 
substances have been often referred to as ‘designer drugs’, 
although today the term ‘legal highs’ is more often used. 
Much overlap exists between these terms but for the purpose 
of the EWS, it is worth delineating the concepts.
Council Decision 2005/387/JHA takes the United Nations 
drug control conventions as a point of reference and defines 
a new psychoactive substance as ‘a new narcotic drug or a 
new psychotropic drug in pure form or in a preparation, that 
has not been scheduled under the 1961 United Nations 
Single Convention on Narcotic Drugs (3), and that may pose 
(1) Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, risk assessment and control of new psychoactive substances  
    (Official Journal L 127, 20.5.2005).
(2) The 27 EU Member States, candidate countries to the EU — Croatia and Turkey — and Norway.
(3) Single Convention on Narcotic Drugs, 1961, as amended by the 1972 Protocol amending the Single Convention on Narcotic Drugs, 1961, United Nations.
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(4) Convention on Psychotropic Substances, 1971, United Nations.
(5) The term ‘legal highs’ is used in inverted commas because describing these substances/products as ‘legal’ can be incorrect or misleading to customers as many 
of them can be covered by e.g. medicines or food safety laws. In addition, ‘legal highs’ products may contain substances controlled under drugs legislation.
(6) European Commission (2011), Communication from the Commission to the European Parliament and the Council ‘Towards a stronger European response to 
drugs’, Brussels, 25.10.11, COM(2011) 689/2.
 
a threat to public health comparable to the substances listed 
in Schedule I, II or IV’ (new narcotic drug) or ‘under the 1971 
United Nations Convention on Psychotropic Substances (4), 
and that may pose a threat to public health comparable to 
the substances listed in Schedule I, II, III or IV’ (new 
psychotropic drug).
It is not new to design a drug using the structure of a parent 
compound with known properties. The term ‘designer drugs’, 
however, emerged in the 1980s and became particularly 
popular with the emergence of the ‘ecstasy’ compounds 
(MDMA, MDA, MDE, etc.) on the illicit drug market. 
Designer drugs were typically manufactured from chemical 
precursors in a clandestine laboratory. They can be best 
defined as unregulated (new) psychoactive substances, 
intentionally designed to mimic the effects of controlled drugs 
by slightly altering their chemical structure in order to 
circumvent existing controls.
‘Legal highs’ (5) on the other hand is an umbrella term for 
unregulated (new) psychoactive substances or products 
claiming to contain them, which are specifically intended to 
mimic the effects controlled drugs. It encompasses a wide 
range of synthetic and/or plant-derived substances and 
products, which may be presented as ‘legal highs’ 
(emphasising ‘legality’), ‘research chemicals’ (implying 
legitimate research use), ‘party pills’ (alternative to ‘party 
drugs’), ‘herbal highs’ (stressing the plant origin), etc., which 
are usually sold via the Internet or in smart/head shops and 
in some cases intentionally mislabelled with purported 
ingredients differing from the actual composition. ‘Legal 
highs’ are usually manufactured in chemical laboratories 
outside of Europe and legally imported, either as chemicals 
or as already packaged products. The ‘legal highs’ market 
is distinguished by the speed at which suppliers circumvent 
drug controls by offering new alternatives to restricted 
products and advertising them with aggressive and 
sophisticated marketing strategies (room odorisers, herbal 
incenses, bath salts, plant fertilisers, collectors’ items, etc.).
The term ‘new’ is not intended to refer exclusively to newly 
invented/synthesised substances, but rather should be 
understood as ‘newly available’ or ‘newly misused’ 
substances.
This publication
This publication consists of 30 short chapters describing the 
different national EWS (N-EWS) in operation in 2011. 
It reflects not only on the current state but also on future plans 
for development. The objective is to present a compendium 
of the N-EWS in their diversity, while using a common format 
to provide a coherent structure and clarity. By doing so, the 
publication aims to promote best practices and to enhance 
the exchange of experiences between different N-EWS.
The European Commission (EC) is currently preparing a 
proposal for the revision of Council Decision 2005/387/
JHA. It is expected that the Commission will propose stronger 
EU legislation on new psychoactive substances, taking into 
account the rapid developments in this field and scientific 
evidence concerning the risks posed by these substances (6). 
Therefore, the existing EWS networks and their reporting and 
monitoring tools and instruments may need to be adapted 
and subsequently implemented and operationalised.
Acknowledgements
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Introduction
The European early warning system (EWS) was implemented 
in Austria in 1997 and started with a simple mailing list, 
operated by the Austrian Reitox focal point. In 2002,  
‘Strychnine’ was identified by the Forensic department of 
the Medical University of Vienna in some samples of heroin, 
which had been seized by the police in Vienna. Information 
surrounding this was spread by the media. This incident led 
to a meeting organised by the drug coordination of Vienna, 
where the reasons and possible health consequences of such 
impurities in heroin were discussed. It was also agreed that 
existing information systems should be improved, to gain new 
insights concerning impurities or other unexpected issues in 
context with drugs and to distribute this information via an 
official network instead of receiving information from the 
media. Subsequently, the Ministry of Health started a 
consultation process on the development of a specific 
Austrian EWS with an extended scope on the basis of the 
European EWS. This process was carried out in close 
cooperation with the Federal Drug Forum and the regional 
coordinators responsible for drug addiction. It was decided 
that the focus of this new Austrian system should be on new 
psychoactive substances but also on relevant health-related 
issues, such as unexpected high doses of psychoactive 
substances, unexpected impurities with dangerous substances 
or new risky consumption patterns. The new concept was 
adopted by the Federal Drug Forum in 2006 and Gesundheit 
Österreich GmbH/Geschäftsbereich ÖBIG (GÖG/ÖBIG) 
was commissioned by the Ministry of Health to implement 
this system. This new Austrian EWS started officially in June 
2008.
Organisational issues
There is no legal basis or formal founding regulation for the 
Austrian EWS. It is based on a decision of the Federal Drug 
Forum, where the concept of the Austrian EWS was adopted, 
and the GÖG/ÖBIG is commissioned on a yearly basis to 
implement this system. This situation is going to change with 
a new law on new psychoactive substances, which should 
become effective in February 2012 and establish the legal 
basis for the Austrian EWS.
The objectives of the Austrian EWS are:
•	 to disseminate information received from the EMCDDA 
(the European EWS) to national partners and —  
if possible — to collect and provide feedback to the 
EMCDDA;
•	 to establish an official network for information about 
new psychoactive substances and unexpected issues in 
the context with drugs in Austria;
•	 to use existing structures and therefore the Reitox focal 
point, where the European EWS is located in Austria;
•	 to include all relevant institutions and experts;
•	 to provide information on health risks for prevention and 
treatment;
•	 to establish an early warning system in Austria;
•	 to establish an Advisory board with experts from  
different areas, who provide advice in critical situations 
but also on strategic issues.
The coordination and implementation of the Austrian EWS is 
done by GÖG/ÖBIG, where the Austrian Reitox focal point 
is also located. The persons responsible for the Austrian EWS 
are the Head of the Austrian focal point (an ecologist), 
a psychologist and a medical doctor.
A link to European institutions is given by the fact that the 
involved persons are also part of the team of the Reitox focal 
point, which enables a close cooperation with the EMCDDA 
and the European EWS. There is no direct link to Europol 
or other European information networks such as the one on 
infectious diseases, but through the Advisory board, there are 
persons from the Ministry of Health and the Ministry of 
Interior involved, who can act as communicator to these 
systems.
The communication runs mainly by e-mail and is defined 
clearly in the concept of the system. A meeting of the 
Advisory board is organised in June each year. In addition, 
there are meetings organised on demand (after consultation 
with the Ministry of Health), either to discuss specific urgent 
issues and to carry out a risk assessment (e.g. for ‘Spice’ 
in 2009) or to discuss strategic issues (e.g. how to handle 
‘research chemicals’ in the future in 2010). Finally, in the 
Austria — early warning system
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beginning of 2010, a web-based discussion forum was set 
up to stimulate the information exchange between emergency 
departments of hospitals.
The Austrian early warning system covers the whole country 
and is carried out in German language only. Due to limited 
resources, it was decided to provide a passive system which 
is not available around the clock. For severe emergency 
cases, however, there is cooperation with the 
Vergiftungsinformationszentrale (Poison Control Centre) 
which is also located at the GÖG.
To ensure scientific and political independence, an 
interdisciplinary Advisory board was established, where 
experts from different areas are involved. These 13 experts 
cover the following areas/expertise: administration (national 
and regional drug addiction coordination); addiction 
prevention; treatment; harm reduction; toxicology; forensic 
medicine; emergency medicine; and addiction research. 
Some additional experts, covering addiction prevention, 
pharmacy, youth psychiatry and forensic chemistry, are 
nominated for specific requests. The first and constituent 
meeting of the Advisory board took place in June 2007.
Core functions and information flow
GÖG/ÖBIG is the central interface of the Austrian EWS. 
All reports/alerts are sent to and validated by GÖG/ÖBIG 
(if necessary, in consultation with the Ministry of Health 
or experts). If relevant and useful/necessary, the information/
warning is (sometimes together with additional useful 
information) disseminated to the network. There is a special 
e-mail address for the system (ews@goeg.at) and a special 
form for alerts/reports about new substances, etc. There are 
also rules on how to label and deal with these reports/alerts.
The network for the information exchange within the Austrian 
EWS is divided into two parts:
•	 Network A, on a federal level, which is informed directly 
by GÖG/ÖBIG, includes relevant ministries (e.g. 
Ministry of Health), the regional drug addiction  
coordinators, relevant institutions on a federal level  
(e.g. medical organisation, pharmaceutical  
organisation, social insurance), laboratories and  
addiction research as well as interfaces to the regional 
level (which is in some cases the regional drug addiction 
coordination):
•	 Network B, on a regional level, includes institutions/
services of the drug help system (outreach, low- 
threshold services, treatment facilities, counselling  
services, secondary prevention, etc.), emergency 
departments and organisations, institutions for forensic 
medicine and administration (public health sector).  
Depending on the case/situation, additional partners 
can be included and informed, such as, for example,  
the police, hospitals, general practitioners, youth  
institutions.
The process is clearly defined and distinguishes between 
‘normal case’ and ‘emergency case’, as shown in the flow 
chart (Figure 1). There are no timelines defined for the 
separate steps of the process. But it is stated clearly in the 
concept that the Austrian EWS aims to exchange relevant 
information as quickly as possible to prevent any negative 
health consequences.
Information on new substances, impurities, especially high 
concentrations or new consumption patterns, etc. can be 
gathered and reported by different partners on a regional 
or federal level of the system. Usually, new substances and 
impurities are analysed and reported by three main partners: 
ChEck iT! (Viennese drug testing service); the OMCL 
(Official Medicines Control Laboratory) located in the AGES 
PharmMed (Austrian Medicines and Medical Devices 
Agency); and the Bundeskriminalamt (Federal Bureau of 
Criminal Investigation, BMI/.BK). ChEck iT! offers voluntary 
analysis of substances to young people at festivals and 
parties to reduce the risk of negative health consequences 
and to collect information on available psychoactive 
substances. The AGES PharmMed is responsible for the 
analysis of counterfeited pharmaceuticals and suspicious 
products, which could contain (illicit) active ingredients, to 
prevent negative health consequences for the general 
population. The BMI/.BK is responsible for the analysis of 
seizures of suspicious pharmaceuticals and substances to 
identify possible illegal activities.
Information on emergency cases is reported by different 
partners. To improve the involvement of emergency 
departments of hospitals, a special web-based discussion 
forum was set up in 2010.
There are no outputs such as annual reports foreseen within 
the Austrian EWS. But it provides the EMCDDA with progress 
and final reports each year. The new law on new 
psychoactive substances, which should become effective in 
February 2012, also establishes the basis for further 
monitoring of new substances in Austria. A tool, which 
enables better documentation and reporting, shall be 
developed during 2012.
12
Figure 1 — Flow chart of the Austrian EWS
NORMAL CASE                                                                                   CASE OF EMERGENCY
                          (additional activities)
      
Systempartner
Information with form to GÖG/ÖBIG
GÖG/ÖBIG
Validation/assessment
of the received information
GÖG/ÖBIG
Decision about input in the system
GÖG/ÖBIG
Summary of information and
dissemination via e-mail to Network A
(federal level)
Provincial interfaces
Dissemination via e-mail to Network B
(provincial level)
    Systempartner
Feedback to GÖG/ÖBIG
GÖG/ÖBIG
Summary of the feedback and
dissemination of the Follow-up info
optional
GÖG/ÖBIG
Decision about organisation of a meeting
of the Advisory board
optional
Advisory board
Consultation on necessary prevention
measures
optional
BMG
Inititation of prevention measures and
examination of their implementation
yes no
Feedback to the
reporting partner
   Parallel to the provincial 
coordinations
Consultation with the
provincial coordinations
Consultation with
experts and BMG
Systempartner
Note ‘emergency’
GÖG/ÖBIG + BMG
Decide about necessary 
immediate measures
BMG
Initiates and examines
immediate measures
Source: GÖG/ÖBIG.
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There is no formal procedure for risk assessments in Austria. 
But the concept of the Austrian EWS also includes risk 
assessments as a major task of the Advisory board. Risk 
assessments are done on an ad-hoc basis and on behalf 
of the Ministry of Health. This is also going to change with 
the new law on new psychoactive substances, which should 
become effective in February 2012 and provides the basis 
for setting up a formal risk assessment procedure.
Case study
‘Spice’
The example ‘Spice’ is chosen to show the process of the 
Austrian EWS.
ChEck iT! contacted GÖG/ÖBIG (also on behalf of the drug 
and addiction coordination of Vienna) with a question about 
possible analysis for ‘Spice’ products within, or financed by 
the EMCDDA. At that time, psychoactive effects of ‘Spice’ 
were reported by users once in a while. But the results of an 
analysis by a private laboratory about a year ago gave no 
hint of the existence of illicit substances in ‘Spice’ products. 
So it was unclear how to explain the psychoactive effects. 
Step 1: The reliability of the information was regarded as 
high because the information came from experts. The 
EMCDDA was informed about the issue, together with a 
request for further information.
Step 2: Together with ChEck iT!, all available information on 
‘Spice’ was collected and summarised. The findings were 
disseminated to the network in combination with a request for 
further information.
Step 3: GÖG/ÖBIG received feedback from experts in 
Upper Austria and Tyrol.
Step 4: In cooperation with ChEck iT! and after 
consultation with the Ministry of Health, a fact sheet on 
‘Spice’ was prepared, which included information on 
counselling and prevention. This was again disseminated to 
the network.
Step 5: After consultations between several ministries and 
discussion at the Federal Drug Forum, an ad-hoc meeting of 
the Advisory board of the Austrian EWS was organised. As 
no severe incidences with ‘Spice’ were reported until that 
time and information on health consequences as well as 
information on psychoactive ingredients was still missing, it 
was recommended to find a solution for the control of ‘Spice’ 
outside the Narcotic Substances Act. At the same time, the 
Ministry of Health commissioned AGES PharmMed to 
analyse ‘Spice’ samples.
Step 6: A German laboratory identified the psychoactive 
substance JWH-018 in ‘Spice’. These results were confirmed 
in Austrian samples by the AGES PharmMed a few days 
later.
Step 7: After consultations of the Advisory board for the 
differentiation of pharmaceuticals and other products, the 
Ministry of Health decided to control ‘Spice’ on the basis of 
the pharmaceutical law. A short-term decree (valid only for 
two weeks) was issued on 22 December 2008, which 
prohibited the distribution of ‘Spice’ and similar products.
Step 8: A regular decree followed on 7 January 2009, which 
prohibited the import and distribution of all products 
containing JWH-018.
Step 9: After the identification of further synthetic 
cannabinoids in ‘Spice’ and similar herbal mixtures, the 
decree was replaced by another one on 3 March 2009. 
This decree prohibited the import and distribution of all 
incense mixtures containing cannabinomimetic substances. 
Those cannabinoids, which have been identified until March 
2009, were listed in the amendment.
Step 10: Another meeting of the Advisory board was 
organised in March 2009, where the current situation was 
discussed. It was agreed that an expert group, which clusters 
synthetic cannabinoids with potential psychoactive effects, 
should be commissioned by the Ministry of Health. These 
clusters would avoid the need for changes of the law after 
identification of further new synthetic cannabinoids. 
It was also agreed that the control of these substances should 
remain on the basis of the pharmaceutical law.
Step 11: In October 2010, the amendment to the decree on 
incense mixtures was updated. It now contains the following 
substances: CP 47,497 and its C6-, C8- and C9- 
homologues, HU-210, JWH-018, JWH-015, JWH-019, 
JWH-073, JWH-081, JWH-200 and JWH-250 and 
o-desmethyltramadol.
Step 12: In January 2011, the fact sheet on ‘Spice’ was 
updated and disseminated again.
Austria — early warning system
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Strengths, limitations and the way forward
The strengths of the Austrian EWS are a good and 
comprehensive network, which involves all kinds of relevant 
experts and information providers, as well as a very 
well-structured information flow in the context of 
dissemination. The identification of new substances or 
impurities is also working well, especially in the context of 
festivals and parties where ChEck iT! is active. The interest 
in the Austrian EWS and the motivation to participate in the 
network are increasing among experts from different areas. 
During the process of setting up the Austrian EWS, a list was 
created with information on analytical methods, tasks and 
contact details of relevant laboratories to support the 
information exchange between them. This turned out to be 
a helpful basis for the implementation of the Austrian EWS, 
especially when it is necessary to gather additional 
information or to assess information on new substances.
Limitations are still observed in the context of gathering 
information on actual health consequences, such as 
emergencies. A crucial factor, which cannot be changed by 
the Austrian EWS, is the lack of analysis of substances within 
emergency departments of hospitals. Therefore, the reason 
for an emergency case and the contribution of a 
psychoactive substance, as well as the type of substance, can 
often only be speculated (e. g. in the context with GHB/GBL). 
The information exchange with the laboratories is limited 
mainly due to contractual and financial issues.
The system started as a work in progress and is still 
improving. Further steps will be the further improvement of 
the information exchange, especially with hospitals but also 
with experts from counselling services. To do so, the 
web-based discussion forum will be adapted and opened to 
all members of the network of the Austrian EWS. The expert 
consensus on possible measures for analysis and prevention 
in the context of ‘research chemicals’ — which was finalised 
at the end of 2011 — shall be completed with possible 
measures for treatment during 2012. It is also planned to 
tackle the issue of media coverage, which is highly sensitive 
in terms of prevention.
Links and references
The concept of the Austrian EWS is published on the website 
of GÖG/ÖBIG (http://www.goeg.at) and in the web-based 
EWS-forum (http://forum.goeg.at/ewsforum).
Early warning system — national profiles
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Introduction
The establishment of the Belgian early warning system 
(BEWS) by the Belgian government followed the adoption 
of the Joint Action on New Synthetic Drugs (Council of the 
European Union, 1997). The first steps in the development 
of this BEWS were taken at the end of 1997 by establishing 
the cooperation between the Ministry of Public Health and 
the Ministry of Justice. The initial aim of the BEWS was the 
collection and distribution of social, medical and cultural 
information on new synthetic drugs and (combinations of) 
high-risk psychoactive substances by the Belgian Monitoring 
Centre for Drugs and Drug Addiction (BMCDDA, the Belgian 
focal point) and the regional focal points (RFPs). From the 
onset, a decision was taken to collect information at 
laboratories’ level. In February 1999, the BMCDDA 
performed a feasibility study to investigate whether a 
web-based database with all analytical results of analysed 
drugs would facilitate the monitoring tasks of the BEWS. 
This web-based database was operationalised in 2002 (Leus 
et al., 2001; Leus and Walckiers, 2002). Currently, a new 
version of this technical platform is under development.
Organisational issues
The BEWS is hosted by the BMCDDA which is embedded in 
the research program ‘Substance use and Related Disorders’ 
(SURD) of the service Surveys, Lifestyle and Chronic Diseases. 
This service is part of the Operational Directory ‘Public 
Health and Surveillance’ of the Scientific Institute of Public 
Health (WIV-ISP), situated in Brussels. The BMCDDA monitors, 
collects, analyses and disseminates drug-related information 
towards the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) and towards its national stakeholders. 
The EMCDDA and the Federal Government Department of 
Public Health, Food Safety and the Environment co-finance 
the BMCDDA and its BEWS.
The main objectives of the BEWS are: (1) the rapid detection 
of new psychoactive substances in Belgium and; 
(2) the monitoring of the composition of known illicit 
substances and trends in the composition of these substances. 
In order to fulfil these objectives, the BEWS relies on the 
reporting of drug analyses by laboratories. 
The reporting of the analysis results to the BEWS is regulated 
by two Royal Decrees (Federale Overheidsdienst 
Volksgezondheid, 2003; Federale Overheidsdienst 
Volksgezondheid, 2006; Service Public Federal Sante 
Publique, 2003; Service Public Federal Santé Publique, 
2006). These Royal Decrees make the reporting of analytical 
results to the BEWS mandatory for the toxicological 
laboratories in Belgium, except for cannabis. The reporting 
of analytical results by clinical laboratories is only 
mandatory for new substances (see also Figure 2).
Complementary to the national BEWS, two regional 
focal points (Eurotox and the Vereniging voor Alcohol — 
en andere Drugproblemen, VAD) host a regional EWS. 
As the BEWS is responsible for the monitoring of trends in the 
compositions of analysed seized drugs, the regional EWSs 
focus on the prevention level. They therefore collaborate with 
services like ‘De Druglijn’, a telephone helpline for people 
(not only users) with questions about drugs. The three EWSs 
collaborate in the dissemination of ‘alerts’ when new or 
high-risk psychoactive substances are reported.
Core functions and information flow
The BEWS collects and disseminates information about the 
composition of drugs within a network including the RFPs, 
laboratories, hospitals, police services, the Federal Agency 
for Medicines and Health Products (FAMHP) and the Federal 
Government Department of Public Health, Food Safety and 
the Environment (FPS) (see Figure 2).
The data registered by the BEWS is mainly provided by the 
laboratories analysing the drug samples. Twenty-three 
laboratories (spread over Flanders, Wallonia and Brussels 
capital) are participating in the BEWS network, of which 
18 laboratories reported results since 2002.
Most of the reported analyses concern drug seizures 
commissioned by the Director of Public Prosecutions. 
Although the samples come from all over Belgium, the 
number of samples sent by the different judicial districts 
may differ.
Belgium — early warning system
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Figure 2 — Information flow in the framework of the Belgian EWS
Most laboratories submit their common analytical results 
(no new or high-risk substances) to the BEWS in the first 
months after the previous reporting year (from 1 January 
until 31 December). Some laboratories report their results 
on a more regular basis. When the results of one registration 
year are complete, the BEWS responsible processes these 
data for the output. The output includes Chapter 10 of the 
Belgian Annual report, Standard Tables 14 and 15 
(European Monitoring Centre for Drugs and Drug 
Addiction, 2011), specific EWS reports and reports on 
request (EMCDDA requests, parliamentary questions, etc.).
In the case where laboratories identify a new or high-risk 
psychoactive substance, the BEWS is immediately informed. 
In a small number of cases (mainly when unexpected effects 
or appearances of psychoactive substances are reported), 
information comes first from police services or prevention 
services and is then followed by an analysis. The available 
Belgium — early warning system
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information (analysis results, origin of the sample, 
appearance of the drug, and reported effects in humans) 
is collected by contacting the involved partners. The 
identification of new or high-risk psychoactive substances is 
first reported to the hierarchical line of the WIV-ISP, the 
communication services of the WIV-ISP, the FPS and the 
cabinet of the Minister of Public health. Secondly, the 
information is disseminated through ‘alerts’ (in the form of 
e-mails) to the BEWS network. The RFPs disseminate the 
information in their regional network of prevention services. 
Furthermore, a log book is created collecting all information 
provided by the partners of the BEWS network.
Every six months, the new substances are also reported in the 
EWS Progress and Final reports on new substances for the 
EMCDDA.
Case study
In January 2011, a local police service informed the BEWS 
about two serious intoxications in drug users (of which, one 
died). The incidents took place after the use of a yellow 
powder bought as ‘yellow speed’ from one and the same 
dealer. The police commissioner of the local police service 
sent the samples to a clinical laboratory, to investigate the 
powder and human samples.
The BEWS immediately informed the regional EWS of 
Eurotox and VAD. These regional EWSs informed the local 
prevention services of their network. The EMCDDA and the 
other BEWS partners were informed although: (a) the 
identification of the psychoactive substances in the powder 
was not available at the time; and (b) it was assumed that 
most of the powder would be off the market. Moreover, it 
was only after identification of the psychoactive substance 
that it could be concluded that the users’ intoxications were 
related to the yellow powder.
The reach of the BEWS is illustrated by the fact that users 
came to low-threshold services with questions about their own 
yellow powder (when feeling bad after the use of a yellow 
powder, or after having bought yellow powder that was sold 
as ‘heavy stuff’). None of these secondary samples were 
identified as parts of the same batch of the initial powder.
Strengths, limitations and way forward
In Belgium, the drug-related aspects (treatment, prevention, 
law enforcement, etc.) are divided over different political 
levels (federal and federate). As a result of the collaboration 
with the RFPs, the BEWS reaches the different types of 
services related to drugs and drug use. The functioning and 
reach of the BEWS is continuously extended, and police 
services find their way to the BEWS (see section ‘Case 
study’).
Since 2002, the majority of the data is provided by four 
laboratories. Although no information of the 
representativeness is available, it is assumed that these four 
laboratories analyse most of the seized drug samples in 
Belgium. Other laboratories in the BEWS provide a smaller 
number of data. However, it is assumed that other smaller 
laboratories do not report their data to the BEWS. In 2011, 
surveys for laboratories and law enforcement services (courts 
and police) were conducted to improve the coverage of the 
BEWS and to estimate the representativeness of the current 
BEWS.
Currently, the BEWS dataflow is interrupted several times as 
there is no connection between the database of the police 
and the information from the judicial courts (circumstances 
and size of seizure, decision for analysis of the sample) on 
the one hand and the BEWS database (data collection based 
on lab results) on the other hand. The information on the 
context of the seizure is only obtained for new and high-risk 
drugs, and only by specific request of the BEWS responsible. 
As a consequence, for the regular drug monitoring, it is not 
clear whether this seizure took place at dealer or user level, 
which proportion of all the seizures is analysed, etc.
To improve the representativeness of the BEWS, the project 
‘Drugs in Circulation’ was started in 2003 analysing all 
seized drugs (not only a selection of them) in specific judicial 
districts (Van Der Biest and Walkiers, 2004). However, due 
to funding and practical matters, this project diminished over 
the years, and has come to an end in 2010. Now, other 
steps are taken to improve the system: the creation of a 
‘unique sample identifier’ used by the police, the directorates 
of public prosecutions, and the laboratories is under 
consideration. This identifier will facilitate the linking of the 
different databases, will make the dataflow more transparent, 
and will also result in a better estimation of the 
representativeness of the system.
The focus on seized drugs by the BEWS has both advantages 
and disadvantages. Some of the disadvantages could be 
minimised by investing in collecting samples at user level. 
Users might be more motivated to have their drugs tested 
after having had a bad or unusual experience, speeding 
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up the detection of new and dangerous drugs. Furthermore, 
users could provide information on the street names used 
for specific drugs, which could also make the alerts more 
specific.
Over the years, drug-testing projects at user-level were 
initialised by the RFPs: the RAPID-project — Risico Analyse 
Project voor het Identificeren van Drugstalen (Schrooten, 
2010) — and the pill-testing project ‘Modus Fiesta’ (Modus 
Vivendi, 2005). However, due to legal, ethical and policy 
considerations and a lack of funding, these projects were not 
easy to maintain.
The BMCDDA currently develops a new technical platform 
facilitating the data submission by the laboratories. Specific 
attention will be paid to the automatic quality control of the 
data. In addition, generic feedback reports (with 
benchmarking) will be programmed for the participants and 
stakeholders of the BEWS. Furthermore, a multidisciplinary 
national Risk Assessment Expert group will be established.
Finally, a BEWS-SharePoint, facilitating the exchange and 
archiving of up-to-date information with the Belgian partners 
is developed.
Links and references
Links
Belgian early warning System on Drugs (BEWSD) — 
http://ewsd.wiv-isp.be
Belgian Monitoring Centre for Drugs and Drug Addiction 
(BMCDDA) — http://workspaces.wiv-isp.be/bmcdda
Belgian Information Network for Drugs and Drug Addiction 
(BINDDA) — http://workspaces.wiv-isp.be/bindda
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Introduction
The history of the early warning system (EWS) in Bulgaria 
started in 2004 with a visit of the EMCDDA, in the 
framework of the project ‘Joint Action on new types of 
synthetic drugs’ at that time. The visit was related to official 
meetings with representatives of the Bulgarian political 
power, dedicated to presenting the work and the nature of 
the EWS in general and the need for establishing such a 
mechanism for information exchange at national level.
The real action in building a working EWS in Bulgaria began 
in 2006 (13 April) with the formation of an expert working 
group of the national focal point (NFP) with the participation 
of representatives of governmental, non-governmental and 
local institutions and organisations related to the drug 
problem and dependence, whose first task was to identify 
key partners and outline key steps in organising activities for 
the exchange of information on new substances in the 
country. The group included experts from the Ministry of 
Health (Department of Emergency Medical Care), Ministry 
of Interior (General Directorate for Combating Organised 
Crime, Research Institute of Forensic Science and 
Criminology (RIFSC)), Ministry of Finance (Customs Agency), 
Alexandrovska Multi-Profile University Hospital for Active 
Treatment — Centre for Forensic Medicine and Deontology, 
Clinic of Toxicology, N.I. Pirogov Multi-Profile University 
Hospital for Active Treatment and Emergency Medicine — 
Department of Information, and partners from the Prevention 
and Information Centres for Addictions in Sofia and Varna.
The newly formed working group took the following 
fundamental decisions:
•	 the rules for the operation of the working group should 
be elaborated urgently;
•	 the process of formation of the working group was not 
completed. Extending the range of key partners  
remained a permanent objective of its operation.  
Whenever necessary, additional short-term external  
contributors/experts can be used to work on certain 
tasks and topics;
•	 regular meetings of the working group should be held 
twice a year.
In 2007, in accordance with one of these decisions, 
representatives of non-governmental organisations doing 
outreach work with users and the Clinic of Toxicology at the 
N.I. Pirogov Multi-Profile University Hospital for Active 
Treatment and Emergency Medicine in Sofia joined the 
group. In 2009, an invitation for cooperation on new 
substances was extended to the Bulgarian Drug Agency and 
the Clinic of Toxicology at the Military Medical Academy in 
Sofia.
The collection of information began by sending a query to 
the Prevention and Information Centres in the country for the 
existence of new psychoactive substances and new patterns 
of use of already established psychoactive substances in the 
drug markets at local level.
In its relatively short period of functioning, the EWS in 
Bulgaria has developed as an active European and national 
partner in the area of new drugs contributing to identify for 
the first time three new psychoactive substances, processing 
over 100 communications from the European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA), 
proposing the supervision by the national legislation of six 
new substances and supporting by information and experts 
the procedure for the inclusion of another 25 new substances 
in the Law on Narcotic Substances and Precursors Control. 
The Head of the national focal point is a member of the 
Expert Committee of the National Drug Council, involved in 
the preparation of risk assessment for emerging substances 
and proposals for placing them under control as drugs. The 
NFP, through its representative in the Expert Committee of 
the National Drug Council, has actively participated in the 
preparation of a proposal for amending the Law on Narcotic 
Substances and Precursors Control, designed to allow for 
faster controls on emerging new (uncontrolled) psychoactive 
substances.
Organisational issues
The work of the EWS in Bulgaria is managed and 
coordinated entirely by the NFP on drugs and drug 
addictions through a manager and an authorised 
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coordinator in the team of the Centre (two full-time 
employees, but not working only with N-EWS). The NFP is 
based at the National Centre for Addictions, which is part of 
the EWS of the Ministry of Health. The total number of 
external experts working on the EWS is approximately 15, 
some of which are members of the working group. 
Freelancers (external experts) working with N-EWS are of a 
diverse educational background and professional 
qualifications — chemists, toxicologists, physicians, nurses, 
psychologists, operatives and experts in the field of law 
enforcement and in the law-enforcement authorities, outreach 
workers, addictions consultants. All members of the expert 
group formed are united by the voluntarily assumed 
responsibility to cooperate in the development and operation 
of the EWS at the national level — a conception enshrined 
in the internal operating draft document entitled ‘Consensus 
rules for the operation of the early warning system in 
Bulgaria’. The document is based on the decisions made at 
the first meeting of the working group in 2006 and its main 
purpose is to describe the relations within the EWS and the 
effective way of exchanging relevant information on 
monitoring and evaluation of new drugs detected in the 
Republic of Bulgaria, and new patterns of use of already 
known drugs. The maintenance and development of N-EWS 
were regulated normatively by a text included in the Law on 
Narcotic Substances and Precursors Control in 2010 reading 
as follows: ‘The Bulgarian national focal point builds and 
maintains a public information system on drugs and drug 
addictions as well as early warning information system about 
new narcotic substances as part of the European early 
warning system’.
The status of the NFP as the basic advisory, expert and 
information unit on drugs in Bulgaria, as an official partner 
of the EMCDDA, as a participant in the European 
Information Network on Drug Addiction (Reitox), and the 
objective circumstances in the dynamic development of the 
problem of new drugs in the country identified the additional 
roles of N-EWS and forced the expansion of its activities. 
The work is organised in several directions, and parallel 
to the main one (participation in the European information 
network on new psychoactive substances with the provision 
of information on such substances identified in the territory 
of Bulgaria and new patterns of use), the capacity of the 
EWS for providing information on new substances at the 
national level, participation in legislative initiatives in the field 
of new drugs and for initiating research projects in this field 
has developed. 
The EWS has the potential for national coverage through the 
Prevention and Information Centres on the problems of drug 
addiction in 26 cities across the country and through the 
subsidiary laboratories for analysis of the Research 
Institute of Forensic Science and Criminology and the 
Customs Agency.
The working language in the National early warning system 
(N-EWS) is Bulgarian; the language of international 
communication is predominantly English.
Core functions and information flow
The exchange of information within the EWS for new drugs 
is done in pursuance of Council Decision 2005/387/JHA 
of 10 May 2005 and is conducted in cooperation with the 
European Monitoring Centre for Drugs and Drug Addiction.
The very concept of the EWS implies simultaneous 
functioning of two major information flows (Figure 3):
•	 Outgoing — from Bulgarian sources (as an EU Member 
State) through NFP and the EMCDDA to the European 
institutions;
•	 Incoming — from sources in the EU Member States 
through the EMCDDA and NFP to the relevant Bulgarian 
institutions.
The purpose of the outgoing flow is to inform the European 
Union Member States and institutions about new substances 
and/or new patterns of use of known substances found in 
the territory of the Republic of Bulgaria. The purpose of the 
incoming flow is to provide the interested institutions and 
experts in Bulgaria with information on the new substances 
and/or new patterns of use of known substances found in the 
territory of other European countries.
Several types of national sources provide the outgoing data 
flow:
•	 laboratories in the field of forensic science (Research 
Institute of Forensic Science and Criminology —  
Laboratory Unit ‘Drugs’; Research Institute of Forensic 
Science and Criminology — Chemical and Toxicological 
Laboratory; Customs Agency Laboratory);
•	 laboratories in the field of forensic medicine (Centre 
for Forensic Medicine and Deontology, Alexandrovska 
Multi-Profile University Hospital for Active Treatment);
•	 clinical laboratories (Chemical and Toxicological  
Laboratory at the N.I. Pirogov Multi-Profile University 
Hospital for Active Treatment and Emergency Medicine; 
Chemical and Toxicological Laboratory at the Military 
Medical Academy);
•	 therapeutic, outreach and other units which have direct 
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Figure 3 — Functional scheme of the early warning system in Bulgaria
contacts with drug users (hospitals, treatment  
programmes, NGOs and others);
•	 law enforcement units, which in their activities have 
direct contacts with drug dealers (Main Directorate for 
Combating Organised Crime — Ministry of the Interior 
(MoI); Customs Agency — Ministry of Finance);
•	 units accumulating information in the field (National 
Focal Point, Prevention and Information Centres for 
Addictions, National Centre for Addictions, Ministry of 
Health and others).
The incoming flow is directed to several categories of 
recipients in Bulgaria with different levels of access to this 
information.
With unlimited access:
•	 laboratories in the field of forensic medicine; 
•	 laboratories in the field of forensic science;
•	 clinical laboratories; 
•	 law enforcement units;
•	 therapeutic and outreach units. 
With limited access:
•	 media; 
•	 users outside the professional community. 
The entire information within the EWS for new drugs in 
Bulgaria is collected, coordinated and directed by the 
National Focal Point for Drugs and Drug Addiction which, 
where necessary, organises its further processing and 
analysis, seeking assistance from the national scientific and 
research units outside the working group or the European 
Partner Network. Each participant in the working group is 
committed to provide the NFP with data within the range 
of their competence on new types of psychoactive drugs 
found, new combinations and new patterns of use of already 
known ones, if possible, immediately after the acquisition 
of such information. The information is submitted to the NFP 
in a format consistent with the database of the institution. 
After processing, the data for new substances obtained from 
national partners is sent directly to the European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA) by filling 
in an established form — Reporting Form. By forwarding the 
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EWS Progress Report and Final Report, full information about 
the condition and operation of N-EWS in the current 
calendar year is provided.
The information submitted through the EWS by the European 
partners of the NFP is timely distributed by the latter to the 
participants in the working group in three main ways — 
in the form of warnings, alerts and reports. Warnings 
disseminate primarily information on new psychoactive 
substances identified and reported through the EWS and 
communication is taking place over the Internet. 
Communication of incidents directly affecting the physical 
health of drug users (death cases, toxic combinations of 
substances, dangerous supplements found in known drugs) 
must be submitted as alerts, especially in private conversation 
on the phone with the relevant representative in the working 
group. Reports are basically used during the annual meetings 
of N-EWS, where experts of the working group are informed 
in detail about the situation with new substances in Europe 
and Bulgaria.
The communication between experts in the working group is 
arranged so that each member may request at any time to be 
provided with information by another member on any matter 
relating to the development and operation of the EWS in the 
country.
In connection with the need to build a complete mechanism 
for dealing with the new psychoactive substances at national 
level, in 2009 the NFP began to work on a proposal related 
to establishing a national system for assessing the risk of 
using such substances by creating a complete cycle of 
activities — from the identification of a new substance to 
placing it under control. The first step to this effect was 
compiling a list of laboratories and assessing their capacity 
(available equipment, library, staff, etc.) to work with the 
new substances. The laboratories were divided into four 
main groups depending on the needs of the N-EWS: 
laboratories for identification and analysis of unidentified 
substances; laboratories for identification and analysis of 
new chemical substances from biological samples; 
laboratories for testing the effects and toxicity of chemical 
substances; and laboratories for synthesis of scientific and 
practical purposes of chemical substances.
Case study
A good example of how the N-EWS works in practice is 
when the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) released information about deceased 
heroin users infected with anthrax — a lot of information 
untypical for the nature of the EWS. Due to the fact that the 
working group includes representatives of institutions and 
organisations working in various fields of drugs and drug 
addiction, the EWS in Bulgaria did not face any obstacles to 
spread this message. The partners in the working group 
having access to drug users were informed immediately. 
Through them, the information reached their colleagues from 
similar organisations in other cities that were not part of the 
working group and feedback was obtained on whether, in 
the population of heroin users in Bulgaria, there were cases 
of individuals infected with anthrax.
On the other hand, the message was also sent to the 
relevant Directorate at the National Centre for Addictions, 
related to this serious case. The experts of the Directorate 
also responded immediately and contacted the National 
Centre for Infectious and Parasitic Diseases (NCIPD) asking 
for assistance. The NCIPD responded with data on the 
presence or absence of such cases and appropriate 
recommendations.
Strengths, limitations and way forward
The major strength of the EWS in Bulgaria is the diverse 
composition of the working group. It covers sources of 
information from all areas of drug addiction, which allows 
obtaining the necessary information on the functioning of 
the mechanism at national and European level. In addition, 
the N-EWS has the capacity to develop additional areas in 
the field of new drugs, going, at national level, well beyond 
its core activities related to the identification and provision 
of information on the availability of new substances in the 
country. It seeks to establish a comprehensive mechanism of 
concrete steps to work in a dynamic environment of the new 
psychoactive substances.
As to the difficulties faced by the EWS in Bulgaria, most of 
them are caused by circumstances beyond the control of and 
independent from the NFP as a coordinator. An outstanding 
problem is the lack of modern equipment for analysis of new 
substances, modern libraries and reference material. 
The non-realised scientific potential (due to lack of funding) 
in the field of new drugs and the lack of a complete national 
mechanism for a comprehensive risk assessment of the use of 
new psychoactive substances, are additional difficulties in the 
work of the N-EWS.
The weak connection with the population of drug users and 
mostly with those experimenting with drugs is a problem in 
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the state of the EWS at the moment. This is a field of 
activity on which the EWS in Bulgaria is now focusing its 
efforts, which undoubtedly is related to its future 
development. 
The possible directions for the development of the N-EWS 
include several aspects: 
•	 expansion of information services, including monitoring 
of the Internet; 
•	 assistance in developing the national legislation on 
new psychoactive substances, including proposals for 
possible amendments to the Law on Control of Narcotic 
Substances and Precursors Control; 
•	 conducting surveys of the popularity and use of new 
substances. 
The focus in the current state of the N-EWS and most likely 
in its future development is to carefully assess the current 
situation in the drug market and bring in line with it the entire 
mechanism for monitoring and placing under control new, 
emerging substances. This is related to the need for 
reducing the time for assessment and possible controls on 
new substances. The market has become much more 
dynamic than it was 10 years ago and requires a new 
speed of responsiveness and perhaps a new organisation 
of work. In general, new substances become available with 
the status of legal ones; they are placed on the market 
aggressively and quickly and provoke strong public pressure 
to bring them under control as quickly as possible. 
This pressure, accompanied by the pressure from law 
enforcement authorities through which quite a few legal 
packets containing such substances pass, which are known 
to feed the market of drugs, reduce the possibilities of 
conducting the process of research and risk assessment of a 
given substance in the ‘classical’ way. In fact, this could be a 
general challenge to the EU Member States.
Links and references
http://lex.bg/bg/laws/ldoc/2134654469
http://www.ews-nfp.bg
Annual National Report on the state of drug-related problems 
in Bulgaria — 2008, National Focal Point on Drugs and 
Drug Addictions and National Drugs Council, November 
2008.
Annual National Report on the state of drug-related problems 
in Bulgaria — 2009, National Focal Point on Drugs and 
Drug Addictions and National Drugs Council, November 
2009. 
Annual National Report on the state of drug-related problems 
in Bulgaria — 2010, National Focal Point on Drugs and 
Drug Addictions and National Drugs Council, November 
2010. 
Annual City Reports of the Municipal Drug Councils, 2010.
Final Annual Report on functioning and development of the 
early warning system in Bulgaria to the European Monitoring 
Centre for Drugs and Drug Addiction, national focal point, 
January 2008.
Final Annual Report on functioning and development of the 
early warning system in Bulgaria to the European Monitoring 
Centre for Drugs and Drug Addiction, national focal point, 
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Final Annual Report on functioning and development of the 
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Centre for Drugs and Drug Addiction, national focal point, 
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Final Annual Report on functioning and development of the 
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January 2011.
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Introduction
The use of designer drugs or other new psychoactive 
substances in Croatia represents a relatively recent 
phenomenon which is, to a large extent, connected with the 
new behavioural trends of young people during their leisure 
time. The emergence of new drugs in Croatia has been 
closely monitored since 2007, in the framework of the 
existing capacities. However, there are not much data 
available on the prevalence of their use, which is planned 
to be improved in the forthcoming period with the aim of 
creating appropriate responses of relevant institutions. 
Even before installing the formal National early warning 
system (N-EWS) in 2007, Croatian relevant authorities have 
been actively cooperating in the exchange of information on 
new psychoactive substances that posed a significant threat 
to the Croatian society and had a clear legal possibility to 
place problematic new substances under legislative control. 
This practice proved to be successful in 2004 when five types 
of piperazine were listed at the national level, using 
available legal instruments. In accordance with the Law 
on Combating Drugs Abuse, the Minister of Health is in 
authority responsible for updating a List of drugs, 
psychotropic substances and plants that drugs can be 
produced from, as well as substances that can be used in 
order to produce drugs (precursors) [List]. The Forensic 
Science Centre (FSC) regularly conducts analyses of all drugs 
seized, including new psychoactive substances. In cases 
where the classic drugs and psychotropic substances are not 
an issue, new substances can be identified by using 
professional literature and a data bank. If a newly detected 
psychoactive substance poses a serious threat to public 
health and has a limited therapeutic value, the Minister of 
Health can specify this substance to be included in the List, 
upon the recommendation of an expert group. Each 
unauthorised possession and trade in substances that are 
on the List is considered a criminal offence.
Organisational issues
The National Strategy on Combating Drugs Abuse in the 
Republic of Croatia 2006–12 (National Strategy) foresees 
the creation of a system for rapid exchange of information 
on production, trade, use and risks related to new 
psychoactive substances in order to prevent negative effects 
and to undertake on time-appropriate actions. Therefore, 
based on the National Strategy and the Protocol on National 
Drug Information System in the Republic of Croatia, there 
has been developed the Protocol on early warning System 
on New Psychoactive Substances in the Republic of Croatia 
(adopted by the Government of the Republic of Croatia, at 
its session held on 2 December 2007) as a basic document 
for setting up identification, communication and exchange 
mechanisms on new psychoactive substances at the national 
level and with EU agencies, which is fully compliant with the 
acquis communautaire in this domain. There has also been 
signed an agreement on institutional cooperation in the 
N-EWS between the Office for Combating Drugs Abuse 
(OCDA) and relevant authorities, which is going to be 
expanded with new stakeholders in 2011. Concrete tasks 
and activities are described in the National Action Plan on 
Drug Information System in the Republic of Croatia (2008–
09 and 2010–11), which enables monitoring of activities 
and progress.
Besides identifying new psychoactive substances that may 
appear on the national drugs market and reporting 
according to the Council Decision (2005/387/JHA), the 
primary objective of the N-EWS in Croatia is to prevent 
(diminish) negative health and social consequences of new 
psychoactive substances and to stop the spread of new 
phenomena in the country. Legal control and decrease of the 
availability of those new psychoactive substances is another, 
equally important aspect of the system. 
The OCDA is an expert service of the Government of the 
Republic of Croatia which is acting as a drugs policy 
coordinator. More specifically, the National Drugs 
Information Unit and International Relations Department is 
playing a key role within the OCDA structure in collecting 
drug-related information from respective institutions to monitor 
the drug situation in Croatia. As such, the OCDA is the 
Reitox national focal point and also coordinator of the 
N-EWS. The OCDA and the Europol National Unit at the 
Ministry of Interior are key institutions of the Croatian N-EWS 
in charge of rapid exchange of relevant information on new 
psychoactive substances at the national level, as well as for 
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direct communication with the top authorities of the EU EWS 
hierarchy, the EMCDDA and Europol. 
In general, the N-EWS in Croatia is acting at the national 
level. However, an ongoing restructure of the system foresees 
stronger activities at the professional, grassroots level, which 
will also enable better coverage in the local communities. 
At the OCDA, tasks related to the operating of the N-EWS 
are shared by two persons. The Head of National Drugs 
Information Unit and International Relations Department 
(criminalist) is in charge of structuring and management of 
the N-EWS, planning of activities, initiating joint projects 
and direct communication with the EMCDDA and national 
experts, whilst one expert associate (social pedagogue) 
provides technical assistance, e.g. dissemination or collection 
of information, assistance in elaborating documents etc. 
The Working Group on the N-EWS meets regularly two times 
per year and ad hoc upon the invitation of the OCDA (e.g. 
discussions on emerging trends). The core expert group 
meets on ad hoc basis, when a ‘risk assessment’ is required 
to make a decision on a necessity to place a specific new 
psychoactive substance under the legal control. After 
reconstruction of the N-EWS, there are foreseen also annual 
and ad hoc meetings of specific focus groups of 
professionals, which are in more detail described under the 
section Core functions and information flow. Besides 
meetings, there is almost daily communication (by phone, 
e-mail) between the OCDA as the N-EWS coordinator and 
relevant experts. Experts will soon also have a possibility 
to exchange information, knowledge and experience at the 
discussion forum (restricted area) which will operate on the 
website of the OCDA (online settings are already available). 
The Croatian N-EWS operates in Croatian language, and 
only seldom some important or urgent information received 
from the EMCDDA is transmitted to national key experts in 
English language (as a prompt reaction). 
The N-EWS, as well as the core expert group, has scientific 
and political independence to implement the national risk 
assessment procedure and to propose legal control for a 
specific new psychoactive substance. In all cases, the 
Minister of Health accepted the proposal and approved 
amendments to the List of controlled substances.
Core functions and information flow
The general principle of the N-EWS is committed 
collaboration between all relevant partners, on a regular and 
ad hoc basis, using a multidisciplinary approach and specific 
expertise in identifying new substances and assessing their 
risks.
The Croatian N-EWS operates at four levels:
Level I — As a national coordinator of the N-EWS, OCDA is 
responsible for providing sound ground for cooperation with 
and between national partners, further development of the 
N-EWS, planning and supervision of implementing activities, 
collection and dissemination of information, reporting and 
direct communication with the EMCDDA. The National 
Europol Unit is in charge of reporting to the Europol Drugs 
Unit as described in the respective legal documents and at 
the national level, assists the OCDA in its coordinative 
function. 
Level II — The advisory body to the OCDA is the 
Working Group on the early warning system (WG N-EWS), 
composed of representatives of key national institutions, non-
governmental organisations and other acknowledged experts 
in the field. It advises the OCDA on general policy of the 
N-EWS, communication strategy, further development, 
discusses actual topics and emerging trends in the area, 
collects and disseminates, participates in production of work 
documents and expert literature. Selected experts from the 
WG N-EWS make a core expert group responsible for risk 
assessment. 
Level III — Key public and scientific services/institutions as 
well as NGOs are organised as Focus Groups according to 
their professional/expert branches and each of them is being 
coordinated by the member of the of the WG N-EWS coming 
from their supervising authority (e.g. a representative of the 
Croatian Institute of Emergency Medicine will coordinate 
work of the focus group on emergency wards, etc.). As 
regular counterparts of the OCDA, they are obliged to 
continuously monitor emerging trends in their field, 
collect any information on new psychoactive substances and 
immediately report to the OCDA (directly or through their 
coordinators). 
Level IV — This level is being activated only in cases when 
important warnings or alerts have to be transmitted to drug 
users, other groups at risk, services, experts and 
professionals concerned or even exceptionally to general 
population. 
All information received from the EMCDDA or national 
authorities are kept in a simple database at the OCDA, 
translated, analysed and used for preparing information 
packages that are adjusted to the needs of specific 
target groups. Urgent warnings are immediately 
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Figure 4 — Organisational scheme of the early warning system on new psychoactive substances in the Republic of Croatia
Source: OCDA.
transmitted to all members of the WG N-EWS, who then 
decide (in consultation with the OCDA) whether information 
should be immediately forwarded to all or just some focus 
groups and potentially further to drug users or specific 
populations concerned and in which format. Other 
information received by the OCDA from EU or national 
counterparts are updated on a  monthly basis and are 
disseminated to 2nd and 3rd level of the N-EWS as an 
informative leaflet on new trends and developments in 
Croatia and the EU.
At the national level, data are collected in the standardised 
reporting form. When receiving a monthly information 
leaflet, all relevant stakeholders are reminded and 
encouraged to inform on new trends and developments 
observed in their field of work or in their environment/local 
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community. Since such practice was introduced only in the 
beginning of 2011, the main data provider on new 
psychoactive substances or dangerous impurities in 
traditional drugs is still the Forensic Sciences Centre at the 
Ministry of Interior. However, more and more information 
on emerging trends is received from the treatment services 
and harm reduction programmes. In the first half of 2011, 
a survey on distribution and prices of illicit drugs in Croatia 
was conducted among clients of harm-reduction services 
(N=622). Although there were also questions asked about 
the availability and prices of ‘legal highs’, there was not 
much information collected, probably due to the surveyed 
population which is more oriented on traditional drugs.
Risk assessment is carried out by a core expert group 
(pharmacologist, chemist, forensic expert, medical doctor, 
specialised police officer, and jurist). When a meeting is 
convened, each appointed expert is obliged to report on 
findings in his/her field of expertise, that could provide 
evidence of health and social risks posed by a specific 
psychoactive substance as a sound ground for proposing 
its legal control at the national level. However, there is no 
written risk assessment procedure with set scientific 
standards.
Besides aforementioned information packages for 
professionals, the OCDA also produces information leaflets, 
brochures, Internet articles etc. targeted at consumption 
population, especially youngsters. There are also regularly 
prepared updates and informative material for the media. 
Upon request, the OCDA prepares presentations and 
lecturers for professionals or specific populations 
(e.g. schools). 
Case study
Mephedrone first appeared in Croatia in 2009. After 
several seizures of that substance and information on its 
availability obtained from the treatment services, the core 
expert group decided to put mephedrone under legal 
control, based on the national risk assessment procedure.
After information received from the EMCDDA about the 
anthrax outbreak and fatalities among heroin users in the UK 
and Germany, the OCDA, in cooperation with relevant 
members of the WG N-EWS produced Instructions for 
protection of officials from possible exposure to anthrax 
spores during their work for police and health workers. 
The alert was also sent to treatment facilities and 
harm-reduction services with the aim to warn domestic drug 
users. 
Strengths, limitations and way forward
The major obstacle in further development of N-EWS is of a 
financial nature. There is ongoing expansion of the N-EWS 
network. The major strength is a wide and well-structured 
network, as well as documents that clearly describe how the 
N-EWS should function.
Links and references
http://www.nijd.uredzadroge.hr/index.php/hr/rano-upozo-
ravanje
OCDA (2007), Protocol on National Drugs Information 
System on New Psychoactive Substances in the Republic of 
Croatia, Office for Combating Drugs Abuse of the 
Government of the Republic of Croatia (OCDA), Zagreb.
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Introduction
The Cypriot early warning system (EWS) in the framework 
of the national focal point (NFP) began its formal operation 
on 17 June 2004, with the first meeting of the EWS network 
data providers, during which the communication procedures 
and other topics were discussed and arranged. At the time, 
the data was to be provided by the following organisations:
•	 State General Laboratory (SGL);
•	 IKAN — Cyprus Police Drugs Unit;
•	 KENTHEA — private sector NGO/therapeutic structures;
•	 Ministry of Health Pharmaceutical Services;
•	 Ministry of Health Mental Health Services.
Regular meetings of the working group, which would also 
act as an evaluation committee for the NSDs, were 
programmed for three-monthly intervals, with ad hoc 
meetings for special circumstances.
The Cypriot NFP, in collaboration with the Greek NFP, 
organised a training day for officers of the Cypriot NFP in 
June 2004 with the Greek EWS representative, followed by 
a training seminar with potential members of the EWS 
network, which was held in Nicosia with the Greek EWS 
representative and the Cypriot NFP in a training role. After 
this training, further contacts were made and the 
participation of the Cyprus EWS network partners/
representatives was ensured.
Organisational issues
The need for the creation of an early warning system was 
prompted as a result of the establishment of the Cyprus NFP. 
Thus, the Cyprus EWS was established following the 
EMCDDA’s recommendations and support. Although the 
National EWS was implemented to serve the Council 
Decision, it has come to take on a broader role and now it is 
the main source of information on which the responsible 
parties rely in order to make new amendments to the drugs 
Law L 29/77. However, there is no formal founding 
regulation or decree for its establishment.
The National early warning system (N-EWS) is one of the 
main responsibilities and functions of the NFP, which is 
under the administrative management of the Cyprus 
Antidrugs Council (CAC), although it is scientifically 
independent. It is located within the NFP’s premises and is 
run by an NFP officer, assisted by the N-EWS working team 
and its operation covers the whole Republic of Cyprus 
(except for the occupied areas).
Most of the information exchange and dissemination takes 
place through e-mail as a way of speedy communication, as 
well as through regular mail or fax for a more formal level of 
exchange. This communication is usually in Greek language. 
The N-EWS is scientifically and politically independent. It is 
noted that according to the National Drug Strategy 2009–
12, the Cyprus NFP is and will continue to be actively 
involved in an interdisciplinary committee aiming at the 
timely and effective recommendation to the Council of 
Ministers of substances needed to be added to the controlled 
substances Narcotic Drugs and Psychotropic Substances Law 
L 29/77.
Core functions and information flow
Once the information arrives at the NFP, the EWS officer 
reviews and translates the informational material 
accompanying the alert. The information is then 
disseminated to the N-EWS network which is comprised of 
the National Laboratory, the Drug Law Enforcement Unit 
(DLEU) of the Police, the Pharmaceutical Services of the 
Ministry of Health, the Cyprus Youth Board, the CAC and 
the National Mental Health Services of the Ministry of Health 
(MOH). The CAC developed an ad hoc committee aiming 
at studying and reviewing the Law L 29/77, thereby adding 
several new reported substances to its controlled lists.
(7) With the assistance of Mrs Maria Avxentiou (State General Laboratory) and Mr John Kkolos (National Pharmaceutical Services).
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Figure 5 — Information flow in the framework of the Cypriot 
EWS
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Each mentioned partner has a contact person assigned for: 
(1) further in-house dissemination of the information; and (2) 
reporting back to the NFP if related information is available 
locally. If this is the case, the information reported is fed 
back to the EMCDDA EWS.
Data collection, information exchange and drug  
monitoring 
The data collection and information exchange is mainly 
done through letters and e-mails, as well as EMCDDA 
reporting forms. Information deriving from general 
population surveys (GPS) or other surveys can also be 
reported, if available.
Timing/deadlines
EWS Final (annual) reports are submitted every January 
and EWS Progress reports every July.
Data appraisal and analysis
The Analysis of Drugs is done by the State General 
Laboratory of Cyprus. The main method used for the 
detection of drugs is Gas Chromatography with Mass 
Spectrometry (GC/MS). Several MS spectrum libraries 
(Willey, NIST, etc.) are used for the identification of drugs. 
A library from SWG ENFSI, with new designer drugs, is also 
available in the Lab. An in-house library has been built with 
the new drugs that are found in Cyprus. 
Risk assessment
The ad hoc committee on L 29/77 essentially operates as 
a risk assessment body at national level.
Case study
Mephedrone
Once the EWS disseminated the reports on mephedrone, 
the N-EWS promptly forwarded the information to its 
network as mentioned above. On 21 April 2010, the CAC’s 
ad hoc committee reviewed the information, and decided to 
prepare a decree suggesting the control of mephedrone and 
its derivatives. On 19 May 2010, the aforementioned 
committee presented the decree via the Ministry of Health, 
to the Ministerial Council. The Council approved the 
suggestion, and the decree for mephedrone’s control was 
published in the Republic of Cyprus government gazette on 
24 September. As of that date, mephedrone and its 
derivates are Class B controlled substances. The operation 
of the EWS information system gives local experts the 
opportunity to be aware of new substances identified on the 
continent, and to apply their expertise and knowledge to the 
particular situation in Cyprus. In the case of mephedrone, 
this collaboration resulted in the control of the substance 
even prior to its control at European level.
Strengths, limitations and way forward
Strengths 
Clearly the communication networked from other EU 
Member States is an advantage in alerting local experts 
to the new substances.
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Limitations
It would be a desirable improvement to include contact 
persons from NGO therapeutic and preventive centres for 
a fuller picture of novel uses of familiar substances and new 
substances traced within the drug users’ community. Further, 
it would be useful to include representatives of all hospital 
emergency units to the N-EWS so that when health-related 
alerts are reported, they are informed. The NFP requested 
the appointment of representatives, although there was no 
response.
Finally, the Cypriot NFP noted the need and proposed the 
development of a local EWS, which will be operating as 
a warning system, alerting all involved parties for the 
trafficking and use of new synthetic substances, as well as for 
the existence of dangerous substance mixtures sold 
locally.
Links and references
EWS progress report to the EMCDDA (2004), 9 July.
Meeting minutes of CAC ad hoc committee on the 29/77 
Law (2010), 21 April.
Meeting minutes of CAC ad hoc committee on the 29/77 
Law (2010), 20 September.
Meeting minutes of CAC ad hoc committee on the 29/77 
Law (2010), 26 October.
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Introduction
The Czech national focal point (the Czech NFP, the National 
Monitoring Centre for Drugs and Drug Addiction) cooperates 
with the EMCDDA within the early warning system (EWS) 
since 2002, when information exchange on new synthetic 
drugs started. Within the period 2003–04, several meetings 
with experts and representatives of the Czech key authorities, 
as well as consultations with the EMCDDA, took place.
As a result of this consultation and inception phase, the 
document named ‘System vcasneho varovani pred novymi 
drogami v Ceske republice’ (The early warning system for 
New Drugs in the Czech Republic) was adopted by the 
Council of the Government for Drug Policy Coordination on 
15 July 2005, providing an official and formal framework for 
inter-institutional and inter-departmental cooperation within 
the EWS in the Czech Republic. This framework document 
defines objectives, principles and rules of the EWS 
cooperation based on the Council Decision 2005/387/JHA 
of 10 May 2005 on information exchange, risk assessment 
and control of new psychoactive substances (Council 
Decision). The EWS coordination working group (the Czech 
EWS WG) was established and the Czech EWS 
correspondent to the EMCDDA was officially assigned.
The objectives of the Czech EWS are based on those defined 
by the Council Decision, although similarly to the EU EWS, 
they are not limited just to new synthetic drugs or new 
psychoactive substances. The Czech EWS is also responsible 
for monitoring newly emerging or re-emerging (potential) 
risks and harms related to drugs and drug use in general 
(such as dangerous adulterants of ‘traditional’ drugs, e.g. 
levamisole in cocaine, contamination of drugs with infectious 
diseases agents, e.g. Bacillus Anthracis in heroin, or the 
outbreak of drug overdoses). The Czech EWS WG 
gathers significant Czech experts and the representatives of 
key authorities and works under coordination of the Czech 
NFP.
Organisational issues
The Czech EWS working group and the institutions 
involved
The Czech EWS WG is an expert apolitical body, the 
chairman of the group is a Czech NFP employee. 
The frequency of the Czech EWS WG meetings is 
biannually. The minutes are done for each meeting and are 
published in limited form on the website of the Czech NFP 
(see below, Links and references section).
Members of the Czech EWS WG are representatives of key 
institutions and authorities. The composition and the roles of 
the members are as follows: 
•	 The Czech NFP — to coordinate the work of the Czech 
EWS WG, to collect, process and distribute the  
information coming from the EMCDDA’s level of the 
EWS, to conduct thematic surveys focused on the 
phenomenon of party drugs and new drugs, to initiate 
legislative and structural changes;
•	 The National Drug Headquarters of the Czech Police — 
to collect the law-enforcement data related to new drugs 
and emerging trends (e.g. monitoring the offer of ‘legal 
highs’, prosecution of trafficking related to new drugs, 
etc.);
•	 The Institute of Criminalistics Prague — to analyse the 
drugs seized by the police forces (mainly by the  
National Drug Headquarters) and by the General  
Directorate of Customs (the Customs Drug Unit), to  
implement research in this field, to identify new  
substances in the seized drugs;
•	 The General Directorate of Customs (the Customs Drug 
Unit) — to provide information on seized new drugs and 
trends in this regard; 
•	 Europol National Unit of the Czech Police — liaison  
office with the Europol headquarters;
•	 The State Institute for Drug Control (the Medicine  
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Control Authority) — to provide information on the  
legislative framework of medical drugs control and 
information from the pharmacovigilance system related 
to the EWS;
•	 The Inspectorate for Narcotic and Psychotropic  
Substances of the Ministry of Health — an authority  
responsible for legal control of narcotic and  
psychotropic substances and for the legislative  
framework in this regard (mainly Act No 167/1998 
Coll., on addictive substances);
•	 The General Directorate of the Prison Service — to 
provide information on new drugs and emerging trends 
among prisoners;
•	 The Institute of Forensic Medicine and Toxicology, 1st 
Faculty of Medicine, Charles University and General 
Teaching Hospital in Prague — to inform about results 
of toxicological analyses with respect to new drugs and 
emerging trends;
•	 The Department of Pharmacology, 3rd Faculty of  
Medicine, Charles University in Prague — to provide 
data resulting from analyses of new (party) drugs; the 
Czech EWS correspondent is an employee of this  
institution and is one of the main providers of  
informative and preventive website focusing on relevant 
information related to party drugs;
•	 The Prague Psychiatric Centre — monitoring the use of 
new (party) drugs and neurobiological research of new 
drugs;
•	 Non-governmental organisations (NGOs) — to monitor 
new drugs and emerging trends among drug users  
(e.g. ‘party goers’), including distributing information on 
risks of new drugs and emerging trends at the national 
level (an NGO named ‘Podane ruce’ provides a  
website focused on prevention and counselling in the 
field of party drugs). 
Communication with European partners
The Czech EWS correspondent and the Czech NFP  
(the chairman of the Czech EWS WG) are responsible for 
communication with the EMCDDA. Each year, the EWS 
Progress and Final Report is sent to the EMCDDA, as well as 
additional (ad-hoc) information on new drugs and emerging 
trends in the Czech Republic. Another institution responsible 
for communication with European partners is the Europol 
National Unit. Another formal or informal communication 
between members of the Czech EWS WG and European 
partners happens and is presented at the Czech EWS WG 
meetings.
Coverage of the Czech EWS 
In general, the Czech EWS operates at national level. 
However, if the data on risks related to new drugs and 
emerging trends come from a specific region, the Czech 
EWS concentrates mainly on this region in order to spread 
appropriate preventive information and to ensure suitable 
preventive measures (for example, an outbreak of heroin 
overdoses in Prague in 2009). 
Communication tools and main sources of  
information
The Czech EWS WG meets, at minimum, twice a year. 
E-mail communication is the standard way for information 
exchange. Each report coming from the EU-level of the EWS 
is sent to all working group members on a regular basis. 
The EWS national activity reports are, before their 
submission to the EMCDDA, communicated within all the 
members of the Czech EWS WG. 
The Police Institute of Criminalistics in Prague and The 
Department of Pharmacology, 3rd Faculty of Medicine, 
Charles University in Prague are the main sources of 
information on identification of new synthetic drugs in the 
Czech Republic in seized or collected samples.
The Institute of Forensic Medicine and Toxicology, 1st Faculty 
of Medicine, Charles University and General Teaching 
Hospital in Prague provide information on the substances 
identified in clinical samples, including new synthetic drugs 
(see also the Case study below). NGOs are providers of 
(rare) reports on health-damage incidents among drug users, 
including incidents related to new synthetic drugs.
Core functions and information flow
There are two ways of information flow:
(a) Information on incidence and prevalence of new drugs 
and emerging trends at the national level — information 
provided through telephone and e-mail by a member of the 
Czech WS WG or by another person (e.g. informed 
provider of some drug service), information on new drugs 
and emerging trends found out in media monitoring, etc. 
These data are consulted by phone or e-mail within the 
Czech EWS WG. This way, a relevance of such data is 
assessed (assessment phase) and the WG is informed. If the 
assessment indicates the need for further action, the bodies 
responsible for implementation and coordination of 
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drug-policy measures are informed, according to extent and 
nature of the incident. In cases of public-health concern, the 
most relevant warning mechanism is chosen (ranging from 
direct e-mail to drug treatment and counselling services 
possibly with a request for additional information to press 
release, disseminated to the mass media). 
(b) Information on incidence and prevalence of new drugs 
and emerging trends at the European level (information 
provided mainly by the EMCCDA). These data are 
distributed to the members of the Czech EWS WG via e-mail 
and the risk assessment with respect to the Czech Republic is 
conducted — in this respect, the feedback coming from the 
National Drug Headquarters, the Institute of Criminalistics 
Prague and NGOs is usually very important. If necessary, 
the most convenient instrument for distribution of appropriate 
information is selected.
Case study
In April 2004, severe intoxication of two individuals by 
2,5-dimethoxy-4-bromamphetamine (brolamphetamine 
or ‘DOB’) occurred in Prague, Czech Republic (Balikova, 
2005). Two men used white powder containing an unknown 
substance described as ‘a new hallucinogenic LSD-like drug’. 
They used it orally. Subsequently, they experienced a rapid 
onset of intense hallucinations (within 15 minutes) followed 
by vomiting and unconsciousness. After an unknown period 
of time, both men were admitted to the hospital in a 
comatose state. The first man (28 years old) survived but 
experienced serious convulsions, was restless and had to be 
treated with strong sedation; the second man (29 years old) 
was in a deep coma without response to pain, with attacks of 
generalised convulsions, and metabolic acidosis — he died 
after six days. The results of toxicological screening from the 
gastric, blood, and urine specimens collected in admission 
were negative. Only thanks to information from an NGO 
working in the dance scene gathered from users, the Czech 
NFP was warned about the possible use and adverse effect 
of a new synthetic drug. An emergency unit and then 
toxicological laboratory were immediately contacted, 
specimens were re-analysed and DOB identified.
Without institutions cooperating within the Czech EWS, DOB 
would not be identified. The press releases were issued in the 
next few days and information about possible risk of 
intoxication with DOB was spread through newspapers, 
radio and TV channels at the national level. Further cases of 
DOB intoxications within the same incident (outbreak) were 
not reported.
Strengths, limitations and way forward
Strengths
If necessary, an effective communication and information 
sharing among members of the Czech EWS WG is 
available.
Limitations
At present, the standard process of assessment of new 
substances with regard to their inclusion to the list of 
controlled narcotic and psychotropic substances is not 
defined. The Czech EWS and the Czech EWS WG supply 
this absent mechanism to a certain extent.
Another issue is an efficient dissemination of information on 
emerging trends and risks related to new drugs among drug 
services providers and implementation of appropriate 
measures into practise are not set up. 
Links and references
Balikova, M. (2005), ‘Non-fatal and fatal DOB 
(2,5-dimethoxy-4-bromamphetamine) overdose’, Forensic 
Science International 153, pp. 85–91.
Other sources: 
Official minutes coming from Czech EWS WG meetings 
(full version available only for members of Czech EWS WG 
meetings).
Standardised EWS reporting forms used for reporting to the 
EMCDDA.
The National Monitoring Centre for Drugs and Drug 
Addiction (the Czech national focal point). 
The website on which contacts of members of the Czech 
EWS WG and limited forms of minutes coming from Czech 
EWS WG meetings can be found here: http://www.drogy-
info.cz/index.php/o_nas/pracovni_skupiny/pracovni_skupi-
na_system_vcasneho_varovani_pred_novymi_drogami
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Introduction
In Denmark, monitoring of new drugs is included in the 
overall monitoring of the drugs problem in Denmark. The 
National Board of Health and the Danish police authorities 
(the National Commissioner) are jointly responsible for 
monitoring the emergence of new drugs and furthermore, 
the National Board of Health undertakes to assess the 
health-related consequences of the new drugs, including 
recommendations to the responsible minister that new drugs 
must be regulated on a current basis and banned. 
From 2000, the EWS stepped up its monitoring of new 
drugs emerging in Denmark. The objective was: (1) to 
comply with a national wish to qualify and improve 
monitoring mechanisms in order to meet and ‘capture’ an 
increasing supply of new drugs traded on the market; and 
(2) to implement Council Decision 2005/387/JHA on 
information exchange, risk assessment and control of new 
psychoactive substances. Earlier on in 1997, this was 
referred to as the Joint Action on New Synthetic Drugs. 
The intensification of the national monitoring and the 
intervention against new drugs, combined with new trends 
surfacing, resulted in the establishment of new monitoring 
systems in Denmark and a national forum/working group 
for information sharing and collaboration. Furthermore, the 
authorities of the Nordic countries have joined together in 
collaboration/network teams in order to exchange 
information on drugs and the associated legislation — a 
Nordic network in extension of the European EWS. This 
chapter provides an outline of the Danish monitoring system, 
its players and network, and the process involved from the 
emergence of new drugs and to a possible regulation and 
ban.
Organisational issues
The responsibility for monitoring new synthetic drugs is 
divided by the National Board of Health (which is also the 
focal point in relation to the EMCDDA) and the National 
Commission (who also refers to Europol). Also, it has been 
agreed that the Danish focal point has the coordinating task 
of ‘operating’ the national EWS network, the primary reason 
being that information sharing in relation to international 
collaboration is carried out under the auspices of the 
EMCDDA. The Danish focal point is thus responsible for the 
national coordination and therefore also responsible for 
recommending new drugs to be banned. 
Monitoring of new drugs in Denmark is a national task and 
is based on reports on drugs seized by all 12 police districts. 
Apart from the drug samples collected on a routine basis by 
the police and submitted for forensic analysis, a so-called 
Ecstasy EWS monitoring system has been established to 
identify new drugs. The project is a collaboration network 
headed by the National Commissioner, the National Board 
of Health and the three institutions of forensic chemistry. The 
basic concept is that all substances which look like illicit 
drugs — pills/tablets, powders and liquids, etc. are 
submitted by the police districts to one of the three institutes 
of forensic chemistry for analysis. 
The EWS network also consists of representatives from all 
the three institutes of forensic chemistry on the three Danish 
universities of Odense, Aarhus and in Copenhagen. The 
network also includes representatives from the Danish 
Medicines Agency, the Ministry of Justice, the Ministry for the 
Interior and Health and a number of medical professionals 
and experts. The expertise represented in the network vary 
a great deal and include pharmacists, forensic chemists, 
medico-legal forensic experts, assistant police prosecutors, 
sociologists, doctors and others holding university degrees. 
An actual estimate on EWS network time consumption on 
monitoring and information sharing has not been made. 
However, an estimate on costs has been made, and it shows 
that forensic analyses made under the Ecstasy and EWS 
monitoring system run into approximately EUR 33 525 (the 
equivalent of DKK 250 000) on an annual basis. This amount 
is paid by the National Commissioner and the National 
Board of Health. In 2009, a total of 43 055 pills and objects 
were examined. 
The purpose of the national EWS network is to inform each 
other immediately on the surfacing of new drugs detected 
nationally or internationally. Information on new drugs 
surfacing in other European countries and reported to the 
Danish EWS network is also used as an inspiration to be on 
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the outlook for such drugs on a national basis. Apart from 
using the network for information sharing and for 
collaboration on monitoring new drugs, the network is used 
during the hearing process on recommendations submitted on 
new drugs under bans consideration. 
In order to capture new trends and user patterns, so-called 
regional hearings were made for a number of years in 
Denmark in the previous 15 counties. These hearings were 
based on qualitative and ‘soft’ information provided by local 
stakeholders such as the School, Social authorities and 
Police (SSP), local police, medical officers, drug use 
therapists, etc. However, the information obtained during the 
process did not provide significant revelations and when the 
counties were abolished during the structural reform in 2007, 
the National Board of Health/the Danish focal point decided 
to stop the hearings. The instruments and channels making 
up a source of information today include information about 
possible new behavioural patterns and drug user groupings 
and include qualitative surveys as well as routine statistics 
— primarily drug-related deaths (DRD), general population 
surveys (GPS) and treatment demand indicator (TDI). 
Apart from the national EWS network, which is naturally 
linked to the European network of focal points in Europe, 
Denmark is part of the Nordic NADiS network (The Network 
for the Current Situation of Drugs in Nordic countries). This 
network includes countries such as Norway, Sweden, Finland 
and Denmark and Iceland and involves the sharing of 
information on new drugs and the associated legislation. 
Apart from the central Nordic authorities (the National Board 
of Health in Denmark), there are national Nordic NADiS 
networks. In Denmark, the NADiS network is more or less 
identical to the Danish EWS network. However, the Danish 
NADiS network has been expanded to include the national 
‘Giftlinje’ (the Poison Control Hotline) and the Danish customs 
and tax authorities. 
Core functions and information flow
The core of the monitoring and information on emerging 
drugs in Denmark is, as mentioned earlier, the chemical 
forensic analyses of the police routine drug samples and the 
analyses made in connection with the Ecstasy/early warning 
monitoring project. However, analyses made as a result of 
specific drug-related deaths or sporadic episodes resulting 
from poisonings treated in emergency rooms and hospitals 
in Denmark may also reveal information about emerging 
drugs. No other targeted monitoring projects and systematic 
reporting systems — for example, drug-user network groups 
or NGOs — have been established. As mentioned earlier, 
special regional hearings have been held without this, 
providing crucial knowledge about new trends. However, 
the media have from time to time played a role when 
covering stories on individuals involved. This has been 
useful information for the authorities and has shed a light on 
new drugs emerging or new behavioural patterns gaining 
ground. An example of this is dextromethorphan (DXM), 
a cough medicine which, after having been an over-the-
counter (OTC) medicine, was placed on the ban list when 
it was gleaned from stories in the media that young people 
were using DXM as a psychoactive substance. However, this 
is still the exception. Primarily, the EWS bases its conclusions 
on the forensic analyses of drugs seized by the police. 
All chemical forensic analyses resulting from the ecstasy/
EWS-monitoring system are compiled in a library database 
under the institutes of forensic chemistry and quarterly and 
annual reports are made and placed on the National Board 
of Health’s website (see below, Links and references 
section). These reports provide an outline of the new drugs 
and show the development over time in terms of ingredients 
and concentration.
When new drugs are found in the forensic analyses — and 
this happens regularly — the National Board of Health/
focal point is informed immediately. The information is also 
conveyed to the Danish EWS network and to the EMCDDA 
(by the focal point) and to Europol (by the National 
Commissioner). Following this, it is up to the National Board 
of Health to assess the need for a risk assessment procedure 
and to decide whether or not to recommend that the drug be 
banned nationally.
With regards to the banning of drugs, The National Board of 
Health plays a special role in submitting new drugs for legal 
regulation. The National Board of Health’s role has been laid 
down in Section 1 and 2 of the Act on Psychoactive 
Substances, after which the minister for the Interior and 
Health shall be authorised to determine that drugs posing a 
particular risk (§1)/risk (§2) as a result of their psychoactive 
qualities as laid down by international resolutions or as set 
out by the National Board of Health shall not exist in 
Denmark (§1)/shall only be used for medical or scientific 
purposes (§2).
Thus, the ban of new drugs can either be made according to 
international resolutions — either under the auspices of the 
UN or the EU — or according to recommendations 
submitted by the National Board of Health. During recent 
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Figure 6 — Information flow in the framework of the Danish EWS
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years, the latter approach has prevailed, as it has been 
possible to regulate on a speedy basis, and since an 
international risk assessment has not been imminent. There 
is a staff ‘overlap’ when it comes to carrying out risk 
assessments within the National Board of Health and the 
focal point coordination of the national EWS network.
The national risk assessment of new drugs includes their 
hazardous potential — particularly in relation to risk of 
poisoning and psychosis (which may lead to accidents 
and violence). Another element of risk assessment involves 
dependency potential, prevalence and legislation in other 
countries. Also, factors such as the framework or practical 
problems (disadvantages) associated with a ban are 
assessed. As documentation on injuries and risk is often 
sparse in relation to emerging drugs, the basis for the risk 
assessment is often the similarity of the new drugs with 
drugs already known and provided for in the regulation. 
Information provided both via the international collaboration 
between the EMCDDA and the Nordic NADiS is crucial to 
the national risk assessment. Another vital source is Internet 
searches on user sites. The final recommendation is sent via a 
hearing to the national EWS network.
The period from the new drug is identified via forensic 
analyses and until the drug has been subjected to risk 
assessment and finally listed in the executive order 
concerning the Act on Psychoactive Substances varies and 
may take from a total of 14 days to a few months. This 
relative ‘speed’ has meant that Denmark only very rarely 
awaits the European risk assessments when it comes to 
regulation of these new drugs. 
The central health authorities in Denmark rarely issue actual 
‘warnings’ on new drugs or particularly ‘hazardous’ drugs 
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on the market. However, when new drugs are regulated, the 
news of this is often issued very broadly and often the newly 
regulated drugs are described in press release material. 
Furthermore, the local police will issue letters of notification 
to users when particularly hazardous (and strong) drugs are 
being sold on the market.
Case study
Synthetic cannabinoids
There are many examples of the Danish EWS network in 
operation. The network operates on a daily basis and its 
work involves reporting, clarifications and communication of 
new drugs emerging nationally and internationally. Recently, 
the focus on synthetic cannabinoids has intensified, and the 
Danish EWS has taken action. Only a few of the synthetic 
cannabinoids have been observed on the Danish market 
so far, but a much higher number of synthetic cannabinoids 
have, however, been regulated in Denmark. 
Immediately after the first reports had been issued on 
synthetic drugs emerging in Europe in 2008, the Danish 
EWS network was informed. The feedback from the EWS 
network was that the cannabinoids had not yet reached the 
Danish market — nor had ‘Spice’ products. In addition to the 
information and questions asked immediately after the first 
European reports were issued, the National Board of Health 
sent out information in February 2009 and a request for 
information on the use of cannabinoids and ‘Spice’ products 
to all the schools under the SSP (School, Social authorities 
and Police) collaboration network. Once again, this request 
did not give any information that ‘Spice’ or cannabinoids 
had yet been observed or found to be used. Following this, 
reports were received from the other EU countries via the 
EMCDDA on the surfacing of synthetic cannabinoids. 
However, not until in March 2009 was the fist Danish 
seizure of cannabinoids (JWH-073) reported from an 
institute of forensic chemistry in Denmark. The information 
on JWH-073 in Denmark was immediately conveyed to the 
Danish network and informed to the EMCDDA as well as to 
the NADiS network. Since then, several cannabinoids have 
surfaced in Denmark and twice, the National Board of Health 
has recommended the prohibition of synthetic cannabinoids, 
following which the drugs have been regulated under the 
Danish drugs legislation.
As far as the cannabinoids are concerned, in Denmark 
reports on the current cannabinoids are regularly ‘compiled’ 
instead of recommending and regulating the cannabinoids 
one by one as they turned up. This means that a number of 
cannabinoids are already prohibited before they are 
observed on the Danish market. So far, Denmark has 
regulated a total of 32 synthetic cannabinoids in two rounds, 
where these cannabinoids have already been observed in 
one or several of the other member countries. Only five of the 
cannabinoids have been seen in Denmark so far.
Thanks to the European EWS, the Nordic NADiS and the 
Danish EWS network and to a speedy and flexible 
information-sharing process on the drugs — as well as the 
availability of the (however relatively sparse) documentation 
and knowledge to all relevant players — it has been 
possible to act relatively quickly on the prevalence of 
synthetic cannabinoids in Denmark. 
Strengths, limitations and the way forward
The Danish EWS is a quick and effective system for the 
monitoring of new drugs. This is probably attributable to a 
long tradition of cooperation across the participating 
players/institutions on drug analyses, coupled with the fact 
that the network’s tasks are well suited for the players’ 
professional work and fields of interest.
As mentioned earlier, no systematic reporting procedures 
are implemented in emergency rooms and hospitals under 
the EWS network. The information on injuries such as 
poisonings resulting from drugs is thus brought to the
attention of the system more sporadically and often stem 
from stories in the media. In the future, it can be considered 
whether more systematic reporting procedures could be 
useful in relation to a qualification of EWS in Denmark. 
Links and references
Danish Medicines Agency — http://lms-lw.lovportaler.dk/
ShowDoc.aspx?docId=bek20080749-b1
Danish National Board of Health — http://www.sst.dk
Danish National Board of Health, content of illicit drugs — 
http://www.sst.dk/Sundhed%20og%20forebyggelse/Narko-
tika/Indhold%20i%20illegale%20stoffer.aspx
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Introduction
The development of the early warning system (EWS) on 
new synthetic drugs in Estonia began in 2002. On 16 April 
2002, the Minister of Social Affairs at that time officially 
appointed an employee at the Estonian Drug Monitoring 
Centre of the Institute of Experimental and Clinical Medicine, 
as the correspondent of the Joint Action on New Synthetic 
Drugs (JANSAD) in Estonia. This title would mean acting as a 
national contact person in everything related to the EWS, as 
well as a liaison officer at both international and local level. 
The first step in developing the EWS was mapping potential 
cooperators and sources of information, as well as 
introducing the system. The first ascertained potential sources 
of information in 2002 were the State Agency of Medicines, 
Tallinn Emergency Medical Service, the Forensic Service 
Centre, the Estonian Bureau of Forensic Medicine, the 
Border Guard, the Police Board and Customs Board. 
The first introduction of the EWS took place at the Drugs 
Committee under the Estonian Ministry of the Interior. 
This advisory committee had been meeting since 2000 
(established on the basis of Directive No 142 of the Minister 
of the Interior of 28 March 2000) and included 
representatives of the Police Board, Criminal Police, Border 
Guard, Customs Board, Prosecutor’s Office, State Agency of 
Medicines, Ministry of Justice and Ministry of Social Affairs. 
A representative of the Estonian Drug Monitoring Centre 
under the area of administration of the Ministry of Social 
Affairs also participated in the committee’s work.
The initial attitude of different agencies on the necessity of 
the EWS was somewhat limited as it was seen only to exist 
to achieve the objectives of an EU agency. Notwithstanding 
that from the very beginning, the potential local needs were 
included in the EWS — in addition to the needs of the EU 
— in order to motivate the local cooperators. The first local 
need considered was a Rapid Exchange System for a fast 
exchange, which would serve public-health purposes and 
inform relevant agencies and service providers dealing with 
drug users immediately of the appearance of a new 
psychoactive substance on the Estonian drug market. As an 
ideal, this kind of rapid exchange of information would have 
contributed to the prevention of overdoses and improved the 
reaction of other agencies to new narcotic substances. 
However, the lack of necessary legislation which would 
have provided a legal basis for rapid information exchange 
of an often confidential nature between different institutions 
became a hindrance to the development of this kind of local 
information exchange. Initially, a suitable basis for exchange 
of information was being sought by the compilation of a 
Memorandum of Understanding. 
Although this document was prepared with the help of a 
foreign expert, it was found at the moment of signing that 
there should be relevant legislation to supervise the exchange 
of information. Since 2003, the Narcotic Drugs and 
Psychotropic Substances Act was being amended, it was 
decided to try to include the EWS into the amendments. It 
was agreed with the Ministry of Social Affairs that the act 
would be supplemented with the following sentences to cover 
the field of the Estonian Drug Monitoring Centre: 
•	 the Estonian Drug Monitoring Centre (hereinafter  
referred to as ‘EDMC’)’, which operates under the  
National Institute for Health Development, shall occupy 
itself with collecting and analysing existing  
epidemiological and statistical data on the situation 
related to drugs and evaluating the spread of drug  
addiction.
•	 In the framework of the cooperation project ‘Joint Action 
on New Synthetic Drugs’ (JANSAD) of the EMCDDA and 
Europol, the EDMC shall be informed immediately about 
the appearance of any new synthetic drug in Estonia.
•	 In the framework of the JANSAD cooperation project, 
the EDMC shall have the obligation of forwarding the 
information related to new synthetic substances to the 
EMCDDA.
As can be seen from the draft clauses above, the initial 
intention was to separately bring out the EWS. However, the 
act was not passed in this wording in 2005, and it only gave 
the EDMC a role of collecting and analysing data on drug 
addiction in Estonia. The approved role of the EDMC as the 
collector of data regarding drug addiction was presented as 
the reason for omitting the EWS from the act, as it was found 
that there was no reason to include such single projects in 
the act. However, according to the passed act, agencies had 
an obligation to respond to the information inquiries of the 
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EDMC, but not to show initiative by immediately forwarding 
the received relevant information to the EDMC. Also, the act 
did not govern exchange of information between institutions 
in the way that would ensure retaining the confidentiality of 
the information. Since the necessary legislation was not 
established, the EWS worked for years and, at the time of 
writing this chapter, is still working — to a certain degree — 
at local level as a project of so-called passive exchange of 
information. In 2009, Estonian cooperations became 
interested again in developing the EWS at local level. 
Partly, it was due to the increasing number of narcotic 
substances on the Estonian market which had not been 
added to the lists of Estonian narcotic and psychotropic 
substances (‘legal highs’), and on the other hand, Estonia 
already had experience with the fentanyl analogues which 
appeared on the Estonian drug market at the beginning of 
the 2000s, causing a number of overdose waves. 
Thanks to the rapid changes in the drug market, the 
cooperation between the Police and the Border Guard 
Board, the Ministry of Social Affairs, the State Agency of 
Medicines, the Estonian Tax and Customs Board and the 
Estonian Drug Monitoring Centre has become closer and 
more active during the last two years. Several meetings have 
taken place between different parties with the aim of 
developing the EWS system at local level, as well as getting 
new narcotic substances under control in a timely manner.
This exchange of information concerning new narcotic 
substances between institutions, with the aim of adding 
such substances to the list of narcotic and psychotropic 
substances as soon as possible, is one of the advantages 
of the local EWS. For collecting background information on 
new narcotic substances, the local EWS network has also 
successfully introduced the EMCDDA database EDND (the 
European database on new drugs). In order to facilitate the 
exchange of information, a relevant legislative base will be 
prepared by the Ministry of Social Affairs at the beginning of 
2012; this legislative base will govern the exchange of 
confidential data between agencies — something that has 
been borne in mind for years. It has been agreed that the 
extranet attached to the website of the National Institute for 
Health Development is the environment through which the 
data is exchanged; experts can enter the extranet using a 
password, and exchange information about new narcotic 
substances and consequences thereof. Hopefully, after the 
legislative base is available for data exchange, information 
on new narcotic substances will be added from the health 
care sector, as well. At the moment, neither Tallinn 
Emergency Medical Service nor services of other regions are 
active members of the EWS.
In summary, development of the EWS has been in progress 
for nearly 10 years. A common web environment for the 
EWS information exchange was created in 2011 and 
legislation is expected at the beginning of 2012. It was 
mostly the local need for a quick reaction and control over 
the new, potentially harmful narcotic and psychotropic 
substances to public health that motivated the development of 
the system.
Organisational issues
The EWS is a nationwide information system. Currently, the 
local EWS is functioning via e-mail correspondence between 
the partners and meetings. As already mentioned in the 
previous section, after establishing the legislation and with 
the use of a new web environment that enables the exchange 
of information, it will become possible to exchange 
information between the EWS partners in a more operational 
manner. However, before establishing the relevant 
legislation, the EWS is more like a passive system for 
distributing information. Most of the EWS’ data movements 
are forwarding the information received by the Estonian Drug 
Monitoring Centre from the EMCDDA to the local information 
network. A majority of the information gathered within the 
framework of the EWS has been collected through the data 
inquiries made by the EDMC. The problem is that the current 
system actually reduces other institutions’ initiative in 
distributing information their agencies have received. 
Gathering all of the information into one system, as well as 
the initiative of different institutions to share information, are 
the most positive features of the new system.
Currently, the EWS has the following local cooperators: 
•	 State Agency of Medicines — according to the statutes 
of the State Agency of Medicines (RTL, 2005), its  
obligations include identifying substances or medicines 
as narcotic or psychotropic substances and  
participating in the preparation of legislation and  
explanatory reports regarding narcotic and  
psychotropic substances and precursors, as well as  
performing supervision over handling narcotic and  
psychotropic substances for medical and scientific  
purposes and issuing relevant permissions,  
supervision and reporting in respect of narcotic and  
psychotropic substances and precursors. The State 
Agency of Medicines belonging to the field of  
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administration of the Ministry of Social Affairs has the 
essential role in taking control over new narcotic  
substances.
•	 Emergency Medical Services — emergency calls for the 
overdoses related to narcotic and psychotropic  
substances. Estonia is lacking a common nationwide 
emergency medical services statistical system. Each  
regional emergency medical service has its own  
separate statistics for emergency calls. 
•	 Estonian Forensic Science Institute (EFSI) was founded 
in 2008 as the result of the merger of two agencies, the 
Estonian Bureau of Forensic Medicine and the  
Forensic Service Centre, and is the legal successor of 
these institutions. EFSI performs forensic researches,  
technical investigations, participates in investigative 
actions and performs forensic medical examinations, 
forensic chemical and forensic biological examinations. 
In summary, all forfeited narcotic and psychotropic  
substances are identified in EFSI, as well as all  
identifications of drug-related deaths and detections of 
narcotic substances in the body of the casualty. 
•	 Police and Border Guard Board commenced working on 
1 January 2010 as the result of the merger of the two 
agencies, the Police Board and the Border Guard Board. 
As a source of information in the field of drug  
addiction, its major role is to provide initial information 
about confiscations of narcotic substances on the border 
and information obtained by surveillance.
•	 Estonian Tax and Customs Board has been operating 
since 2004 and is the legal successor of the Tax Board 
and the Customs Board. As a source of information in 
the field of drug addiction, it provides information in the 
field of detecting crimes related to narcotic substances in 
the economic environment. 
Core functions and information flow
In the Estonian EWS information system, the Estonian Drug 
Monitoring Centre (EDMC) has a central role and position. 
EDMC is the only one who communicates with the EMCDDA 
and forwards information from the EMCDDA to the local 
network of information. On the Figure 7, the arrows with 
two ends indicate the institutions with which the EMCDDA 
exchanges information. Although the initiative of EWS’s  
partners to exchange information is limited for several  
reasons as already mentioned, information about narcotic 
substances moves without any particular problems when 
needed. In the future, when the EWS has its own legislative 
basis, better cooperation with the health-care sector is 
expected and if possible, also with the harm-reduction 
services. At the moment, components such as information 
from the users and information about the health 
consequences related to the use of drugs are insufficient. 
Figure 7 — Information flow in the framework of the Estonian EWS
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In Estonia, the harm-reduction services cannot be taken for 
a fully-fledged partner of the EWS with whom to share all of 
the information available in the system; it should rather be 
developed as a source of additional information and a 
necessary channel of information with an aim to reduce the 
risk behaviour of drug users.
Case study
The fentanyl situation is described under the case-study 
paragraph because it was the first substance that raised the 
importance of the development of the local EWS. As the 
fentanyl appearance determined the wide-scale overdoses 
wave, the rapid information exchange between the relevant 
institutions was crucial. When China White and White 
Persian appeared on the drug market, the Estonian Drug 
Monitoring Centre, Estonian Forensic Institute, Police Board 
along with services providing harm-reduction services, 
collected and exchanged the relevant information on the 
fentanyl situation. The appearance of fentanyl in Estonia was 
related to the shortage of heroin caused by the Afghanistan 
war period in 2001. Heroin was available only in small 
quantities with a high price and low purity level. Estonian 
opiate users began to find a  substitute for their daily drug 
and used fentanyl as a replacement. Fentanyl has been 
widely on the Estonia market since 2002. When fentanyl first 
appeared, it was sold and used as heroin to IDUs. 
As fentanyl potency is much higher than that of heroin, the 
use of it created an overdose wave. According to Tallinn 
Medical Service, there were 401 drug-related overdose 
cases in 2001 and 971 in 2002. Between 1999 and 2010, 
there have been a total of 825 drug overdose related death 
cases, and 89 % of them have been males (a total of 736 
cases). The average age of deceased individuals who died 
as a consequence of an accidental drug poisoning was 29 
years and, according to the Estonian Forensic Science 
Institute, most of them are related to the use of fentanyl. 
The fentanyl prevalent in Estonia is illicit fentanyl produced in 
clandestine laboratories, known by its street name as China 
White and 3-methylfentanyl known as White Persian. 
Fentanyl mainly originates from the Saint Petersburg region. 
Based on the IDUs risk behaviour and infectious diseases 
prevalence studies in the time period 2005−10, the fentanyl 
used as a main injected drug in the last four weeks varied 
from 13−64 % among IDUs in different Estonian towns.
Strengths, limitations and way forward
The strength of developing the EWS in Estonia is definitely 
the smallness of the country, where the statistics of an entire 
country are gathered, in most cases, into one central national 
institution. Also, before establishing the necessary legislative 
basis for exchanging information, the essential factor of fluent 
information flow in the framework of the EWS is close 
cooperation amongst the experts involved and good 
professional relationships. As already mentioned, the further 
development of the EWS is related to the establishment of 
the legislative basis for exchanging information, as well as 
developing the necessary online environment for experts. 
The new online environment enables the experts to exchange 
information in an interactive forum in a prompt manner and 
send rapid information requests to their collaborators. After 
establishing the new online environment, there is no need 
anymore for e-mailing the partners upon any new 
information received from the EMCDDA.
Links and references
The statutes of the State Agency of Medicines (2005), RTL 
105, pp. 1606. Available at: 
https://www.riigiteataja.ee/akt/948276
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Introduction
In Finland, there is a strong tradition of inter-agency 
cooperation. The N-EWS in Finland is built upon this tradition 
of both formal and informal cooperation, but the system is 
currently under transition to better face the new challenges 
posed by the new psychoactive substances.
Organisational issues
The home of the N-EWS has been with the focal point in the 
National Institute for Health and Welfare (THL). The EWS 
network consists of the Poison Information Centre, Finnish 
Customs Laboratory, Finnish Customs, National Bureau of 
Investigation, Forensic Laboratory, Finnish Medicines Agency 
(Fimea) and the Department of Forensic Medicine at the 
University of Helsinki. 
Originally, the EWS network was formed to meet the 
demands of the EMCDDA’s EWS-cooperation. It has been 
working on a relatively loose basis, mainly functioning via 
e-mail. 
Starting from spring 2011 onwards, the duties are shared 
with the Finnish Medicines Agency (Fimea). This is due to a 
change to the Narcotics Act, which has enabled a national 
classification of new narcotic substances from 1 June 2011 
onwards. Fimea is the leading agency in this process. It is 
stipulated in the 2011 legislation that only such emerging 
psychoactive substances which have been reported to the 
European early warning system can be classified nationally 
as narcotic drugs. However, this premise is not applicable to 
active pharmaceutical ingredients which may also now be 
nationally classified as narcotics. From 2011, the N-EWS 
serves also as an elemental part in the national classification 
efforts and will therefore be more formal by nature. 
To prepare a legislative proposal and looking ahead to the 
foreseen changes, the key persons and agencies have met 
almost monthly. The collaboration has continued to be 
frequent in 2011, although lately in the inter-agency 
cooperation the main tool of communication is e-mail. 
The EDND database and the Nordic NADIS database (see 
Chapter on the Danish early warning system) are also widely 
used by the experts of different fields in different agencies. 
The communication language within N-EWS is in Finnish, yet 
material originally in English (or in Swedish) is forwarded as 
such.
Core functions and information flow
Prior to 2011, the N-EWS has functioned mainly as an 
information exchanging tool. The information about new 
substances emerging in Europe has been distributed 
nationally to the national network. Since Finland has been 
very active in reporting new substances for the first time in 
the European level, the information exchange has been well 
motivated. 
The N-EWS has been organised by the EMCDDA focal point 
until early 2011. It is planned that Fimea will take a more 
active role from 2011 onwards after the legislative changes 
and also of new personnel. 
Much information provided through the N-EWS is 
nevertheless provided by the law enforcement agencies 
(the Finnish Customs, the National Bureau of Investigation 
(NBI) and the National Police Board) and their forensic 
laboratories. Other laboratories in the network include the 
forensic laboratory of the Department of Forensic Medicine 
in the Hjelt Institute, part of the University of Helsinki and the 
laboratory with the National Institute for Health and Welfare 
(THL). 
Other partners in the N-EWS network but also on the 
foreseen national classification effort include the Poison 
Information Centre and the national drug policy 
coordination. The social aspects are looked after from the 
National Institute for Health and Welfare (THL).
Case study
MDPV 
In 24 November 2008, Finnish Customs seized 2 x 1 g of 
MDPV from an incoming post and the new substance was 
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reported to the EWS in November 2008. The substance 
was simultaneously emerging for the first time in the UK, 
Sweden and Denmark. The Finnish Customs asked Fimea if 
the new substance in hand was a medicinal substance and 
the Agency classified MDPV as a medicinal product on 20 
January 2009. 
MDPV gained some popularity among drug users and 
received attention in the mainstream media. The first efforts to 
gain comprehensive knowledge on the substance were made 
during summer/autumn 2009. The N-EWS provided a good 
platform for finding laboratory-based information. 
Nevertheless, as it was established that MDPV was in fact 
circulated to a great extent, it became more important for the 
outreach workers, the health-care personnel and the law 
enforcement to learn more about the substance itself and 
about its properties. Gaining reliable knowledge on the 
substance was difficult and it took almost a year before a 
fact sheet about MDPV was published by the focal point. 
By summer 2010, the politicians were also taken by the 
MDPV phenomenon and the substance was controlled as 
a narcotic drug on 28 June 2010.
The lessons learned from the MDPV phenomenon were that 
the N-EWS was geared for formal cooperation of relatively 
rare substances. The reliable information on substances is 
hard to find even within the established cooperation and the 
spheres of communication have to be enlarged in case of 
exceptional substance and prevalence. The new legislation 
and national classification aims to prevent such a 
phenomenon but also to include more medical knowledge in 
the network and a clearer link to the other non-governmental 
forums. 
Strengths, limitations and way forward
The strength of the Finnish N-EWS will in the future be the 
inter-agency trust and mostly straightforward and low-
bureaucracy cooperation within the network. In the future, 
one of the main functions of the N-EWS will not only be the 
collection of data but also sharing this information more 
efficiently not only to the monitoring and law enforcement 
personnel but also to treatment facilities, health-care 
personnel — and possibly also to the public. The problems 
posed by the nature and increasing number of new 
psychoactive substances will nevertheless be best addressed 
through European cooperation, rather than national solutions 
only.
Links and references
Department of Forensic Medicine at the University of Helsinki 
— http://olo.hjelt.helsinki.fi/english/index_english.htm
Finnish Customs — http://www.tulli.fi/fi
Finnish Customs Laboratory — http://www.tulli.fi/en/finn-
ish_customs/about_us/customs_laboratory/index.jsp
Finnish Medicines Agency (Fimea) — http://www.fimea.fi
Forensic Laboratory — 
http://www.enfsi.eu/page.php?uid=166
National Bureau of Investigation — http://www.poliisi.fi/
poliisi/krp/home.nsf/pages/5A23874F6668B910C22570
2F0023A86E?Opendocument
Poison Information Centre — http://www.hus.fi/default.
asp?path=59,403,19336,9739,9541
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Introduction
The French early warning system (EWS) was created in 1999 
within the context of the French national focal point (OFDT: 
Observatoire français des drogues et des toxicomanies — 
French Monitoring Centre for Drugs and Drug Addiction) at 
a time when the French public authorities were concerned 
about the arrival of new substances in France as a result of 
the growing popularity of the ‘techno’ movement. Focusing 
on the identification of emerging phenomena linked to drugs, 
it very quickly began to draw on a network of local partners 
before setting up a network of monitoring centres in 2001 
covering the major cities in France. This network appeared 
to be necessary in order to be close to conditions in the field 
and drug users while at the same time ensuring the use of 
reliable information collection methods common to all sites. 
The system, focusing on identification of products in 
circulation and real-time transmission of information (SINTES, 
Système d’identification national des toxiques et substances 
— National detection system of drugs and toxic substances) 
is backed up by a surveillance system (TREND, Tendances 
récentes et nouvelles drogues — Recent trends and new 
drugs) for more in-depth observation of uses (description of 
users, substances used, practices, representations and, 
insofar as possible, consequences) in populations with a 
high prevalence of use; in addition, local markets and 
micro-trafficking (availability, accessibility, price, substances 
in circulation).
In 2006, the scope of the surveillance activities of the SINTES 
system, which had previously concerned only synthetic 
substances, was extended to include all illicit drugs. The zone 
monitored was also extended to include every region of the 
country. At the same time, the SINTES system was divided 
into two parts: an ‘observation’ part and a ‘monitoring’ part, 
based on two different collection approaches.
The system as a whole enables the OFDT to provide an 
innovative and reliable overview of populations that are 
generally difficult to access, as well as the substances in 
circulation, by getting as close as possible to users.
Organisational issues
The main objective of the French EWS is to provide the 
general public and the state authorities with reliable, real-
time information on new trends concerning the composition 
of drugs and their uses. The system was validated in its 
current state of operation at an interministerial meeting on 
1 February 2006. It is therefore in line with the decision of 
the Council of the European Union of 10 May 2005 on the 
information exchange, risk assessment and control of new 
psychoactive substances. 
Collection of information and products 
The core of the French EWS information system is based on 
seven sites located in seven cities (Bordeaux, Lille, Marseille, 
Metz, Paris, Rennes and Toulouse). Each of these sites has 
a local coordinator responsible for leading ethnographic 
observers collecting continuous information on uses and 
substances in circulation. Local coordinators are generally 
health and welfare professionals — several are sociologists, 
one is a pharmacist and another, a youth worker — 
working within a healthcare and/or health information 
structure receiving drug users and with a ‘historic’ presence 
in the region.
This system conducts the annual ‘observational’ surveys of the 
SINTES system. These provide information on the 
composition of a substance in circulation on the basis of 
simultaneous collection of a drug sample (for laboratory 
analysis) and a questionnaire from drug users. They 
supplement data resulting from seizures by providing a 
snapshot of the composition of substances used or ready to 
be used. The most recent observational survey conducted 
in 2011 deals with heroin. It involves 108 collectors at the 
seven different sites. The number of collections is estimated to 
be 400.
Collectors carry cards bearing their names and authorising 
them to collect in accordance with the scheduled procedure 
(collection kits are specific and numbered). These cards also 
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mention the telephone number of the responsible coordinator 
and the address of a website giving access to all the official 
documents authorising the system and the list of people 
authorised to collect without a specific project order.
Observation concerning illicit products is extended to other 
healthcare structures or professionals. They are encouraged 
to consult the national EWS in order to have a product that 
is novel in terms of its nature or one having caused unusual 
adverse effects in a user among their patients analysed or 
transmit an alert via the network.
This extended system represents the surveillance component 
of the SINTES system. It is part of a health-focused approach 
in that it enables quantitative analysis of substances that 
might represent a particular risk or that are novel in nature 
and/or the transmission of alerts concerning the same 
phenomena.
In particular, it is used to analyse new synthetic substances 
and substances suspected to be the source of overdose (OD) 
among one or more users. In 2009, the notion of ‘active 
surveillance’ was introduced, allowing the OFDT to have a 
substance actively investigated (for example, heroin in the 
event of the occurrence of several overdoses).
As part of this component, the person needing to make the 
collection must contact his local coordinating site if his zone 
is covered by part of the network or the national coordination 
system. If the collection is authorised, the person is supplied 
with a specific project order in his name by e-mail or fax in 
real time, authorising him to collect and store the product. 
He then receives a collection kit by post, along with the 
original of the project order.
All the products collected are transported to laboratories 
contracted by the national EWS for analysis.
Rapid exchange of information
The French EWS also helps ensure the rapid exchange of 
information between several external sources. 
•	 Drug user reception and care structures. All the structures 
in France are linked to the NFP, which conducts annual 
national activity and assessment surveys.
•	 Data supplied by law-enforcement service seizures. The 
French EWS has signed partnership agreements with 
scientific laboratories dependent on the Customs  
Department (SCL), the police (INPS) and the National 
Gendarmerie. These agreements commit both parties to 
share information concerning the composition of drugs 
and specific events (specific cutting agent, high purity, 
newly identified substance). 
•	 Healthcare institutions. The French EWS is a major 
player in terms of transmission of alerts relative to 
psychoactive substances to the Cellule nationale d’alerte 
(CNA — National Alert Unit) for psychoactive  
substances. This unit is composed of the national EWS, 
the Narcotics Department of AFSSAPS (Agence française 
de sécurité sanitaire et des produits de santé, French 
Health Products Safety Agency), the Ministry of Health 
and the Department of Infectious Diseases of the InVS  
(Institut national de veille sanitaire, French National 
Health Monitoring Institute). The CNA’s role is to  
assess, investigate and propose a healthcare response 
to any specific alerts linked to drug use that represent 
an immediate potential risk to public health. A regularly 
reviewed procedure determines the role of each party, 
the methods of information sharing within the unit and 
with the networks of each party and the decision-making 
methods. It also considers the various potential actions 
that can be implemented.
The role of the TREND system: contextual information 
The OFDT monitoring system is a major transmitter of alert 
signals. It also provides feedback of grassroots information 
and draws a picture of drug use practices constantly  
updated, year on year. It therefore enables rapid evaluation 
of a signal (plausibility, unusual nature, cross-checking of 
information, etc.) and also enables sorting out of the 
numerous signals received. The TREND observer network 
can also be used to launch rapid investigations to shed light 
on an alert signal.
Publications aimed at partners (feedback)
The provision of feedback to the players involved 
representing the core of the SINTES system and its partners 
can take several forms:
•	 SINTES information notes (online, freely accessible) — 
see Links and references section for more information; 
•	 SINTES information bulletins (every four months —  
online, access limited to partners);
•	 SINTES observational survey report; 
•	 e-mails; 
•	 TREND annual report (qualitative observations on the 
basis of regional reports produced by each TREND site); 
•	 updating of the www.ofdt.fr website.
In addition, the person supplying information or  
collecting a substance is systematically kept informed of the 
outcome of this alert or the results of sample analysis.
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Figure 8 — Bodies involved in the monitoring of psychoactive substances
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Notes: 
AFSSAPS: Agence française de sécurité sanitaire des produits de santé (French Agency for the Safety and Healthcare Products)
CAARUD: Centre d’accueil et d’accompagnement à la réduction des risques des usagers de drogues (Reception and Support Centre to Reduce Risks Among Drug 
Users)
CEIP: Centre d’évaluation et d’information sur les pharmacodépendances (Centre for Drug Addiction Evaluation and Information)
CSAPA: Centre de soins d’accompagnement et de prévention en addictologie (Centre for Supportive Care and Prevention of Addictions)
DGS: Direction générale de la santé (Government Department Health)
EMCDDA: European Monitoring Centre for Drugs and Drug Addiction (=OEDT)
EWS: early warning system – European network for information on new phenomena linked to drugs. The EWS is coordinated by the EMCDDA, which is responsi-
ble for circulating the information among the 27 Member States of the European Union. The French representative of the EWS is the SINTES system.
INPS: Lyon Institut national de police scientifique  (Lyon National Forensic Police Institute) (incorporating all forensic police laboratories)
InVS: Institut national de veille Sanitaire (French National Health Monitoring Institute)
IRCGN: Institut de recherche criminelle de la gendarmerie nationale (National Gendarmerie Institute for Criminal Research)
LPS: Laboratoire de police scientifique (Forensic police laboratory)
MILDT: Mission interministérielle de lutte contre la drogue et la toxicomanie (Interministerial mission to control drugs and drug addictions)
OFDT: Observatoire français des Drogues et des Toxicomanies (French Monitoring Centre for Drugs and Drug Addiction)
OEDT: Observatoire européen des drogues et des toxicomanies (=EMCDDA)
OCRTIS: Office central pour la répression du traffic illicite des stupéfiants (Central Office for the Control of Illicit Drug Trafficking)
SINTES: Système d’identification national des substances et toxiques (National system for the identification of substances and intoxicants (OFDT)
SCL: Service commun des laboratoires (Joint laboratory service) (Customs Department laboratories)
TREND: Tendances récentes et nouvelles drogues (Recent trends and new drugs) (OFDT).
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Case study
Heroin overdoses
Between December 2007 and May 2008, 17 death cases 
linked to heroin use were recorded in the Metz area (eastern 
France). The health authorities at first suspected a batch of 
high-purity level heroin. But the different samples collected by 
the SINTES network along this time frame show no increase 
in the purity of the available heroin. The users interrogated 
by the TREND device also declared that they hadn’t heard 
about high-purity heroin available in the area.
In June 2008, the OFDT and the local TREND/SINTES 
coordination investigated different health actors 
(low-threshold structures, toxicological laboratories etc.). 
This investigation concluded that a new type of consumption 
was being faced, rather that a simple purity issue:
•	 the victims were young (< 35 years);
•	 they showed no trace of injection in their arm(s);
•	 besides heroin, many other substances were found;
•	 the large majority of the victims were unknown to the 
low threshold structures in the area.
New evidence enlightened by the recent TREND 
observations confirmed the above-mentioned elements:
•	 greater availability of heroin; 
•	 drug use among people socially inserted, notably young 
people who are used to snorting heroin;
•	 users unaware of/underestimating the related risks of 
snorting opiates;
•	 low transmission of harm-reduction practices toward 
these ‘new’ users, born after the ‘HIV generation’ and 
less aware of the risks (dose, effects, mix with others 
drugs).
A TREND/SINTES note to the public health institutions led to 
a press release considering the dangers of heroin, even if not 
injected and to recall the basics of harm reduction. 
Lidocaine
In 2008, several reports of a new substance called COCA 
PEP were quoted by the local TREND/SINTES coordination 
of Metz. The substance seemed to have a good reputation 
among users, although they had no idea of the composition. 
The substance was presented as a powder with slight 
stimulant effects. It was finally collected from a person who 
had experimented this product several times.
•	 The analysis of the collected sample finally identified 
lidocaine. 
•	 A second analysis on a new sample collected in 2009 
under the same name confirmed the composition.
•	 This was the first time that lidocaine was used for its own 
properties and not only as cocaine cutting agent. It was 
also the first cocaine derivative analysed in France.
Strengths, limitations and way forward
The strength of the French EWS lies primarily in the 
implementation of a permanent network of healthcare 
players working with drug users. This continuity enables 
reactive feedback of information. The French EWS also 
leans on its permanent network to conduct more specific 
investigations (Cadet-Taïrou et al., 2006; Reynaud-
Mauruptand Hoareau, 2010; Escots and Suderie, 2010).
The collection methodology guarantees analysis in a 
laboratory of uncut samples actually intended for 
consumption by drug users. 
The SINTES system launches initiatives designed to extend 
its network to structures located in regions where TREND is 
not yet implemented. Information in hospital emergency 
departments is also being studied in order to enable the 
analysis of samples of drugs directly related to overdoses.
Since 2011, the observational scope has also been 
extended to include the Internet. Continuous observation 
and specific one-off surveys are currently being implemented 
on the subject of new synthetic substances. 
Links and references 
Observatoire français des drogues et des toxicomanies 
(OFDT) — http://www.ofdt.fr
Cadet-Taïrou, A., et al., (2006), ‘Usage de cocaïne et de 
crack — prévalence, risques et réponses’, in OFDT, 2006 
National report (2005 data) to the EMCDDA by the Reitox 
National Focal Point France, New development, trends 
and in-depth information on selected issues, French version, 
OFDT, St Denis, pp. 87–101.
Cadet-Taïrou, A., et al., (2007), ‘Phénomènes émergents 
liés aux drogues en 2005’, Septième rapport national du 
dispositif TREND, OFDT, St Denis, p. 105.
Cadet-Taïrou, A., et al. (2010), ‘Drogues et usages de 
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drogues en France. État des lieux et tendances récentes 
2007–09’, Neuvième édition du rapport national du 
dispositif TREND, OFDT, St Denis, 281 pp.
Escots, S. and Suderie, G. (2010), Usages problématiques 
de cocaïne/crack. Quelles interventions pour quelles 
demandes?, OFDT, St Denis, 246 pp.
Lahaie, E. (2007), ‘Phenacetine — Produit de coupe de la 
cocaïne en augmentation’, Notes d’information SINTES, 21 
December. Available at: 
http://www.ofdt.fr/BDD/sintes/ir_071129_phen.pdf
Lahaie, E. (2009), ‘m-chlorophénylpipérazine (mCPP) 
augmentation de la diffusion’, Notes d’information SINTES, 
29 April. Available at: 
http://www.ofdt.fr/BDD/sintes/ir_050131_mcpp.pdf
Lahaie, E. (2009), ‘Collecte de MDMA pure (100 %) dans 
la région Aquitaine’, Notes d’information SINTES 2009, 19 
June. Available at: 
http://www.ofdt.fr/BDD/sintes/ir_090619_mdma.pdf
Lahaie, E. (2009), Enquête SINTES 2009 sur la composition 
des produits de synthèse. OFDT, St Denis, 47 pp.
Lahaie, E. (2010), ‘Analyse d’héroine fortement dosée à 
Strasbourg’, Notes d’information SINTES 2010, 31 March. 
Available at: 
http://www.ofdt.fr/BDD/sintes/ir_100331_herococa.pdf
Lahaie, E. (2010), Identification de cocaine à la lidocaïne’, 
Notes d’information SINTES, 31 Mar. Available at: 
http://www.ofdt.fr/BDD/sintes/ir_100331_lidocaine.pdf
Lahaie, E., Cadet-Taïrou, A. and Janssen, E. (2010), 
Composition de l’héroïne et connaissance des usagers. 
Résultats de l’enquête SINTES Observation (mars 2007 à juin 
2008) 2010, OFDT, St Denis. p. 36.
Lahaie, E. (2011), ‘Méphédrone et autres nouveaux 
stimulants de synthèse en circulation’, Notes d’information 
SINTES, 31 Jan. Available at: http://www.ofdt.fr/BDD/
sintes/ir_100331_mephedrone.pdf
Lahaie, E. (2011), ‘Répertoire des nouvelles drogues 
de synthèse identifiées en France depuis 2008’, Notes 
d’information SINTES, 9 May. Available at: 
http://www.ofdt.fr/BDD/sintes/ir_110509_nds.pdf
Lahaie, E. (2011), ‘Héroine. Teneurs et adultérants. 
Evolutions récentes’, Notes d’information SINTES, 25 May. 
Available at: 
http://www.ofdt.fr/BDD/sintes/ir_110525_coupe.pdf
Reynaud-Maurupt, C. and Hoareau, E. (2010), Les carrières 
de consommation de cocaïne chez les usagers « cachés », 
OFDT, St Denis, pp. 273.
SINTES (2005), Cocaïne et levamisole’, Notes d’information 
SINTES 2005.
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Introduction
The German early warning system (EWS) is an informal 
network consisting of relevant national, as well as selected, 
regional and local institutions. The main objective of this 
network is the exchange of information concerning new 
drugs and modified patterns of drug use. The information 
flows both from the EMCDDA via the German national focal 
point (NFP) to the participants of the national EWS and from 
the local or national institutions via the NFP to the EMCDDA. 
As the German NFP is co-funded by the Federal Ministry 
of Health (Bundesministerium für Gesundheit, BMG), the 
NFP also provides information to the BMG and the Federal 
Institute for Drugs and Medical Devices (Bundesinstitut für 
Arzneimittel und Medizinprodukte, BfArM) and acts as one of 
their advisors concerning new drugs.
The German EWS has been initiated in 1997 in line with 
the Joint Action of the European Council on New Synthetic 
Drugs (Council of the European Union, 1997). Similar to the 
EU-level cooperation between the EMCDDA and Europol, 
the German NFP initiated a cooperation with the Federal 
Criminal Police Office (Bundeskriminalamt, BKA) to cover the 
area of sentencing, as well as to receive chemical analyses 
of new, unknown substances and additionally established a 
network with key persons from important national, regional 
and local institutions covering the areas of epidemiology, 
prevention, treatment and harm reduction. With the 
adoption of Council Decision 2005/387/JHA of 10 May 
2005 on the information exchange, risk-assessment and 
control of new psychoactive substances, the focus has been 
expanded (medicine misuse and biogenic drugs have been 
included) and new partners (BfArM; Phar-Mon) have been 
recruited.
Organisational issues
The coordination of the EWS is located at the German NFP 
(staff: approximately 3.5 full-time jobs, one part-time 
employee is, beside other issues, responsible for the EWS) 
and has access to all its resources (e.g. the network of 
relevant national and local scientists, drug commissioners, 
workers in the drugs care system). Accordingly the NFP is 
responsible for information flow from the EMCDDA to 
national level and from national level to the EMCDDA. Once 
a year, the German NFP organises a regular meeting of the 
national EWS. As German NFP has no formal mandate to 
obligate any institution to participate, the network on national 
level is informal – all partners participate on a voluntary 
basis and provision of information is voluntary as well.
The German EWS includes key persons from governmental 
and non-governmental organisations on national, regional 
and local level which represent in most cases networks with 
sub-units. The participating partners in the German EWS are 
(see also Figure 9):
•	 Federal Criminal Police Office (Bundeskriminalamt 
(BKA)): the BKA is responsible for reducing the supply of 
illicit drugs at federal level and, accordingly, is the  
German actor in the Europol framework. The BKA  
collects all information from police units on Länder level 
which, on their part, receive information from  
subordinate units. The BKA-laboratory is the most  
important source of analytical data in the framework of 
the German EWS.
•	 Robert Koch Institute (RKI): the Robert Koch Institute is 
one of the major institutions for monitoring infectious 
diseases and health protection in Germany. It serves as 
a central scientific institution in the field of biomedicine 
for the Federal Ministry of Health. The Institute combines 
risk research with political advice. Its most important 
tasks include protection against infectious diseases and 
the analysis of the health situation in Germany.
•	 The Federal Institute for Drugs and Medical Devices 
(Bundesinstitut für Arzneimittel und Medizinprodukte 
(BfArM)): the BfArM is an independent high federal 
authority within the portfolio of the Federal Ministry of 
Health. The aim of BfArM’s work is preventing health 
risks by continuous improvement of the safety of  
medicinal products and by risk monitoring of medical 
devices as well as by monitoring the legal traffic in 
controlled substances scheduled in the UN-Conventions 
of 1961, 1971 and 1988.
•	 Phar-Mon: the Phar-Mon system monitors medicines 
misuse among clients of outpatient addiction treatment 
centres. The reference centres deliver data on medicines 
misuse three times per year. The main purpose of the 
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project is to serve as an early warning system for  
medicines misuse. In order to enhance the early warning 
nature of the Phar-Mon project, a pilot study on  
medicines misuse data gathered from external sources 
(e.g. police, pharmacies, hospitals, fitness studios) is  
under way. The Phar-Mon project is funded by the  
Federal Ministry of Health and works in close  
cooperation with the Federal Centre for Drugs and  
Medical Devices as well as with the German national 
focal point.
•	 Poison Control Centres (Giftinformationszentren (GIZ)): 
physicians and scientists who work in GIZs in  
Austria, Germany and Switzerland are organised in 
the Association of Clinical Toxicology (Gesellschaft für 
Klinische Toxikologie e.V.). The aim of the GIZs is fast 
and substantiated counselling of the population and of 
physicians in cases of intoxication. The GIZs are usually 
located at university hospitals in the capitals of the  
Federal Länder. They are documenting all cases of  
intoxication and have a broad data collection.
•	 Youth Counselling and Help Centre for Youth  
(Jugendberatung und Jugendhilfe, (JJ), Frankfurt am 
Main): this non-governmental organisation serves the 
EWS as a model of the drug help system at the local 
level and its employees are in close contact with users 
in the well-established drug scene of Frankfurt am Main. 
The JJ offers prevention programmes, centres for drug 
counselling, outpatient substitution centres, detoxification 
centres, inpatient drug treatment centres, facilities for 
assisted accommodation, schools for students with risks 
of drugs and former drug dependents, living and care 
facilities as well as help for children, adolescents and 
families. 
•	 Lower Saxony Centre for Addiction Issues  
(Niedersächsische Landesstelle für Suchtfragen (NLS)): 
the NLS is the umbrella organisation of all addiction 
care facility centres and all self-help organisations of the 
non-statutory public welfare in Lower Saxony. The NLS 
represents the drug help system of the Federal Länder 
within the German EWS.
•	 Bureau for Prevention of Addiction (Büro für  
Suchtprävention (BfS), Hamburg): the BfS is located at 
the Hamburg Centre for Addiction Issues and its aims 
are the collection of practice-related data, the  
development and implementation of prevention  
concepts, as well as the evaluation and quality  
assurance of implemented measures. The offers  
concerning universal and selective prevention are  
primarily addressed to both individuals and  
institutions who play an active role in their work field  
or life environment, in order to implement addiction  
preventive measures. 
•	 Centre for Drug Research Frankfurt am Main (CDR): the 
CDR is located at the University of Frankfurt am Main. 
The CDR is continuously conducting local school surveys 
and monitors the open drug scene, as well as other 
party scenes in Frankfurt am Main (local monitoring 
system). In 2011, the CDR started the EU project ‘Spice 
and synthetic cannabinoids: Fast responses by means of 
forensic, toxicological and socio-scientific analyses with 
direct impact on prevention measures’ in cooperation 
with the Institute for Forensic Medicine Freiburg (IRF) and 
the BKA. 
•	 Institute for Forensic Medicine of the University Hospital 
of the city of Freiburg (Institut für Rechtsmedizin des 
Universitaetsklinikums der Stadt Freiburg, IRF): the IRF 
represents forensic institutes within the German EWS. 
The laboratory of the IRF identified the synthetic  
cannabinoids CP-47,497 homologues in the herbal 
incense ‘Spice’ (Auwärter et al., 2009). As the IRF is a 
partner of the CDR in the aforementioned EU project, the 
laboratory searches for synthetic cannabinoids in herbal 
incenses. In this function, the IRF has identified several 
synthetic cannabinoids and provided reports via the NFP 
to the EMCDDA. 
Core functions and information flow
As described in the previous section (see also Figure 9), the 
German NFP is responsible for the flow of information. 
Usually, information is provided via Internet or telephone, 
ad-hoc information is gathered from case to case by the NFP. 
Like the EMCDDA, Europol and the European Medicines 
Agency (EMA) also have partners on a national level (in 
Germany, the BKA and the BfArM) and continuously 
exchange information from European to national level and 
vice-versa. As the BfArm and the BKA are also part of the 
EWS, a systematic link exists between the EWS and other 
European networks (Europol, EMA) exchanging information 
on new drugs. 
All nationwide institutions (BKA, RKI, BfArM, Phar-Mon, GIZ) 
receive information from subordinate units on regional and 
local level and provide this information to the German EWS. 
As the monitoring of the drug scenes in Frankfurt am Main, 
Hannover and Hamburg is well established, local scientists 
and street-workers are well informed about new substances, 
trends and patterns of use and represented within the EWS.
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Figure 9 — Information flow in the framework of the German EWS
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Case study
The ‘Spice’ phenomenon
Already in December 2007, experts of the CDR Frankfurt am 
Main reported on ‘Spice’ to all participants of the national 
EWS meeting (BKA, BfArM, JJ, NLS, NFP, GIZ) for the very 
first time. This information was received from headshop staff 
within a ‘trendscout’ panel (the official report was published 
in July 2008). It was reported that ‘Spice’ is a herbal mixture 
with cannabis-like effects which is just a bit more expensive 
than cannabis products (approximately EUR 10 per gram).
The media hype started in August 2008, when newspapers 
reported on the abundance of a legal psycho-drug. 
After this, all relevant TV and radio stations as well as all 
nationwide and regional newspapers reported on herbal 
incenses. From the very beginning of the media hype in the 
summer of 2008, the German EWS acted as an advisor 
and provided information to the BMG and the EMCDDA 
(e.g. at two meetings and the survey on ‘Spice’ among the 
NFPs in 2009) from its participants and from other 
European countries (information received from the EMCDDA 
or through bilateral contacts). Since August 2008, purchases 
and consumption (due to the extensive media reports) rapidly 
increased. In the autumn of 2008, the Drug Emergency 
Service in Berlin conducted a non-representative survey 
among approximately 250–300 new clients, of whom 
10–15 reported at least an occasional use of ‘Spice’. At this 
time, lab-tested knowledge of effects of ingredients still was 
insufficient and no common alkaloids had been found so far 
(only vitamin E) in several toxicological analyses in Federal 
State Laboratories and at Forensic Departments of 
Universities. Thus, legislative bodies had no clear concept 
how to deal with the matter (using the Narcotics Law, 
Tobacco Law, Pharmaceutical Act). The political answer 
was an invitation by the Federal Drug Commissioner to all 
relevant departments of the responsible ministries (health, 
youth, interior, agriculture, justice) and their subordinated 
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government agencies (BKA, BfArM, Federal Institute for Risk 
Assessment) on 2 December 2008, to discuss further 
suggestions to deal with the problem.
On 3 December 2008, the Federal Institute for Risk 
Assessment published a warning on the use of ‘Spice’ and 
similar products because of possible health risks. 
The Management Board of the EMCDDA was informed and 
the EMCDDA conducted a rapid survey among the NFPs 
(only the NFPs from Germany, Austria and Poland reported 
the phenomenon). Besides this, some drug service 
organisations published warnings for their clients, mostly 
young cannabis users, not to ‘substitute’ cannabis with 
‘Spice’. The media were informed by the Federal Drug 
Commissioner that the Government is investigating, with high 
pressure, possibilities of prevention and a subsequent ban on 
the purchase of these products. On 16 December 2008, the 
Drug Coordinator Office of the City of Frankfurt am Main, 
together with the research company THC Pharm (specialised 
in research of cannabinoids for pain treatment) published 
that the psychoactive ingredient of ‘Spice’ was the synthetic 
cannabinoid receptor agonist JWH-018. On 19 December 
2008, the Federal Bureau of Criminal Investigation published 
a press release on new findings of further analytical results 
conducted by the IRF. The IRF joined the German EWS in 
January 2009 and continuously provides analytical data on 
new synthetic cannabinoids, as does the laboratory of the 
BKA. Analysed samples contained not only JWH-018, but 
also other synthetic cannabinoids.
The responsible department of the Federal Ministry of Health 
prepared a fast track regulation for the prohibition of 
producing and purchasing of ‘Spice’ containing the 
identified ingredients, which was ready on Christmas Eve. 
On 30 December 2008, the media had been informed by 
the Federal Drug Commissioner that ‘Spice’ would be banned 
as soon as possible. By adoption of the 22nd Amending 
Regulation on Narcotic Drugs (22 January 2009), certain 
synthetic cannabinoids were placed under schedule II of the 
German Narcotics Act (narcotics eligible for trade but not 
for medical prescription). Trafficking, production, acquisition, 
possession of herbal incenses which contain these active 
agents, became illegal. As this fast-track regulation was 
only valid for one year, the 24th Amending Regulation on 
Narcotic Drugs (January 2010) placed the aforementioned 
synthetic cannabinoids and additionally JWH-019 and 
JWH-073 permanently under schedule II of the German 
Narcotics Act. While some synthetic cannabinoids have been 
banned, many new, not controlled, cannabinoids have been 
synthesised and added to new herbal incenses. This poses 
the question whether legal restrictions and bans could be 
the answer to this phenomenon and how to deal with new 
synthetic cannabinoids.
On behalf of the NFP, an item on the prevalence of herbal 
incenses like ‘Spice, Smoke’ etc. was added to the General 
Population Survey in Germany in 2009 (Epidemiological 
Survey of Substance Abuse, ESA) (Kraus et al., 2010). 
The results of the ESA 2009 (N=8,030; 18–64 years) show 
that the lifetime prevalence (ltp) of herbal incense 
consumption is 0.8 %, the last year prevalence (lyp) 0.4 % 
and the last month prevalence (lmp) <0.1 %. In contrast to 
the prevalence across all ages, the prevalence among young 
adults (especially ltp and lyp) is much higher (18–20 years: 
2.5 % ltp, 1.9 % lyp, <0.1 % lmp; 21–24 years: 2.5 % ltp, 
1.8 % lyp, 0.1 % lmp; 25–29 years: 2.1 % ltp, 1.0 % lyp, 
<0.1 % lmp).
The CDR conducted a study on consumption and motivation 
for consumption of herbal mixtures (Werse et al., 2010) 
and concluded that most of the users of herbal incenses are 
typical cannabis users, who are already in trouble with the 
law (e.g. those who have lost their driving license). Others 
have to take drug tests and therefore use ‘Spice’ products 
as substitutes for cannabis, so that drug consumption will 
remain unnoticed. The CDR is currently conducting a study in 
cooperation with the laboratories of the IRF and the BKA on 
‘Spice and synthetic cannabinoids: Fast responses by means 
of forensic, toxicological and socio-scientific analyses with 
direct impact on prevention measures’ in order to answer 
the question: How can we reach potential users with specific 
measures of prevention and treatment?
Strengths, limitations and way forward
The information flow within the German EWS improved 
noticeably in the last years. Most of the relevant multipliers 
are included in the EWS, therefore making regular 
information flow and the exchange of ad-hoc information 
fast. 
As the German EWS acts as one of many advisors to the 
Ministry of Health and doesn’t have any formal mandate for 
decision-making processes, the possibilities of the German 
EWS are restricted to the areas of information collection and 
exchange.
Furthermore, the German EWS is intended to stabilise the 
partnership within the network, to increase information flow 
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and to recruit new partners from the medical field and from 
party projects. Cooperation with party projects are aimed at 
improving drug-use prevention.
Links and references
Links 
Bureau for Prevention of Addiction (Büro für Suchtprävention 
(BfS), Hamburg) — http://www.sucht-hamburg.de
Centre for Drug Research Frankfurt am Main (CDR) — 
http://www.cdr-uni-frankfurt.de
Federal Criminal Police Office (Bundeskriminalamt (BKA)) — 
http://www.bka.de
German Monitoring Centre for Drugs and Drug Addiction 
(Deutsche Beobachtungsstelle für Drogen und Drogensucht 
(DBDD)), German NFP — http://www.dbdd.de
Institute for Forensic Medicine of the University Hospital of the 
city of Freiburg (Institut für Rechtsmedizin des 
Universitätsklinikums der Stadt Freiburg (IRF)) — 
http://www.uniklinik-freiburg.de
Lower Saxony Centre for Addiction Issues (Niedersächsische 
Landesstelle für Suchtfragen (NLS)) — 
http://www.nls-online.de
Phar-Mon monitoring system — 
http://ift.de/index.php?id=335&L=0
Poison Control Centres (Giftinformationszentren (GIZ)) — 
http://www.klinitox.de
Robert Koch Institute (RKI) — http://www.rki.de
The Federal Institute for Drugs and Medical Devices 
(Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM)) 
— http://www.bfarm.de
Youth Counselling and Help Centre for Youth  
(Jugendberatung und Jugendhilfe (JJ) Frankfurt am Main) — 
http://www.drogenberatung-jj.de
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Introduction
The Greek early warning system (EWS) was established in 
1998. In fact, a meeting was convened where the Greek 
Reitox focal point informed the representatives of the 
competent services on the objectives of the project and asked 
for their participation in the EWS network and providing the 
requested information. 
The role of the partners was substantial during the 
establishment of the N-EWS. In fact, they contributed to the 
development of the tools addressing information sources 
(laboratories, law enforcement authorities, specialised drug 
users’ oriented services) and some of them became members 
of the Committee of experts for the appraisal of the incoming 
data.
Organisational issues
There was an agreement between the Greek focal point and 
the representatives of the law enforcement authorities, 
forensic/toxicological laboratories and treatment agents for 
their participation in the EWS in 1998. In fact, the Greek 
focal point convened a meeting where the representatives of 
the competent services and the focal point discussed in detail 
the development of a EWS national network for the collection 
of information on new drug phenomena in Greece.
Following the decision on the development of the EWS 
network, the type of collected information and the collection 
procedure was discussed by a working group composing 
of professionals of the services participating in the network 
and of the members of the focal point. According to the 
working group decision, the Greek EWS monitors both new 
psychoactive substances and new ways of using already 
known substances and new combinations of substances. The 
collected information written in Greek and English language 
is exchanged at national and European level. 
The N-EWS is located within the Greek focal point. A social 
scientist (sociologist) has been working part-time for it since 
1998.
The N-EWS collaborates closely with the EMCDDA and 
provides information upon request on new psychoactive 
substances to different international and European 
organisations (e.g. WHO, Pompidou Group, etc).
The exchange of information between the N-EWS and the 
data providers is done by e-mail. A national database was 
operating from 2001 to 2006 for the early exchange of 
information at national and European level (national data 
providers, collaborators from the EMCDDA and the focal 
points). During the annual meeting of the Committee of 
experts for the appraisal of the incoming information, the 
experts are informed on the main actions of the project.
There is scientific independence regarding the operation of 
the N-EWS.
Core functions and information flow
Data collection, information exchange and monitoring
National partners
•	 Forensic laboratories: General Chemical State  
Laboratory (seizures) (2nd Chemical Service of  
Thessaloniki, 3rd Chemical Service of Athens —  
Department of Narcotics), Medical School of Athens 
University, Medical School of Thessaloniki University. 
•	 Law Enforcement Authorities: Central Anti-drug  
Coordination Unit and the competent services of the 
Ministries of Citizen Protection (police departments, 
coastguard services), and Finance (customs services). 
•	 Specialised drug users’ oriented services: Drug  
treatment programmes, low-threshold programmes, 
outreach services.
Training of the data providers 
It aims at improving the quality of the incoming data and 
strengthening collaboration. Data providers are informed on 
the data collection procedure and other issues related to the 
EWS, such as the risk assessment, the role of Europol 
and so on. 
Data collection tools
Three semi-structured questionnaires addressing the various 
sources of information (law enforcement authorities, 
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laboratories, specialised drug users’ oriented services) were 
constructed. The information categories of the questionnaires 
are based on those provided by the Reporting Form.
Information categories of the questionnaires addressing law 
enforcement authorities and laboratories:
•	 New drugs: Name/street name, chemical description, 
chemical description on the biological material,  
description of the biological material, physical  
description, chemical precursors, extent of use, possible 
risks of using a new substance, circumstances of  
detection, country of origins/domestic production,  
price of unit, involvement in the organised crime,  
socio-demographic data of offenders. 
•	 New ways of using already known substances/new 
combinations of substances: description data.
Information categories of the questionnaire addressing 
specialised drug users’ oriented services:
•	 New drugs: Name and street name, physical  
description, route of administration, experience of  
using the new substance, extent of use, groups of users, 
side effects, sources of purchasing (online shops, head 
shops, open drug scenes, etc).
•	 New ways of using already known substances/new 
combinations of substances: Experience of use, extent of 
use, groups of users, side effects.
The tools have been revised at least once so that they have 
become more user-friendly for the data providers.
— National database: It was operating for six years aiming 
at strengthening the flow of information between the national 
partners and the Greek Reitox focal point; and facilitating 
the early information of the European EWS collaborators 
(EMCDDA, focal points) on the Greek data. Owing to the 
information included being confidential, the access to the 
database was restricted to the national partners and the 
European collaborators (password protected). 
Data appraisal and analysis
Firstly, the N-EWS makes a qualitative check of the incoming 
information which it records in tables. Secondly, the 
Committee of experts is convened to appraise the data. 
Committee of experts
The Committee, which represents all types of agents/services 
participating in the EWS network, is an inter-scientific group 
of experts with expertise at theoretical and practical level. 
In fact, the criteria for their recruitment were related to their 
having specialised knowledge (psychiatrists, toxicologists, 
chemists, pharmacists, social scientists, officers of the law 
enforcement authorities) and being experienced in the drug 
field. The N-EWS facilitates their task through their early and 
systematic information regarding the actions of the European 
and national EWS. Beyond their main task related to the 
appraisal of the national data, they contribute to the 
updating of the questionnaires, the training of the data 
providers and so on.
The main reason for its not operating any more is considered 
to be its limited use.
Outputs, reporting, publications and dissemination
Annual Report: It includes information on new psychoac-
tive substances, new drug phenomena and emerging trends 
which is collected through the national network during 
the reporting year. Chapters on the actions of the EWS are 
developed occasionally for the Annual reports of the focal 
point published into the Greek language.
ADAT (Adequacy in Drug Addiction Treatment and Care) 
Project (Swiss Research Institute on Drug Addiction in 
collaboration with the World Health Organization, European 
Union, 2000): A document describing the structure and the 
achievements of the Greek EWS was included in the report 
of the project due to the fact that it was regarded as a 
well-organised information system for the collection of 
information on emerging trends.
Standard table 17: The incoming data is used for the 
completion of the table. 
EWS progress and final reports on the implementation of the 
Council Decision: The Greek data is presented in the EWS 
reports.
Translation of the information on NPS: The information 
received by the EMCDDA on new psychoactive substances 
is translated into the Greek language for the national 
participants.
Scientific articles on new psychoactive substances written 
by Greek scientists (see Links and references section). 
Seminars and projects:
Twinning projects: Training of the staff and the data 
providers of the focal points of the candidate countries: 
Cyprus (2004) and Turkey (2005, 2006), on the EWS 
included the operation of the N-EWS. 
Presentations on the N-EWS in the First Reitox Academy 
Foundation Course (Athens, February 2002) and in the 
Early warning system — national profiles
67
Reitox Academy Special Seminar on Joint Action on New 
Synthetic Drugs (Slovenia, April 2002). The seminars 
addressed scientists of national focal points of candidate 
countries to be incorporated in the European Union.
Presentations on the N-EWS operation in seminars organised 
by Greek specialised organisations in the drug field. 
Euro-trend project: The scientists participating in the N-EWS 
network contribute to the implementation of the project. 
The N-EWS information system was considered to be the 
basis for the development of a model of an Early Information 
Function (EIF) for Emerging Drug Phenomena (EDP) in Greece 
(Alvarez et al., 2003).
Dissemination process: There is a constant feedback to the 
national partners through the dissemination of information on 
NPS, health alerts, relevant articles, books and reports. 
Case study
The N-EWS responds to any request regarding the new 
psychoactive substances. In other words, it informs the 
competent services on any issue related to NPS and 
motivates them to provide the relevant information. Below, 
there are two paradigms related to the actions of the EWS 
at national level.
Quantitative analysis of Ecstasy tablets
Considering that several Member States sent information on 
Ecstasy pills with a high concentration of precursors, such as 
MDMA and other substances in 2003, the N-EWS took 
the initiative to discuss with the director of the General 
Chemical State Laboratory (Forensic Drugs Laboratory) the 
issue regarding the quantitative analysis of Ecstasy tablets. 
The decision taken during the meeting was that the 
Laboratory engaged to make the quantitative analysis on 
the majority of the samples of seized Ecstasy tablets. 
Exchange of information on the circulation of a  
dangerous substance in open drug scenes in Athens
The N-EWS informed the competent services on a 
dangerous substance circulating in the open drug scenes in 
Athens in 2011. The responsible persons of the street work 
programmes of the Therapy Centre for Dependent 
Individuals (KETHEA) and the Organisation against Drugs 
(OKANA) informed on the issue. The Greek focal point asked 
them to collect information (user reports) and prepared a 
letter for the competent services (forensic laboratories and 
law enforcement authorities) for further action. According to 
drug user reports (N=40), the dangerous substance is called 
‘SISA’ or ‘SHISA’ and it may contain, among others, ‘battery 
fluids’. In addition to this, it is in crystal or powder form and 
it is smoked/inhaled or it is used intravenously. Its effects 
were reported to be similar to those of methamphetamine, 
cocaine or methadone. The main side-effects of the substance 
are related to insomnia, hallucinations and aggression. 
Considering the aforementioned information, it was 
mentioned that ‘SISA’/‘SHISA’ might be a methamphetamine-
like substance. 
Strengths, limitations and way forward
Strengths
•	 The N-EWS contributes to the submission of the new 
psychoactive substances under control at national level 
by informing directly the Drugs Committee on the misuse 
of new substances at European level.
•	 The EWS network is frequently expanded by the  
participation of new sources of information which have 
been developed or already exist, and which are found 
that they could provide the EWS network with data.  
This results in the constant flow of information on account 
of the fact that the proportion of information coming from 
the new sources is usually greater than this deriving from 
the old ones. 
•	 The N-EWS has easy access to all relevant sources at 
national level.
•	 The collection of further information contributes to an 
extent to the identification of emerging trends in Greece.
Limitations
•	 The rather limited information on new psychoactive  
substances is mainly attributed to the fact that Greece is 
not a priority drug market. As a result, the new  
substances are imported long after they are used in other 
drug markets. This is confirmed by the fact that there 
have not been found clandestine laboratories and/or 
online drug markets in Greece.
•	 The short delay of the data from the laboratories is put 
down: (a) to practical issues, i.e. the great number of 
samples of drugs which have to be analysed and the 
long process of the analysis of synthetic drugs; and (b) to 
the inadequate number of the personnel working at the 
laboratories.
•	 The emergency wards of state hospitals and the informal 
data sources, i.e. nightlife settings, are unexploited due 
to the lack of a recording system in the public hospitals 
and the limited number of interventions in nightlife  
settings (Alvarez et al., 2003). 
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Conclusion
The structure and the function of the N-EWS are related to 
the specific needs and the social and cultural factors of the 
country. 
Links and references
Alvarez, J., Bello, PY., Faasen, I., Feijao, F., Karahaliou, K. et 
al. (2003), Emerging drug phenomena: A European manual 
on the Early information function for emerging drug 
phenomena, Observatoire francais des drogues et des 
toxicomanies (OFDT), Paris.
Vardakou, I., Pistos, C. and Spiliopoulou, Ch. (2010), ‘Spice 
drugs as a new trend: Mode of action, identification and 
legislation’, Toxicology Letters 197, pp. 157–162.
Vardakou, I., Pistos, C. and Spiliopoulou, Ch. (2011), ‘Drugs 
for youth via Internet and the example of 
mephedrone’, Toxicology Letters 201(3), pp. 191–195.
Other sources:
EWS progress and final reports
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Introduction
Hungary joined the European Union in 2004 and, as a 
consequence, set up its own Reitox national focal point to 
meet the EU requirements. The Hungarian national focal point 
(NFP) started its operation on 1 January 2004. Aside from 
the development of data collection and information flow on 
the fields of the key indicators, the NFP started to work on 
the establishment of a national early warning system 
(N-EWS). Since there were no similar initiatives earlier, 
bringing together experts from different fields related to new 
psychoactive substances, the NFP had to set up its own 
channels, identify and involve the relevant institutes, 
organisations and experts. As a first step, the EMCDDA 
guidance on implementation of the early warning system 
(EMCDDA, 1997) was translated to provide an overview on 
the goals and tools of the system for possible members of the 
network. By the second half of 2005, following an expert 
meeting organised in cooperation with the EMCDDA, the 
core of the network was set and the information exchange 
started. By the end of 2005, the network had 22 members. 
Currently, the network works with 53 members representing 
30 organisations, institutes and authorities.
In 2007, the EMCDDA early warning system on new 
psychoactive substances — Operating guidelines was 
translated into Hungarian and published by the NFP.
In 2008, the NFP initiated the clarification of the legal 
background of scheduling substances, as a result of which 
in 2009, the government adopted a decree defining which 
ministries are responsible for initiating control measures 
regarding new psychoactive substances (Government Decree 
1196/2009 on the duties regarding the scheduling of new 
or already known substances that are hazardous concerning 
misuse). The Decree also defined from which institutes, 
authorities and professional organisations (including the NFP) 
an expert opinion could be requested in order to provide a 
basis for the decision. After issuing the Decree, in 2010, the 
Committee on Controlled Substances was established with 
the aim of assisting the ministries (in charge of drug 
regulation) by providing an evidence base (by carrying out 
risk assessment) for their decisions. The Committee carried 
out the first risk assessment (of mephedrone) in 2010.
Organisational issues
To ensure data and information sources for the operation of 
the NFP the government issued ‘28/2004 Government 
decree about completing the tasks of the national focal point’ 
(http://drogfokuszpont.hu/dfp_docs/?id=28_2004_gov_de-
cree.pdf). It does not include tasks specially related to new 
psychoactive substances but it defines the data provision 
obligation concerning the five Key indicators of authorities 
and institutes which get in touch with these substances. The 
other legal background for the operation of the N-EWS is 
‘Government Regulation 142/2004 on the activities allowed 
to be done with illegal drugs and psychotropic substances’ 
which defines the reporting obligations in case of the 
appearance of new psychoactive substances and it also 
includes the Hungarian version of the EMCDDA Reporting 
form on new psychoactive drugs.
The responsible body for N-EWS is the NFP which operates 
under the National Public Health and Medical Officer 
Service, in the National Centre for Epidemiology. Tasks 
related to the N-EWS are coordinated by one staff member 
of the NFP. The N-EWS was set up to serve the Council 
Decision; therefore its objectives, tools and members were 
shaped according to the goals defined in the Decision.
The N-EWS consists of the representatives of relevant 
ministries, centres of national institutes, authorities and 
NGOs, providing harm-reduction services in a recreational 
setting. In theory, these representatives disseminate and 
collect information in/from their sub- or regional 
organisations. However, the Institute for Forensic Sciences 
delegates a representative from each of its regional 
laboratories. The N-EWS is in direct contact with the Europol 
National Unit (ENU) as its representative is a member of the 
professional network in the national system. All in all, it can 
be stated that the Hungarian EWS has a national coverage.
The NFP developed several tools in order to disseminate 
information and to enhance information exchange among 
professionals. The main element of the N-EWS is a mailing 
list where the NFP can share all the relevant information 
arriving from the EMCDDA with members, while members 
can also inform the NFP and other members about issues 
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related to new psychoactive substances. To improve 
knowledge concerning psychoactive substances, the NFP 
publishes information on its website about the activity of the 
N-EWS, the legal background, key facts and figures and 
shares the relevant links related to the topic. To discuss 
current trends and issues, the NFP organises an expert 
meeting for the members of the N-EWS annually. Due to the 
growing interest of the professional scene and the media, in 
2011 — for the first time — the NFP organised a conference 
on new psychoactive substances for a wider audience, to 
introduce the N-EWS to those who work on the related fields 
but are not in touch with the system and to provide reliable 
information on the phenomena. Besides, information on 
current events, publications, etc. related to the N-EWS is 
included in the monthly newsletter of the NFP. 
Core functions and information flow
Information on new psychoactive substances might be 
requested from the N-EWS by the EMCDDA, by the 
Committee on Controlled Substances (or the Coordination 
Committee on Drug Affairs) — the NFP is a permanent 
member of the Committee on Controlled Substances and 
provides European and national information on new drugs 
for the Committee on request — or professionals and 
organisations operating in the related fields. In all cases, 
information is requested via the NFP. The standardised tools 
for data collection are the ‘Progress and Final Reporting 
form’ of the EMCDDA and the so-called ‘142/2004 EWS 
Reporting form on new synthetic drug’ which was developed 
alongside the ‘Europol–EMCDDA Reporting form on new 
psychoactive drug’, in accordance with the Council Decision 
(Council Decision 2005/387/JHA of 10 May 2005 on 
information exchange, risk assessment and control of new 
psychoactive substances). As mentioned above, a specific 
reporting obligation exists only in case of the latter 
Reporting form. In theory, all authorities, official bodies, 
functionaries, drug analytical laboratories, toxicological 
laboratories, healthcare service providers, research institutes 
and detention facilities are obliged to report to the ENU and 
NFP when new drugs or new forms of use appear and drug 
use (including production, trafficking or use) is detected. 
However, in practice only drug analytical laboratories 
had reported new substances or new forms of use by the 
‘142/2004 EWS Reporting form’ until now. Besides formal 
routine reporting, all members of the N-EWS can take part 
in a general information exchange on the mailing list and at 
expert meetings and sometimes are asked to reply to ad hoc 
requests.
An important initiative in the field — although not directly 
related to the N-EWS — is the monitoring project of the 
Institute for Forensic Sciences named ‘Increased monitoring 
of the active substance content of hazardous drugs’ aiming 
to follow the change of the drug market (principally of heroin 
and amphetamine) to prevent overdose cases. The launched 
system monitors the change of dangerous components, 
street-level purity, other characteristics of these drugs and 
new psychoactive substances. The results of the analysis are 
published quarterly to provide reliable information on trends. 
An immediate alarm is released in cases of extreme rates 
and the appearance of hazardous compounds. 
Recognising the role of the Internet in the trade of new 
psychoactive substances, the NFP conducted an Internet 
snapshot in January and February 2011 to explore the online 
market of ‘legal high’ substances in Hungary and to collect 
information on its main characteristics. The snapshot focused 
on the trade of four popular ‘legal highs’ (GBL, MDPV, JWH-
018 and mefildronon) and identified 19 online shops selling 
at least one of these products.
As it has already been mentioned above, following the 
‘Government Decree 1196/2009 on the duties regarding 
the scheduling of new or already known substances that are 
hazardous concerning misuse’, the Committee on Controlled 
Substances was established to prepare proposals on 
changing drug schedules for ministries in charge. The first 
proposal was prepared on mephedrone following a 
procedure of risk assessment of the substance. The risk 
assessment procedure was based on the EMCDDA risk 
assessment procedure.
Case study
At the end of May 2010, a notification arrived from the 
EMCDDA that a new synthetic cannabinoid receptor agonist, 
RCS-4, had been identified in Belarus. No notification on 
this compound had arrived from European countries before 
this case. The e-mail had been sent out to the members of the 
N-EWS and soon afterwards, the NFP received an inquiry 
from the Institute for Forensic Sciences if analytical data on 
the substance is available in a digital format. The EMCDDA 
managed to obtain the mass spectrum of the RCS-4 and 
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forwarded it to the Hungarian NFP shortly. It was sent out 
to drug analytical and toxicological laboratories in the 
country. Some weeks later the Hungarian Customs and 
Finance Guard seized a substance which, thanks to the 
information received from Belarus via the EMCDDA, could 
be identified as RCS-4.
Strengths, limitations and way forward
Following the first five years operation of the N-EWS its 
gap-filling role is unambiguous. Experts, organisations and 
authorities whose activity is related to new psychoactive 
substances would not meet, exchange information otherwise. 
Since the second half of 2010, the treatment and harm 
reduction services also faced the increased appearance 
of cathinones at the market. According to the information 
received from these services and the outcome of small local 
snapshots in their clientele the injecting use of cathinones 
became prevalent in 2011. Due to these changes of the 
market and the patterns of use, service providers face new 
problems that should be addressed, but to do so they need 
more information on new substances. To address their needs, 
the NFP wants to improve and extend the current system of 
the N-EWS to involve these service providers. 
The development of the N-EWS also aims to improve the 
horizontal information exchange within the system and the 
revision of current reporting practices.
Links and references 
Hungarian national focal point — http://drogfokuszpont.hu
Hungarian Institute for Forensic Sciences — alerts and 
newsletters of their monitoring system http://bszki.hu/page.
php?532
28/2004 Government decree about completing the tasks 
of the national focal point (http://drogfokuszpont.hu/dfp_
docs/?id=28_2004_gov_decree.pdf)
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Introduction
This early warning and emerging trends sub-committee was 
originally set up in September 1997 by the Department 
of Health as the ad-hoc early warning Committee on New 
Synthetic Drugs to consider national issues arising from the 
1997 Joint Action on New Synthetic Drugs by the Council 
of the European Union concerning information exchange, 
risk assessment and control of new synthetic drugs where 
each Member State had to set up a system of early warning 
to monitor the emergence of this phenomenon. In 2001, the 
committee was placed on a formal basis within the National 
Advisory Committee on Drugs (NACD) and its remit 
extended to include the monitoring of emerging trends.
The National Advisory Committee on Drugs (NACD) was 
established in July 2000 under the auspices of the 
Department of Tourism, Sport and Recreation. Between June 
2002 and May 2011, the NACD was under the auspices of 
the Department of Community, Rural and Gaeltacht Affairs, 
later known as Community Equality and Gaeltacht Affairs. 
In May 2011, following a general election, the government 
relocated the NACD to the Department of Health. 
The objectives of the NACD are to:
•	 conduct, commission and analyse research on issues 
relating to drugs and;
•	 advise the government on policy development in the 
area. 
The NACD advises the government in relation to monitor 
emerging drug trends, prevalence, prevention, treatment, 
rehabilitation and consequences of problem drug use in 
Ireland using high-quality research.
Organisational issues
The NACD’s early warning and emerging trends sub-
committee advises the Irish government on emerging drug 
trends or practices as well as the consequences of such drug 
use. This is a national committee and is set up under an 
administrative rather than legal basis. The committee meets 
each quarter and each of the members report on trends 
in drug use or consequences of drug use noted during the 
preceding quarter. In addition, members of the committee 
communicate with each other by e-mail in order to report a 
new drug, a new trend in drug use, serious consequences of 
drug use, in particular, those consequences seen in 
emergency departments, acute hospitals or drug treatment 
services. The members of the early warning committee cover 
a wide range of government departments, professional 
disciplines and services which include: police and customs, 
human, chemical and forensic toxicology, pharmacology 
and pharmaceutical science, emergency medicine, drug 
treatment, harm reduction, public information and research, 
including the EMCDDA’s focal point (the Irish national focal 
point for the EMCDDA is located in the Health Research 
Board, which is the lead agency in Ireland supporting and 
funding health research). Each member of the committee 
represents a wider body from whom they receive information 
and to whom they disseminate information. There are no 
full-time staff allocated to early warning and all staff 
incorporate this function into their other work.
The members of the current early warning and emerging 
trends sub-committee belong to the following institutions: 
Department of Health; Department of Justice and Law Reform; 
Health Services Executive; Emergency Department, Adelaide 
and Meath Hospital, incorporating the National Children’s 
Hospital, Tallaght representing emergency department 
consultants; Customs and Excise at the Revenue 
Commissioners; Garda National Drugs Unit; Drug Treatment 
Centre Board Forensic Science Laboratory; Irish Medicines 
Board; Medical Bureau of Road Safety; State Laboratory; 
Toxicology Department, Beaumont Hospital; School of 
Pharmacy and Pharmaceutical Sciences, Trinity College, 
Dublin; Pharmacology and Therapeutics, Trinity Centre for 
Health Sciences; National Voluntary Drug Sector represented 
by the Ana Liffey Drug Project; Health Research Board 
(EMCDDA focal point); and the NACD.
Core functions and information flow
The functions of the early warning system for Ireland are to: 
identify new drugs; describe new trends in drug use, and 
report the serious and unusual consequences of drug use. 
The function of the system for Europe is to identify the 
emergence of new synthetic drugs in line with the 
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aforementioned Joint Action. The information flow is 
presented in Figure 10. There is no routine surveillance 
system although the members have being considering the 
possibility of developing such a system over the past 12 
months. At present, members write short quarterly reports 
covering trends in drug use over the preceding quarter, any 
new or unusual substances encountered and any unusual 
negative consequences experienced. In addition, members 
report urgent situations by e-mail.
The Committee is currently in the preliminary stages of 
developing a national protocol for notifying drug use 
emergencies. The purpose of the protocol will be to facilitate 
the identification of significant public health issues associated 
with drug use requiring a rapid and coordinated response 
and disseminate appropriate public health messages and 
information. 
The committee has completed two formal pieces of research 
to inform its work: 
1. National drug trend monitoring system pilot (2007). 
The NACD developed and tested three new indicators for use 
in a Drug Trend Monitoring System (DTMS). The three 
indicators piloted were:
•	 a media monitoring system to monitor current drug 
seizures, drug-related court cases, and local drug issues 
around the country;
•	 a network of trend monitors consisting of frontline  
workers from around the country to complete a  
twice-yearly trend questionnaire on the drug situation in 
their area, and notify the DTMS when new trends arise;
•	 a series of focus groups with drug users to assess latest 
drug trends. 
Figure 10 — Information flow in the framework of the Irish EWS
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The results of the pilot indicate that, apart from media 
monitoring, the other tools could be useful methods for 
identifying new drugs and new methods of drug use. 
2. An overview of psychoactive substances and outlets 
supplying them (2011). This overview presents the available 
knowledge on new psychoactive substances within the Irish 
context, and provides new insights into this multifaceted 
phenomenon. Specifically, the overview sought to assess the 
availability and accessibility of new psychoactive substances 
in retail outlets throughout Ireland and online, and to identify 
and describe the products, and where possible, identify their 
specific contents. A range of new psychoactive substances 
were purchased or acquired and were subjected to Gas 
Chromatography-Mass Spectrometry (GC-MS) chemical 
analysis in order to identify active constituents. The 
availability of reference standards for the analysis of 
new psychoactive substances was also determined. In 
addition, an online survey was completed to describe the 
nature and extent of new psychoactive substance use.
Case study
There are two case studies of note for the Irish early warning 
system:
Irish government bans sale of ‘magic’ mushrooms
Magic mushrooms are hallucinogens that grow wild in 
autumn or they can be cultivated for commercial sale. 
Their use in Ireland largely began in the mid-1970s when 
they emerged as an alternative to LSD. In 2005, the 
National Advisory Committee on Drugs (NACD) and the 
Drugs and Alcohol Information and Research Unit (DAIRU) 
of the Department of Health, Social Services and Public 
Safety in Northern Ireland published jointly the first results 
from an all-Ireland general population drug prevalence 
survey, which revealed that 5.9 % of young adults had tried 
these mushrooms at some point in their life.
 
A man in his thirties, from Dublin, died in 2005 after he 
jumped from a balcony at his apartment. He had consumed 
magic mushrooms, along with alcohol and cannabis, 
while entertaining a group of friends. The man’s family 
believes that the hallucinogenic effects of the mushrooms 
contributed to the actions that led to his death. The man’s 
family subsequently lobbied the Irish government to ban the 
sale or possession of fresh psilocybin-containing mushrooms.
As of 31 January 2006, the Irish government, in the exercise 
of powers conferred on them by section 2(2) of the Misuse of 
Drugs Act, 1977, has ordered that ‘any substance, product 
or preparation (whether natural or not), including a fungus of 
any kind or description, which contains psilocin or an ester 
of psilocin is a controlled drug for the purposes of the Act’. 
The effect of this order is to render the possession or sale of 
so-called ‘magic’ mushrooms criminal offences under the Act. 
Irish government ban the sale of psychoactive  
sustances in head shops and other outlets
In January 2010, at the request of the Minister with 
responsibility for the National Drugs Strategy, an expert and 
multi-disciplinary Research Advisory Group (RAG) was 
established by the NACD’s early warning and Emerging 
Trends Sub-Committee to carry out a review of new 
psychoactive substances and the outlets supplying them. 
The multidisciplinary Research Advisory Group (RAG) 
comprised representatives from Citywide Drug Crisis 
Campaign, Customs Drug Law Enforcement, Department of 
Health and Children, Department of Community, Equality and 
Gaeltacht Affairs, Department of Justice and Law Reform, 
Food Safety Authority of Ireland, Forensic Science 
Laboratory, Garda Síochána, Health and Safety Authority, 
Health Research Board, Health Service Executive, Irish 
Medicines Board, and the NACD itself.
In addition to designing and commissioning the research, 
each representative examined what action they could take in 
their respective area. For example, the Garda Síochána 
enumerated and mapped the location of each head shop. 
They updated their map on a regular basis between January 
and August 2010. At their peak in early 2010, there were 
113 head shops in the country, with at least one in every 
county. The Gardaí, along with their colleagues in customs 
seized substances when suspected controlled under the 
Misuse of Drugs Act, 1977. The Forensic Science 
Laboratory tested all substances seized by the Gardaí and 
customs. The academic and clinical laboratories worked 
closely with the Forensic Science Laboratory to maximise 
resources and share knowledge. Together, all of the 
laboratories identified a number of new substances. The 
Irish Medicines Board took action using its legislation when 
a substance contained a legal drug while the Food Safety 
Authority of Ireland expressed a willingness to do likewise if 
a substance contained a food. The Food Safety Authority also 
examined the issue of misleading labelling and the possibility 
of taking action against retailers for misleading their 
customers. The Department of Health and other relevant 
members worked on legislation to control the sale or 
possession of: specific synthetic cannabinoids; 
benzylpiperazine (BZP) and piperazine derivatives; specific 
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cathinones; gamma butyrolactone (GBL) and 1,4-butanediol; 
ketamine; and tapentadol. On 11 May 2010, the 
government ban or controlled the aforementioned head shop 
products and on this day there were 102 shops opened, 
11 having closed for a variety of reasons. On 12 May, the 
Gardaí visited all head shops and warehouses and seized all 
banned products. By 13 May, there were 34 head shops 
selling psychoactive substances and in early August, the 
number increased to 39 shops. The Department of Health 
and other relevant members continued to examine the need 
to control other drugs and the Forensic Science Laboratory 
and other laboratories continued to identify new 
psychoactive products. On 16 August 2010, the 
Department of Justice and Law Reform introduced The 
Criminal Justice (Psychoactive Substances) Act 2010. This 
legislation was enacted to introduce more general control 
by way of criminal justice legislation to deal with head shop 
products as they emerged. The Act also gives appropriate 
powers to the Gardaí and to the courts to intervene quickly, 
by way of prohibition notices and prohibition orders, to 
prevent the sale of psychoactive substances. Following the 
introduction of this Act, the Gardaí visited head shops 
in early September 2010; only 19 were open and none 
were selling psychoactive substances (An Garda Síochána, 
personal communication, 2010). On 4 October 2010, the 
number of head shops open had decreased to 10.
Strengths, limitations and way forward
Strengths
This is a national network, with representation from a broad 
range of sectors which have collaborative relationships and 
can detect problems quickly. Each member of the network 
represents a wider audience and can exchange information 
quickly and easily.
Limitations and way forward
The committee need to develop a formal data collection 
system through formal submissions from forensic science, 
police, ambulance services, emergency departments and 
harm-reduction services. However, some of these services 
need to put such information systems in place. 
The availability and cost of chemical standards seriously limit 
the laboratories ability to confirm the identity of new 
substances. 
A more structured process for the conduct of formal risk 
assessments is needed in order to identify and classify the 
harm caused by new drugs and make proposals for the 
imposition of regulatory controls on these new drugs. 
The NACD Report on New Psychoactive Substances and the 
outlets supplying them suggested that legislation that permits 
a temporary ban on substances that are deemed dangerous 
would be highly desirable.
Links and references
National drug trend monitoring system pilot (2007). 
Available at: http://www.nacd.ie/publications/DTMSRe-
port_Final.pdf
An overview of psychoactive substances and outlets 
supplying them (2011). Available at: http://www.nacd.ie/
publications/Head_Report2011_overview.pdf
National Advisory Committee on Drugs and Drug and 
Alcohol Information and Research Unit (2005), ‘Drug use 
in Ireland and Northern Ireland: first results (revised) from 
the 2002/2003 drug prevalence study’, Bulletin 1. Dublin: 
National Advisory Committee on Drugs.
Misuse of Drugs Act 1977 (Controlled Drugs) (Declaration) 
Order 2006. Available at: http://www.irishstatutebook.
ie/2006/en/si/0055.html
Connolly, J. (2006), ‘Government bans sale of ‘magic’ 
mushrooms’, Drugnet Ireland 17, pp. 9. Available at: http://
www.drugsandalcohol.ie/11230
Long, J. (2010), ‘Further update on psychoactive substances 
sold in head shops and on line’, Drugnet Ireland 35, pp. 
15–16. http://www.drugsandalcohol.ie/13971
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Introduction
According to what is indicated by Council Decision 
2005/387/JHA, in order to strengthen the functioning of 
a national early warning systems network in support of the 
national focal point (NFP), an early warning system (EWS) 
project, sponsored by the Ministry of Health, was assigned to 
the Veneto Region (Verona Addiction Department, ULSS 20) 
in 2007. In the framework of this project, the procedure for 
real-time collection of information and alerts activation was 
developed and described in a theoretical model.
In June 2008, the coordination of national policies on drugs 
was assigned to the Presidency of the Council of Ministers. 
The new Department for Anti-drug Policies was designated 
as the coordination office. The Italian focal point was based 
within the Department. 
The new Department for Anti-drug Policies capitalised 
network and experiences gained by the national EWS 
project held by the National Institute of Health and the 
abovementioned Verona Addiction Department to make 
a new national EWS project at institutional level.
As a number of national experts had already been involved, 
as procedures for notifications and alerts had been 
highlighted and since results gained had been significant, 
on March 2009 the Department for Anti-drug Policies 
institutionalised and promoted the new national early 
warning system (N-EWS).
Organisational issues
The N-EWS has a double goal: on one side, it is aimed at 
early identification of phenomena potentially dangerous for 
public health and related to the appearance of new drugs 
and/or new patterns of consumption, new formulations 
and mixes of ‘traditional’ substances, new peculiarities at 
toxicological, clinical, behavioural and control level. On the 
other side, the N-EWS is aimed at promptly activating alert 
notifications involving all those organisations responsible for 
public health and for setting off suitable actions. The N-EWS 
acts with national coverage.
The N-EWS is characterised by a rapid management of 
notifications, shortening the time between notification and 
a possible alert starting up. Moreover, the system circulates 
specific and validated information (specificity), such as 
information coming from analytical laboratories. It is also 
able to catch no explicit symptoms and signs (sensibility) 
thanks to its direct connection with drug users. That allows a 
high degree of efficacy and a real capability of reducing or 
preventing drug-related risks.
The N-EWS operates through working groups. These are 
organised in four functional levels, according to the 
responsibility criteria coming from the institutional role and 
responsibility covered by each single group’s member. 
First level — decision: The first level is directed by the 
Department for Anti-drug Policies. Deployed within the 
department, the national focal point represents the sole 
institutional interface between the N-EWS and the EMCDDA. 
It rules the informative flow between national and European 
levels.
Second level — coordination: The N-EWS direction avails 
itself of the advice and cooperation of three organisations, 
each one expert and responsible for a specific area:
•	 National coordination of bio-toxicological aspects — 
National Institute of Health, Therapeutic Research and 
Medicines Evaluation Department, Rome;
•	 National coordination of clinical-toxicological aspects 
— Pavia Poison Control Centre ‘Salvatore Maugeri’ 
Foundation IRCCS;
•	 National coordination of operational aspects —  
Addiction Department, ULSS 20 Verona.
The three organisations work according to the Chief 
Department’s indications; they concur to alert decisions, 
enrolment of new collaborative units, analysis/assessment of 
incoming data/information, preparation of reporting forms 
and outputs communication, field research.
Third level — consultancy: The third level has the purpose 
of study and support for the decisional level in the 
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technical-scientific field. It is composed of consultants setting 
up the Early expert network, a network of 59 experts for 
early consultancy. It gives opinions about incoming 
notifications and activation of possible alerts.
Fourth level — practicality: The fourth level is made up of 
collaborative operative units feeding data, information and 
notification flow (input units) directed towards the N-EWS 
They are responsible for the activation of response actions 
when they receive warning and alert communications (output 
units). Collaborative units are located all over the national 
territory.
National early warning system collaborative centres
Istituto Superiore di Sanità Dipartimento del Farmaco, 
Centro Antiveleni Pavia Centro Nazionale di Informazione 
Tossicologica IRCSS Fondazione Salvatore Maugeri, 
Dipartimento delle Dipendenze ULSS 20 Verona, 
Ministero dell’Interno UTG Trieste Nucleo Operativo 
Tossicodipendenze, Ministero della Salute, Centro Antiveleni 
Az Osp Universtaria Careggi Firenze, Centro Antiveleni 
Bergamo Az Ospedali Riuniti, Centro Antiveleni Milano Az 
Osp Ospedale Niguarda Cà Granda, Centro Antiveleni 
Policlinico Umberto I Roma, Centro Antiveleni Policlinico 
Gemelli Roma, Centro Antiveleni Ospedale Cardarelli 
Figure 11 — Organisational chart of the Italian early warning system
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Napoli, Centro Antiveleni Ospedale Gaslini Genova, Centro 
Antiveleni Foggia, Laboratorio Tossicologia Analitica IRCCS 
Policlinico San Matteo di Pavia, TF Università degli studi di 
Firenze, TF Università degli studi di Bologna, TF Università 
degli studi di Napoli, TF Università degli studi di Bari, TF 
Università Cattolica del Sacro Cuore Roma, TF Università 
degli studi di Padova, TF Università ‘La Sapienza’ Roma, 
TF Università degli studi di Verona, TF Università degli studi 
di Perugia, Laboratorio di Tossicologia Azienda sanitaria 
provinciale di Catanzaro, Laboratorio Generale Azienda 
Ospedaliero Universitaria Careggi, Dipartimento di Scienze 
Farmaceutiche Università degli studi di Pisa, Dipartimento di 
Scienze Farmaceutiche ‘P. Pratesi’ Università degli studi di 
Milano, University of Hertfordshire Department of Pharmacy, 
Dipartimento di Scienze anatomiche istologiche medico-legali 
e dell’apparato locomotore Università ‘La Sapienza’ Roma, 
Direzione Centrale Servizi Antidroga III Servizio, Direzione 
Centrale Anticrimine Polizia di Stato Servizio Polizia 
Scientifica, Servizio Polizia Scientifica Sez Indagini sulle 
droghe d’abuso Polizia di Stato, Arma dei Carabinieri 
Reparto Investigazioni Scientifiche, Reparto Carabinieri 
Investigazioni Scientifiche di Parma, Agenzia delle Dogane 
Laboratorio chimico di Roma, Agenzia Delle Dogane 
Laboratorio e Servizi Chimici Napoli, Polizia di Stato 
Squadra Mobile di Bologna, Presidenza del Consiglio dei 
Ministri, Tossicologo Consulente per il Tribunale di Busto 
Arsizio, Laboratorio Analisi Doping Torino, ARPAC 
Dipartimento tecnico di Benevento, AIFA Agenzia Italiana del 
Farmaco Ufficio Valutazioni e Autorizzazioni, UO Biochimica 
clinica e tossicologia Az Sanitaria USL2 Lucca, Laboratorio 
di Sanità Pubblica Area Vasta Toscana Centro Azienda 
Sanitaria di Firenze, Laboratorio di Igiene Ambientale e 
Tossicologia Forense Dipartimento di Prevenzione ULSS12 
Veneziana Regione Veneto, Azienda Ospedaliera ‘Ospedale 
S. Anna’ di Como, Sezione Medicina Legale Dipartimento 
Neuroscienze Università Politecnica Marche, Procura della 
Repubblica di Torino, Direzione Politiche Sociali Servizio 
promozione e inclusione sociale Comune di Venezia, 
Università degli Studi di Modena e Reggio Emilia Tossicologo 
Forense, UO Chimica e Clinica Tossicologica ASP Catania 
Regione Sicilia, Laboratorio di Sanità Pubblica — Area Vasta 
Toscana Centro — Azienda Sanitaria di Firenze, Laboratorio 
di Igiene Ambientale e Tossicologia Forense — Dipartimento 
di Prevenzione ULSS12 Veneziana — Regione Veneto, 
Laboratorio Ospedale ‘S. Anna’ — Como, Laboratori di 
Ricerche di appartenenza Analitiche e Tecnologiche su 
Alimenti e Ambiente — Università degli Studi di Milano, 
Istituto di Medicina Legale — Dipartimento Neuroscienze 
Università Politecnica Marche, Direzione Politiche Sociali 
Servizio promozione e inclusione sociale — Comune di 
Venezia.
Core functions and information flow
Management of notifications and alerts at European and 
international level is the competence of the national focal 
point. That is the only channel through which the information 
flow between Italy, Europe and other foreign countries gets 
fed. The EMCDDA sends notifications and alerts concerning 
foreign states to the Italian focal point. In turn, the Italian 
focal point acts as the collector of Italian alerts: it forwards 
them to the EMCDDA and from the EMCDDA, the information 
reaches other Member States.
At national level, in order to gather information, the N-EWS 
avails itself of an articulated input network involving different 
kinds of units: health units, public facilities, poison control 
centres, forensic, clinical, research, law enforcement and 
custom laboratories, law enforcement agencies, emergency 
departments, outreach mobile units, schools, no profit 
associations, media and entertainment settings (see 
Figure 11).
Once the N-EWS receives a notification, according to its 
content it is possible to activate alerts, in collaboration with 
the Ministry of Health and law enforcement agencies, with 
recommendations for clinical centres and/or with reference 
materials for laboratories. In the first case, the system allows 
the early identification of symptoms and specific cures for 
intoxicated patients; in the second one, the system eases 
laboratories to early identify the new substances. It is also 
possible to start up the procedure to put new molecules 
under control and, once a molecule has been registered as 
illegal, to boost law enforcement agencies’ controls all over 
the country. That usually ends up in seizures of illicit 
substances and captures of traffickers and drug dealers 
(Figure 12).
On the Italian territory, notifications and alerts are 
operatively managed by the Addiction Department, ULSS 
20 Verona. The management gets supported by a 2.0 web 
software called ‘N-EWS’ (www.allertadroga.it). That is a 
groundbreaking technology allowing to geo-locate input 
notifications and to address alerts (output) towards well 
defined geographical areas. The System can receive 
notifications through different communication channels 
(telephone, e-mail, fax, sms, mms, web) and is able to reach 
every kind of organisation through a contemporary and 
multichannel transmission.
The macro-functioning of the N-EWS information flow may 
be described as follows. Notifications coming from operative 
units stream into the N-EWS following seizures, observations, 
admissions to emergency departments by drug intoxications, 
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Figure 12 — Output and concrete actions following notifications to the Italian National early warning system
news referred by users, etc. Therefore, the information does 
not reach the System on a regular basis but on the 
occurrence. Notifications are assessed by the N-EWS 
direction and, if necessary, the information gets detailed 
through field research and contacts with technical-scientific 
consultants. Notifications may generate different kinds 
of communication: the System can elaborate and send 
simple Informatives, Warnings or Alerts. Alerts may be 
differentiated in level 1, 2 or 3 according to the severity of 
the notified event and health risks. For the recipients’ sake 
and for a more effective fruition, the System also supplies 
communication with specific technical reports, pictures 
and information coming from the scientific literature, 
when available. The System selects case by case the 
geographical areas and the output units to send the alert to, 
when that is not of national relevance. Output units are 
responsible for the activation-implementation of rapid 
response actions in order to face the notified event and to 
avoid, or at least reduce, users’ and general population’s 
health risks.
Case study
Since 2010, the N-EWS recorded 227 notifications coming 
both from the EMCDDA and from the national units (106 in 
2010 and 121 in 2011). 30 alerts were produced, most of 
them related to the appearance of new high-risk substances 
or adulterated ‘traditional’ drugs. Synthetic cannabinoids 
found in herbal blends, as well as the related intoxications, 
were the main matter of the alerts. 
Between 2010 and 2011, the N-EWS registered in Italy 29 
cases of acute intoxication by synthetic cannabinoids with 
admissions to emergency departments. Almost all of them 
(28) occurred in the north of Italy; one in Naples. Patients 
(15–55 years old) smoked herbal blends labelled as Njoy 
(n=6), Jungle Mystic Incense (n=5), Bonzai (n=8), Forest 
Green (n=3), Bonzai Summer Boost (n=2), Spice Arctic 
Synergy (n=1), Orange Alesya New (n=1), Atomic Bomb 
(n=1) and non-labelled products (n=2). LC-MS/MS analysis 
on samples available detected the following molecules: 
JWH-018 (11 intoxications), JWH-122 (9), JWH-081 (2), 
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JWH-250 (3), JWH-122 (1), JWH-018 + JWH-073 (1), 
unknown (2).  
The first intoxication cases were recorded in February 2010: 
patients reached the emergency department after consuming 
‘Njoy’. Following the identification of substances responsible 
for the intoxications, the Department for Anti-drug Policies, 
in collaboration with the Ministry of Health, activated a 
procedure to put them under control according to Italian Law 
(D.P.R. 309/90). In three months, it was possible to include 
JWH-018 and JWH-073 in the list of illicit substances, 
together with the synthetic cathinone mephedrone.
After that, the Department notified all the Public Prosecutor’s 
Offices and Prefects’ Police Offices in order to foster active 
controls of shops still selling herbal blends that might be a 
danger for the users’ health. In 21 Italian cities, law 
enforcement agencies carried out seizures and closed down 
shops selling illicit products. In Milan, an international 
agency distributing illicit herbal blends was shut down. 
Controls were carried out in 78 other cities but no 
irregularities were detected.
Thanks to the several controls performed, more than 80 
different brands of herbal mixtures were analysed and the 
related results were communicated to the N-EWS. New 
abovementioned synthetic cannabinoids were identified, 
besides JWH-018 and JWH-073. The Department for 
Antidrug Policy has put under control JWH-122 and 
JWH-250, as well as derivatives of 3-phenylacetylindole 
and 3-(1-naphthoyl)indole.
Strengths, limitations and way forward
The new control measures on ‘smart’ drugs, previously freely 
sold, has allowed the Department for Anti-drug Policies to 
act against smart shops and to reduce the opportunities for 
buying these products. The decreased availability of such 
products may have contributed to the reduction of 
intoxication cases.
In order to allow a fast detection of new molecules in seized, 
collected and biological samples, the System purchased and 
supplied the collaborative laboratories network with 
analytical standards of several synthetic cannabinoids and 
other new molecules. That made detection of analytical 
compounds easier and increased the data flow to the 
System.
Information like that had been very useful to the N-EWS 
emergency units network. Knowing rapidly the substance by 
which a person got intoxicated, although negative to the 
usual screening drug test, allows a diagnosis without delay, 
as well as an appropriate and prompt patients’ treatment and 
care. Emergency units and Poison Control Centres are very 
important elements in the N-EWS network because they 
allow the collection of clinical information about new 
psychoactive substances, otherwise impossible to gain from 
labs and law enforcement agencies.
Since 2010, the N-EWS registered a 59 % increase of 
adhesion to the input/output network. At the present time, 
collaborative centres of the N-EWS early expert network are 
59. That has contributed to increased system visibility and 
effectiveness, to enlarge the national coverage and to boost 
the number of notifications coming from input units.
According to the positive results gained in the last three 
years, it is possible to argue that the working method so far 
adopted is valid, reliable and effective. Therefore, it is 
suitable to proceed along the traced way. However, there are 
still a few aspects deserving attention the N-EWS intends to 
focus on in the next months.
The first aspect is the need to systematise clinical and 
analytical information on new substances detected through 
the N-EWS activity. According to that, the system is building 
a database for the collection of data, notifications and any 
other information on new identified substances. The database 
will be fed by the whole collaborative centres which will have 
an additional opportunity to share knowledge and tools in 
order to facilitate their work.
The second aspect is the Internet sales of illicit substances. 
This phenomenon has been known for at least five years. 
The N-EWS has created a monitoring unit aimed at 
periodically checking the web and trying to identify which 
sites are used for illicit traffic. The work is being conducted 
in collaboration with the Central Directorate for Anti-drug 
Services and with the Italian Communication Police. 
However, several difficulties emerged in identifying the real 
commerce on the Internet and the criminal organisations 
hiding behind those web sites. Therefore, further work is 
needed to tackle this issue.
Finally, a working group for activation and management of 
sewage analysis has been established within the N-EWS, in 
order to measure the consumption of new psychoactive 
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substances in the general population in Italy. The study is 
meant to be carried out in collaboration with a laboratory 
network and research centres.
Links and references
Dipartimento Politiche Antidroga, National early warning 
system (N-EWS) — www.allertadroga.it
Serpelloni G., Rimondo C., Seri C., Workshop Il Sistema 
Nazionale di Allerta Precoce (NEWS) (2011), stato dell’arte 
e confronto sugli aspetti operativi, laboratoristici e clinici, 
19 December 2011.
Dipartimento Politiche Antidroga, Sistema Nazionale di 
Allerta Precoce (2010), ‘Report di attività e risultato. Anno 
2011 — Base dati 2010’.
Dipartimento Politiche Antidroga, Sistema Nazionale di 
Allerta Precoce (2010), ‘Il fenomeno dei cannabinoidi 
sintetici in Italia e le azioni di contrasto’.
Dipartimento Politiche Antidroga, Relazione Annuale al 
Parlamento sullo Stato delle Tossicodipendenze in Italia, 
2011 (database 2010).
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Introduction
The National early warning system on new psychoactive 
substances (N-EWS) was founded within the Reitox national 
focal point in 2004 (two partners in the local network — 
State police and State Medicine Agency) but, practically, 
development of the system began in 2007 when several 
institutions e.g. the Ministry of Health, the Health 
Inspectorate, Latvian Border Guard, the State Revenue 
Service Customs, Latvia State Centre for Forensic Medical 
Examination and others joined the local network of the early 
warning system (EWS). Due to 2008 and 2009, the local 
network of the N-EWS continued to enlarge and at the 
beginning of 2011, the network involved slightly more than 
40 experts from various government institutions, law 
enforcement agencies, hospitals, treatment centres and 
NGOs.
Institutionally, the Latvian Reitox unit and the N-EWS have 
been hosted by several institutions. Until 2007, it was hosted 
by the State Addiction Agency, from 2007 until 2009, it was 
under the Public Health Agency, from 2009 until November 
2011 by the Centre of Health Economics and finally now 
— the Reitox unit and the N-EWS is located under new 
organisation — the National Health Service (NHS). 
The NHS was developed by merging two institutions — the 
Centre of Health Economics and Health Payment Centre.
Organisational issues
The Latvian N-EWS formally serves mainly the Council 
Decision 2005/387/JHA of 10 May 2005 on information 
exchange, risk-assessment and control of new psychoactive 
substances without a wider role. At national level, the 
existence of the Latvian N-EWS is not regulated. Functions 
are regulated at institutional level by the Reitox national focal 
point and are developed according to EMCDDA guidelines 
(EMCDDA, 2007).
The aim and objectives of the Latvian EWS are directly 
related to the Council Decision 2005/387/JHA of 10 May 
2005 and define the establishment of a mechanism for 
the rapid exchange of information on new psychoactive 
substances that may pose public health and social threats, 
including the involvement of organised crime.
Objectives:
•	 information collection on new psychoactive substances 
that are notified in Latvia (identification, use patterns, 
trafficking, etc.);
•	 regular and on-request reporting to a national network 
of experts on new psychoactive substances notification, 
usage, health risks, trafficking in Latvia and Europe;
•	 coordination of the risk assessment procedure and  
collection of necessary information in order to promote 
controlling measures of new psychoactive substances;
•	 regular and on-request reporting to the EMCDDA on the 
situation in Latvia (progress and final reports on the new 
psychoactive, notifications, legal measures, etc.).
Core functions and information flow
In order to maintain the aim and objectives, the N-EWS has 
developed network at national level that includes experts 
from ministries, law enforcement agencies, health and care 
institutions, laboratories and prevention centres (see 
Figure 13). 
Information on the situation in Latvia is derived from several 
sources. The N-EWS mainly cooperate with the State Police 
which, twice a year, reports official data (EWS official 
Reporting form) on seized and notified new psychoactive 
substances. On request, the State Police or in some cases the 
State Revenue Service provide additional information on the 
detection conditions. Other law enforcement authorities 
(Latvian Border Guard, Organised Crime Bureau, etc.) 
provide information on request.
Healthcare institutions (hospitals, Centre of Toxicology, etc.) 
typically provide data in cases of intoxication. Officially 
recorded cases are very rare and hospitals provide data 
rarely and in most of the cases on request. 
The Latvia State Centre for Forensic Medical Examination 
and toxicological laboratories provide data on identified 
substances and their chemical analysis profile. Until now, four 
new psychoactive substances have been notified for the first 
time in Latvia (JWH-081, JWH-122, JWH-203 and 
AM-2201) by the Latvian Institute of Organic Synthesis. 
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Figure 13 — Information flow in the framework of the Latvian EWS
Of all the network partners least likely to information 
obtained from healthcare, prevention centres, and NGOs 
where information on new substance is obtained when 
the prevalence of the substance is essential and visible. In 
addition, in some cases, information is obtained from other 
sources, such as the media and various surveys like ECAD 
(Rīgas Domes labklājības departments, 2010). The flow of 
information is mostly based on a local network and 
institutions responsible for the framework. The early warning 
system avoids the diffusion of information to the public as 
information on new substances may promote the circulation 
and visibility, and that may higher the risk of use. So far, the 
information on new psychoactive substances in the media 
was disseminated only in the case of ‘Spice’ product 
distribution in 2009, in order to inform about possible health 
risks.
The most frequently used communication tools for rapid and 
efficient flow of information is electronic correspondence and 
telecommunications. An effective tool for rapid and timely 
information exchange as well as the identification of key 
challenges is biannual meetings of the national network. 
In addition, seminars serve as a feedback for the N-EWS 
maintainers to continue maintenance and development of 
the system.
Outputs:
Core functions and output of the N-EWS is information 
exchange, risk assessment and proposals for changes in 
control measures of new psychoactive substances. 
The system’s routine mode is reporting collected information 
on the situation in Latvia to the EMCDDA (reports, warnings, 
alerts). To local partners, the N-EWS mainly disseminate 
formal notifications, alerts and warnings and information on 
request about new psychoactive substances in Latvia and 
Europe, e.g., notifications in other EU countries, health risks, 
trafficking, etc. 
The N-EWS has been the main initiators of the proposals to 
the Ministry of Health for amendments in legal measures of 
new psychoactive substances in 2009. The system usually 
collects necessary information to justify amendments. Also, 
the N-EWS is the main initiator to develop the risk 
assessment procedure at national level. 
In addition, the N-EWS is publishing information on thematic 
issues about the EWS, notified new psychoactive substances 
and related health and social risks (e.g. Sīle, L., 2010 and 
Zīle, A., 2010).
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Risk assessment:
Due to the increase of identification of new psychoactive 
substances in Europe, the list of controlled narcotics and 
psychotropic substances needed to be updated. 
In the existing situation, a specific mechanism of listing 
new psychoactive substances was not created and the 
procedure was long and complicated. Aware of the 
situation and under the proposal of the N-EWS, the involved 
institutions agreed on a specific risk assessment procedure at 
national level which would be the basis for legal measures. 
Development of the risk assessment procedure at the national 
level is included in the National Drug Program 2011–17. 
Risk assessment guidelines are developed in accordance with 
the Council Decision of 10 May 2005 and the EMCDDA 
guidelines (EMCDDA, 2010) which will be adapted to the 
national situation. The Latvian EWS participates in the 
development of guidelines and is going to be the coordinator 
of the risk assessment procedure.
Case study
The benefit of the N-EWS was visible when it significantly 
increased prevalence of various ‘legal highs’, especially 
‘Spice’ products in late 2008 and 2009. Riga City Welfare 
department reported there was a rousing interest in 
Salvia Divinorum among adolescents. Almost simultaneously 
with the distribution of Salvia Divinorum, an even greater 
resonance was caused by the smoking blend ‘Spice’, which 
could be purchased in small shops in the capital, and other 
Latvian cities. Several intoxication cases were reported by 
hospitals and Riga Psychiatry and the State Addiction 
Centre. The N-EWS collected available information on health 
risks and disseminated it to hospitals, healthcare centres and 
main prevention centres. Based on available information on 
usage, trafficking patterns, health risks that were known in 
Europe, the N-EWS prepared a proposal to the Ministry of 
Health with a request to put under control certain synthetic 
cannabinoids. In November 2009, the list of controlled 
substances (Regulations N 847 regarding Narcotic 
Substances, Psychotropic Substances and Precursors to be 
Controlled in Latvia, 2005) was amended with a number of 
synthetic cannabinoids — HU-210, JWH-018, JWH-073, 
JWH-250, JWH-398, CP 47.497 and three of its 
homologues C6, C8 and C9. Due to another proposal of the 
N-EWS in 2010, ‘Law on tobacco product marketing and 
advertising, limited use’ was amended with paragraph 8 
‘shall be forbidden to carry out a mixture of vegetable 
products with smoking, sniffing, chewing or inhaled as a 
result are secreted or ingested substances that cause severe 
substance similar psychiatric disorders to the user, and the 
use of which can be addictive’ (Law On Restrictions 
Regarding Sale, Advertising and Use of Tobacco Products, 
2010). A significantly decreased number of shops which sold 
smoking mixtures and most commercial sites on the Internet 
were also closed. The situation with the ‘Spice’ products 
raised the issue of the identification of new psychoactive 
substances, which promoted improvement of identification of 
new psychoactive substances.
Strengths, limitations and way forward
Practically, the N-EWS has been running a couple of years 
and the development of the system and optimisations are still 
in progress. The system’s strengths are the direct link to the 
EMCDDA, as well as support at national level of the Ministry 
of Health and the Drug Addiction Restriction Coordination 
Council. Similarly, the assessment of new psychoactive 
substances spread in Europe, at the national level the EWS is 
a significant institution that allows to quickly identify 
hazardous substances in order to put them under control.
System limitations are mainly related to the external factors, 
e.g. the current capacity delay rapid notification (technical 
equipment, reference materials, lack of knowledge) of new 
psychoactive substances, so that at the national level it is 
difficult to gather data on spread of new psychoactive 
substances. If the law enforcement agencies in the last year 
raised the capacity, clinical data from medical institutions 
and treatment centres are very poor. Internal factors are 
related to a lack of cooperation with certain local partners, 
like hospital and psychiatric centres, and a lack of necessary 
skills and knowledge in chemistry within the N-EWS.
Future activities mainly related to development of the system 
and improvement of information flow and quality of data. 
The main objectives to improve the N-EWS include:
•	 development of the risk assessment procedure together 
with other stakeholders and coordination of the system 
after the approval of the guidelines;
•	 improve cooperation with healthcare institutions,  
improving the flow of information and data quality. 
Currently, information from treatment centres on the new 
drug or other poisoning cases, the use of consequences 
is reported only in exceptional cases. The system should 
encourage the reporting of information on a regular 
basis, both of those cases where the use of a substance 
shown in clinical investigations and the self-reporting;
•	 enlarge capacity and quality in research and  
publications on issues, the new psychoactive substance 
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use among young people, spread of certain synthetic 
substances, Internet monitoring, etc.
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Introduction
In order to improve and coordinate better the activities of 
state and municipal institutions in the field of prevention of 
drug addiction and drug control, to ensure international 
cooperation and implementation of legal acts of the 
European Union, the Lithuanian Government on 1 January 
2004 established the state-financed organisation, the Drug 
Control Department under the Government of the Republic of 
Lithuania (from 1 April 2011 — Drug, Tobacco and Alcohol 
Control Department), which was nominated as the focal point 
according to the requirements of the EMCDDA.
Director of the Drug Control Department under the 
Government of the Republic of Lithuania approved the 
Rules of Procedure of Information Exchange Concerning 
Occurrence of New Psychoactive Substances in 2005 
(revised of the Director of the Drug, Tobacco and Alcohol 
Control Department in 2011). Under these rules, 
responsible state institutions are obligated to exchange 
information about the occurrence of new psychoactive 
substances in a timely fashion. These Rules of Procedure were 
developed according to the Joint Action of 16 June 1997 
concerning the Information Exchange, Risk-Assessment and 
the Control of New Synthetic Drugs and amended based on 
Council Decision 2005/387/JHA of 10 May 2005 on the 
Information Exchange, Risk-Assessment and Control of New 
Psychoactive Substances. In order to assess the risk of new 
psychoactive substances and to implement control measures, 
an Inter-agency Commission of the Assessment of New 
Psychoactive Substances including representatives of 
competent authorities was established in 2009 (revised 
by the Director of the Drug, Tobacco and Alcohol Control 
Department in 2011).
Organisational issues
In Lithuania, the Drug, Tobacco and Alcohol Control 
Department is responsible for the organisation and 
coordination of the exchange of information concerning new 
psychoactive substances and preparations and important 
questions associated with narcotic drugs and psychotropic 
substances.
The following are institutions, the competencies of which 
include the collection of information about the occurrence of 
new psychoactive substances and providing it to the Drug, 
Tobacco and Alcohol Control Department according to the 
template approved in the Procedure of Information Exchange 
Concerning Occurrence of New Psychoactive Substances 
(early warning system (EWS)):
•	 Prisons Department under the Ministry of Justice of the 
Republic of Lithuania;
•	 State Forensic Medicine Service under the Ministry of 
Justice of the Republic of Lithuania;
•	 Customs Department under the Ministry of Finance of the 
Republic of Lithuania;
•	 Health Emergency Situations Centre of the Ministry of 
Health;
•	 State Medicines Control Agency under the Ministry of 
Health of the Republic of Lithuania;
•	 State Mental Health Center;
•	 State Non-Food Products Inspectorate under the Ministry 
of Economy of the Republic of Lithuania;
•	 State Public Health Service under the Ministry of Health 
of the Republic of Lithuania;
•	 State Food and Veterinary Service of the Republic of 
Lithuania.
The early warning system covers the entire territory of 
Lithuania. There has been no information about poisoning 
caused by new psychoactive substances and related deaths 
in Lithuania. This could be associated with difficulties in 
diagnostics.
In accordance with the established procedure, the Drug, 
Tobacco and Alcohol Control Department provides 
summarised information to the European Monitoring Centre 
for Drugs and Drug Addiction. Important information that 
should be known to the public is presented to the media. 
The Police Department under the Ministry of the Interior of the 
Republic of Lithuania collects data concerning the occurrence 
of new psychoactive substances and preparations and, in 
accordance with its competency, shares this information with 
the Drug, Tobacco and Alcohol Control Department and 
Europol.
The Drug, Tobacco and Alcohol Control Department was 
appointed a National Center of the European Information 
Network on Drugs and Drug Addiction (Reitox) by the 
Resolution of the Government of the Republic of Lithuania 
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No 244 of 23 February 2011. The Drug, Tobacco and 
Alcohol Control Department provides the abovementioned 
institutions with information concerning new psychoactive 
substances and other relevant information obtained from the 
EMCDDA. Information exchange takes place on a feedback 
basis. Analytical data are directly sent to laboratories of the 
authorised state institutions: the Lithuanian Police Forensic 
Science Centre, Forensic Science Centre of Lithuania, State 
Forensic Medicine Service under the Ministry of Justice of 
the Republic of Lithuania, Customs Laboratory at the Customs 
Department under the Ministry of Finance of the Republic of 
Lithuania.
The Drug, Tobacco and Alcohol Control Department 
continually collects information concerning possibly 
psychoactive products that are distributed through online 
stores and Lithuanian shops. In case of suspicion that 
marketed products may have a psychoactive effect, the 
Drug, Tobacco and Alcohol Control Department will put in 
a request with the Police Department under the Ministry of 
the Interior of the Republic of Lithuania, the State Non-Food 
Products Inspectorate under the Ministry of Economy of the 
Republic of Lithuania, the State Food and Veterinary Service 
of the Republic of Lithuania to check if the requirements 
of legal acts have not been violated during distribution of 
abovementioned products.
An Inter-institutional Commission for the assessment of risk of 
psychoactive substances was established at the Drug Control 
Department at the beginning of 2009 (from 2011 under the 
Drug, Tobacco and Alcohol Control Department). The 
Inter-institutional commission was established on an 
individual basis, its activities and Rules of Procedure were 
approved by the Order No T1-15 of 28 January 2009 of the 
Director of the Drug Control Department under the 
Government of the Republic of Lithuania. Below is the list of 
institutions, which have delegated their specialists to work at 
the Inter-institutional commission:
•	 Drug, Tobacco and Alcohol Control Department;
•	 Ministry of Health of the Republic of Lithuania;
•	 State Forensic Medicine Service under the Ministry of 
Justice of the Republic of Lithuania;
•	 State Medicines Control Agency under the Ministry of 
Health of the Republic of Lithuania;
•	 Lithuanian Police Forensic Science Centre;
•	 Customs Department under the Ministry of Finance of the 
Republic of Lithuania;
•	 Lithuanian Forensic Medicine Centre;
•	 National Food and Veterinary Risk Assessment Institute;
•	 National Public Health Surveillance Laboratory;
•	 Faculty of Pharmaceutics of the Lithuanian University of 
Health Sciences;
•	 Faculty of Philosophy of Vilnius University;
•	 Faculty of Natural Sciences of Vilnius University;
•	 Institute of Botany of Nature Research Centre.
The Inter-institutional Commission analyses and assesses 
information concerning new psychoactive substances as well 
as other relevant information obtained from Lithuanian state 
authorities, EMCDDA and other sources in the event when 
substances may potentially endanger human health, as well 
as other information concerning important issues associated 
with narcotic drugs and psychotropic substances. 
The EMCDDA European Database on New Drugs is used 
as a basis for the collection, analysis and assessment of 
information concerning new psychoactive substances. 
Sessions of the Inter-institutional Commission are held when 
necessary (no schedule of sessions has been established). 
Following information analysis and assessment, the 
Inter-institutional Commission develops (approves) 
proposals for restriction and control measures for the market 
of psychoactive substances and control and submits them to 
the Drug, Tobacco and Alcohol Control Department. In the 
event that the Inter-institutional Commission decides that a 
certain substance should be included in the Lists of narcotic 
drugs and psychotropic substances, the Drug, Tobacco and 
Alcohol Control Department shall issue a proposal of the 
Inter-institutional Commission to the Ministry of Health in 
an official letter. Substances shall be included in the Lists of 
narcotic drugs and psychotropic substances per Order of the 
Ministry of Health of the Republic of Lithuania.
In 2004–10, 42 new narcotic drugs, psychotropic 
substances and plants were included in Lists I and II of 
narcotic drugs and psychotropic substances approved by the 
Order of the Minister of Health of the Republic of Lithuania 
No 5 of 6 January 2000 (6). Furthermore, in 2011, generic 
definitions for cathinone derivatives and for six groups of 
synthetic cannabinoid receptor agonists were also added to 
List I. Amyl nitrite and cyclohexyl nitrite are included in the 
List of Toxic Substances according to their toxicity, approved 
by the Order of the Minister of Health of the Republic of 
Lithuania No V-975 of 30 December 2004. 
List I: substances, the use of which is prohibited for 
medicinal purposes (includes substances included in 
Schedule IV of the United Nations Single Convention on 
Narcotic Drugs of 1961, substances included in Schedule I of 
the United Nations Convention on Psychotropic 
Substances of 1971, and some substances included in 
Schedules II, III and IV of the United Nations Convention on 
Psychotropic Substances of 1971).
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List II: substances, the use of which is allowed for medicinal 
purposes (includes substances from Schedules I and II of 
the United Nations Single Convention on Narcotic Drugs 
of 1961, and remaining substances in Schedule II of the 
United Nations Convention on Psychotropic Substances of 
1971).
List III: substances, the use of which is allowed for medicinal 
purposes (includes remaining substances from the Schedules 
III and IV of the United Nations Convention on Psychotropic 
Substances of 1971).
An amendment to the Republic of Lithuania Law on the 
Control of Narcotic Drugs and Psychotropic Substances was 
adopted in 2010, by which control of not only individual 
narcotic drugs and psychotropic substances, but also 
derivatives of narcotic drugs and psychotropic substances 
was approved.
Case study
After information was obtained by the Drug, Tobacco and 
Alcohol Control Department that distribution of various 
herbal mixtures called ‘Spice’ with psychoactive effects has 
been launched in Lithuania, it immediately appealed to state 
regulatory authorities (Police Department under the Ministry 
of the Interior of the Republic of Lithuania, State Non-Food 
Products Inspectorate under the Ministry of Economy of the 
Republic of Lithuania, State Food and Veterinary Service 
of the Republic of Lithuania) with the request to find out if 
distribution of these products does not violate the 
requirements of applicable legal acts. Within one month, the 
State Non-Food Products Inspectorate under the Ministry of 
Economy of the Republic of Lithuania inspected shops and 
based on the Lithuanian Law on Product Safety, adopted a 
decision to prohibit pro tempore business units to provide to 
the market, offer to provide to the market and demonstrate 
eleven products: incense ‘Smoke’, incense ‘Spice Gold’, 
Figure 14 — Exchange of information on new psychoactive substances, their assessment and application of control measures
      
Institutions taking part in the exchange of information
on new psychoactive substances Police Department
under the Ministry of Interior
of the Republic of Lithuania
EMCDDA
Drug, Tobacco and Alcohol 
Control Department
(’Reitox’ NFP)
Europol
Ministry of Health of the Republic
of Lithuania (inclusion of 
the substances into 
the Lists of narcotic drugs
and psychotropic substances)
Europol
National Unit
Inter-institutional
Commission for 
the risk assessment 
of psychoactive
substances
Lithuania — early warning system
Core functions and information flow
94
‘Tagetes Lucida’, ‘Wild Dagga 20X’, ‘Snow blow’, ‘Blow 
out’, ‘Snowberry’, incense ‘African Wild’, incense 
‘Oaxacan High blend’, incense ‘Pink lotus’, incense 
‘Marahuanila’. When information was obtained from the 
EMCDDA that synthetic cannabinoids are being added to 
‘Spice’ products, the Drug, Tobacco and Alcohol 
Control Department appealed to the Ministry of Health of the 
Republic of Lithuania with the proposal to include synthetic 
cannabinoids in the Lists of narcotic drugs and psychotropic 
substances. In May 2009, synthetic cannabinoids JWH-018, 
JWH-073, CP-47,497, CP-47,497-C6, CP-47,497-C8, 
CP-47,497-C9 and HU-210 were added to the Lists of 
narcotic drugs and psychotropic substances.
Strengths, limitations and way forward
The legal basis for the inclusion of new psychoactive 
substances in the Lists of narcotic drugs and psychotropic 
substances is functioning well, accredited laboratories 
equipped with modern equipment and experts are present. 
However, due to lack of information concerning methods of 
identification of new substances and limited possibilities to 
obtain new standards, identification of new psychoactive 
substances is complicated and often impossible.
Links and references
Narkotikų, tabako ir alkoholio kontrolės departamento 
nuostatai, patvirtinti Lietuvos Respublikos Vyriausybės 2011 
m. vasario 23 d. nutarimu Nr. 244 (Žin., 2011, Nr. 28-
1331). [Drug, Tobacco and Alcohol Control Department 
Regulations, approved by the Resolution of the Government of 
the Republic of Lithuania No 244 of 23 February 2011].
2011 m. balandžio 20 d. Narkotikų, tabako ir alkoholio 
kontrolės departamento direktoriaus įsakymas Nr. T1-53 
„Dėl Keitimosi informacija apie naujas psichoaktyvų efektą 
sukeliančias medžiagas tvarkos patvirtinimo“ (Žin., 2011, 
Nr. 49-2410). [Order of the Director of the Drug, Tobacco 
and Alcohol Control Department No T1-53 of 20 April 2011 
‘On the approval of the Rules of Procedure of Information 
Exchange Concerning Occurrence of New Psychoactive 
Substances’].
97/396/JHA: Joint Action of 16 June 1997 adopted by the 
Council on the basis of Article K.3 of the Treaty on European 
Union, concerning the information exchange, risk assessment 
and the control of new synthetic drugs (Official Journal  of the 
European Communities L 167, 25.6.1997, pp. 0001–0003)
Council of the European Union (2005), ‘Council 
Decision 2005/387/JHA of 10 May 2005 on the 
information exchange, risk-assessment and control of new 
psychoactive substances’, Official Journal of the 
European Union, 20.5.2005, L 127, pp. 0032–0037. 
Available at: http://eur-lex.europa.eu/LexUriServ/LexUriS-
erv.do?uri=CELEX:32005D0387:EN:HTML
Narkotikų, tabako ir alkoholio kontrolės departamento 
direktoriaus 2011 m. gegužės 10 d. įsakymas Nr. T1-90 
„Dėl Tarpžinybinės naujų psichoaktyvų efektą sukeliančių 
medžiagų rizikos vertinimo komisijos sudarymo ir jos darbo 
reglamento patvirtinimo“ (Žin., 2011, Nr. 62-2950). [Order 
of the Director of the Drug, Tobacco and Alcohol Control 
Department No T1-90 of 10 May 2011 ‘On the 
Establishment of the Inter-institutional Commission for the 
Assessment of Risk of Psychoactive Substances and the 
Approval of its Rules of procedure’].
Lietuvos Respublikos sveikatos apsaugos ministro 2000 m. 
sausio 6 d. įsakymas Nr. 5 „Dėl narkotinių ir psichotropinių 
medžiagų sąrašų patvirtinimo“ (Žin., 2000, Nr. 4-113; 
2011, Nr. 103-4861). [Order of the Minister of Health of 
the Republic of Lithuania No 5 of January 6, 2000 ‘On the 
approval of the Lists of Narcotic Drugs and Psychotropic 
Substances’].
Lietuvos Respublikos sveikatos apsaugos ministro 2004 
m. gruodžio 30 d. įsakymas Nr. V-975 „Dėl Nuodingųjų 
medžiagų pagal jų toksiškumą sąrašo patvirtinimo“ (Žin., 
2005, Nr. 3-47). [Order of the Minister of Health of the 
Republic of Lithuania No V-975 of 30 December 2004 ‘On 
the Approval of the List of Toxic Substances According to their 
Toxicity’].
Lietuvos Respublikos produktų saugos įstatymas (Žin., 1999, 
Nr. 52-1673). [Republic of Lithuania Law on Product safety].
Lietuvos Respublikos narkotinių ir psichotropinių medžiagų 
įstatymas (Žin., 1998, Nr. 8-161); Lietuvos Respublikos 
narkotinių ir psichotropinių medžiagų kontrolės įstatymo 2, 
3, 10 straipsnių, penktojo skirsnio pavadinimo pakeitimo ir 
papildymo ir įstatymo papildymo 211 straipsniu įstatymas Nr. 
XI-1073 (Žin., 2010, Nr. 132-6718). [Republic of 
Lithuania Law on the Control of Narcotic Drugs and 
Psychotropic Substances; Republic of Lithuania Law No 
XI-1073 on the Amendment of the Articles 2, 3, 10 and the 
Name of the Fifth Section of the Republic of Lithuania Law on 
the Control of Narcotic Drugs and Psychotropic Substances 
and on the Addition of the Article 211].
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Introduction
The basic national drug law from 19 February 1973 (last 
modified in 2001), under Article 7, defines categories of 
substances to be controlled by means of Grand-ducal 
decrees. Currently, four Grand-ducal decrees list 
psychoactive substances controlled at the national level: Toxic 
substances 4 March 1974, psychotropic substances 20 April 
1974 and 6 February 1997, narcotics 26 March 1974. 
Precursors are addressed by specific regulations 8 May 
1993 and 2 February 1995. The annexes of the referred 
Grand-ducal decrees list the substances, common names if 
available, and individual chemical formulae, as appropriate.
The implementation of the national early warning system on 
drugs and patterns of use (hereinafter referred to as N-EWS) 
was implemented in 1997 following the Joint Action on the 
information exchange, risk assessment and the control of 
new synthetic drugs subsequently replaced by the Council 
Decision 2005/387/JHA of May 2005 on the information 
exchange, risk assessment and control of new psychoactive 
substances. The N-EWS developed progressively, including 
an increasing number of data providers. Over the last five 
years, the number of involved stakeholders has been stable 
and the N-EWS networks currently include the following 
partners:
•	 national EMCDDA focal point (NFP);
•	 specialised drug unit of the Judicial Police (also national 
Europol Drug Unit);
•	 Anti-drugs division of Customs;
•	 National Laboratory of Health (centralisation of  
toxicological analysis of suspect substances and the 
National Centre for Forensic Medicine);
•	 National Drug Addiction Prevention Centre;
•	 all specialised drug agencies (NGOs) (12);
•	 a series of General Practitioners.
Organisational issues
The legal basis of the N-EWS is enshrined in the ministerial 
decree establishing the national Inter-ministerial Committee 
on Drug Addiction (ICD), which includes representatives from 
the Ministry of Health, Ministry of Justice, Prosecution 
Authority, Ministry of Interior, Police, Customs Administration, 
Ministry of Foreign Affairs, Ministry of Family, Ministry of 
Education and National Service of Youth, Ministry of 
Transport and determining its mandate. Thus, the ICD is 
officially mandated to maintain, develop and coordinate the 
N-EWS and related measures. The EWS information 
sharing is addressed as a permanent item on the agenda of 
ICD meetings.
The Luxembourgish EWS network relies on a nationwide 
coverage. Its primary objectives are the earliest possible 
detection of:
•	 the emergence of new psychoactive substances or  
products (including ‘legal’ highs);
•	 new patterns of use, including new types of use of  
already known or controlled substances or products; 
•	 psychoactive products containing potentially dangerous 
adulterants or cutting agents;
•	 relevant information provided by forensic evidence  
(e.g. toxicological analysis/autopsies).
Furthermore, the N-EWS is designed to guarantee 
multilateral, top-down and bottom-up information exchange. 
It plays a crucial role in the process, which may lead to 
adopt national control measures on non-controlled substances 
as the ICD directly reports to the Minister of Health and 
recommends actions to be taken in terms of new regulations 
or public alerts. The ICD is currently chaired by the National 
Drug Coordinator, who is also the head of the national 
EMCDDA focal point. Also, the head of the national Europol 
Drug Unit is a member of the ICD and the Minister of Health 
mostly attends personally ICD meetings. The rapidity of 
the EWS-related information flow benefits largely from this 
constellation. 
Luxembourg is also actively promoting the set-up of 
trans-border information exchange mechanisms on new 
psychoactive substances or products and new drug use 
patterns in the framework of the Benelux cooperation 
schemes. Trans-border interregional data are deemed crucial 
when it comes to the early detection of potentially dangerous 
substances and use trends.
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In terms of financial resources, no specific state budget line 
is currently attributed to N-EWS activities. This is partly 
explained by the fact that the vast majority of the N-EWS 
partners (including the national EMCDDA focal point, that 
disposes of a EWS dedicated budget line) are in one or 
the other way financed or co-financed by the State and that 
EWS-related tasks are included, whether directly or indirectly 
it their mission framework.
Communication means that the N-EWS is based upon, are 
various and their respective use depends on the observed 
situation and the rapidity of a required response. Urgent 
notifications are most frequently made by phone and 
backed-up by e-mail. The flow of information received via 
international partners are generally distributed electronically 
to N-EWS partners, as are the EWS implementation progress 
reports to the EMCDDA due on a biannual basis. Meetings of 
the ICD are held three to four times a year, although 
competent members of the ICD may convene to address 
urgent matters if the situation requires so. Meetings with 
competent ministers are held ad hoc if the situation asks for 
rapid and/or important decisions. 
The fact that a majority of EWS stakeholders are 
multilingual (LU, DE, EN, FR) largely facilitates 
communication and especially the gathering of information 
on new drugs or patterns of use (e.g. web search, scientific 
publications, grey literature).
Core functions and information flow
N-EWS data may be provided via seizures, voluntary drug 
profiling demands, forensic evidence, (online) headshops’ 
offer screenings, drug treatment agencies or the National 
Drug Prevention Centre (CePT). The latter also performs ad 
hoc rapid assessment studies on specific topics (e.g. 
inhalants). International incoming data are mostly channelled 
via the NFP and the national Europol Drug Unit to the ICD 
and the N-EWS network.
Most commonly, N-EWS network partners listed above 
notify new substances/products or new patterns of use in an 
informal way first, whether to the NFP or the national 
Europol Drug Unit. The NFP in collaboration with the 
Figure 15 — Information flow in the framework of the Luxembourgish EWS
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national Europol Drug Unit and, where appropriate, 
with other national experts, assesses the pertinence and 
relevance of the provided information and if required, assists 
data providers in the completion of the notification form to 
be transmitted to the EMCDDA. Simultaneously, the ICD is 
informed on any relevant issue. All EWS data are processed 
confidentially to avoid any iatrogenic effects, unless public 
warning is deemed necessary by the ICD and the competent 
minister.
Case study 
The utility and reactivity of the N-EWS has been proven on 
numerous occasions, by providing the NFP and the ICD with 
valuable information on drugs via national or international 
channels or by contributing to general public warnings. 
It also has contributed significantly to adopt rapid control 
measures on 4-MTA, PMMA, 2C-I, 2C-T-2, 2C-T-7, TMA-2, 
GHB, BZP, in the context of the so-called ‘Spice’ and ‘legal 
highs’ phenomena on the whole range of synthetic agonists 
of cannabinoid receptors and most recently on mephedrone 
(cathinone), which use and seizure was notified in 2010 by 
police forces to the NFP and ICD trough the EWS network 
and subsequently to the EMCDDA via the NFP.
As far as delays between Council decisions and effective 
control measures at the national level are concerned, the 
following has been observed:
•	 4-MTA: 3 months;
•	 PMMA: 2 months;
•	 2C-I, 2C-T-2, 2C-T-7 and TMA-2: 11 months;
•	 BZP: 2 months;
•	 Mephedrone: put under control in Luxembourg before 
the actual Council decision in December 2011 on an 
EU-wide control.
Up to 2011, two public alerts by the Ministry of Health, 
based on data gathered via the EWS occurred; a first one 
in 2007 concerning the possible presence of glass beads in 
herbal cannabis and the second in 2009, informing on the 
risks of heroin contaminated with anthrax.
Strengths, limitations and way forward
The national reference laboratory disposes of the required 
resources to perform high-quality toxicological analysis, even 
though most ‘unknown’ substances are currently profiled in 
other countries before they arrive on the national market. 
The toxicological department of the National Laboratory of 
Health is currently working on new methods to detect and 
profile uncommon psychoactive substances by using 
high-performance gas chromatography in association to mass 
spectrometry.
Also worth mentioning are the relatively short delays between 
the risk assessment results, mostly provided by the EMCDDA, 
or the respective Council decision and the change of the 
national legislation allowing to control a given substance. 
These changes occur via Grand-ducal decrees modifying the 
annexes (lists) of respective regulations previously described.
Although the N-EWS is highly operational, there is obviously 
space for improvement, particularly as far as supplementary 
data sources are concerned. Thus, non-fatal drug-related 
emergencies requiring medical intervention are not reported 
systematically. Moreover, emergency services do not index 
drug-related interventions separately, which means that no 
valid monitoring of those cases can be performed. 
The referred situation is not likely to change and thus, 
the inclusion of emergency services in the N-EWS still 
appears to be unfeasible at the present stage.
National drug legislation does not expressively foresee a 
legal framework for on-site testing, profiling of illicit drugs 
(e.g. night clubs, public events or rave parties) or amnesty 
bins which could provide valuable first-line data. Also, new 
challenges are ahead as far as the surveillance of ‘legal 
highs’ products are concerned, since the marketing of these 
products obviously exploits the constraints of legal 
procedures substance control measures are generally based 
on. Furthermore, the acquisition of the products mainly occur 
via the Internet and new psychoactive molecules possibly 
included in these products are firstly difficult to detect and 
secondly, risk assessments are difficult to perform since 
long-term studies on adverse effects are generally not 
available.
Links and references 
Links
Centre de Prévention des Toxicomanies: 
http://www.cept.lu
Centre de Recherche Public de la Santé: 
http://crp-sante.lu
Laboratoire national de santé, Grand-Duché de Luxembourg: 
http://www.lns.public.lu/index.html
Ministère de la Santé, Direction de la Santé Grand-Duché de 
Luxembourg: http://www.ms.etat.lu
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Portail Santé, Grand-Duché de Luxembourg: 
http://www.sante.public.lu
Réseau Luxembourgeois d’Information sur les Stupéfiants et 
les toxicomanies, RELIS (Luxembourg Information Network on 
Drugs and Drug Addiction): http://www.relis.lu
References 
Origer, A. (2000), ‘Les drogues synthétiques à la lumière 
des nouvelles techniques de monitoring épidémiologique’, 
CULTURES en Mouvement, Ed. Cultures No 25/2000, Paris.
Origer, A. (2010), Annual national report on the state of the 
drugs problem — Grand Duchy of Luxembourg, EMCDDA 
focal point, CRP-SANTE, Luxembourg.
Luxembourg — early warning system
100
101
Introduction
The early warning system was originally set up in Malta 
in 2004/5. This was done in compliance with the Council 
Decision 2005/387/JHA of 10 May 2005 on information 
exchange, risk assessment and control of new psychoactive 
substances, early warning system of the EU Joint Action Plan 
on New Synthetic Drugs. The project was initiated by the 
Maltese national focal point (NFP), and brought together the 
Malta Police Drug Squad, the Europol Liaison Officer, the 
Malta Forensic Laboratory and the Toxicology Laboratory, 
with the aim to establish a means of exchanging information 
among Member States of the EU regarding the detection, risk 
and control of new synthetic drugs.
Organisational issues
The purpose of the EWS system in Malta is to establish a 
network of communication among stakeholders within the 
country, as well as to actively contribute and share 
information regarding the emergence of new synthetic drugs 
on an international level.
The members of the EWS in Malta come from different 
governmental departments and incorporate professionals 
within law enforcement, forensic toxicology, health and 
medical entities. 
In line with its international obligations the Maltese EWS also 
communicates with Europol (Europol National Unit (ENU) 
and Europol Liaison Bureau) and the EMCDDA. The EWS in 
Malta covers the whole geographical area of the country.
Core functions and information flow
The functions of the Maltese EWS network are to identify new 
synthetic drugs and to notify all local entities involved in the 
network as well as the EMCDDA. 
The Local EWS network comprises of:
•	 The Malta Police Drug Squad;
•	 Malta Customs;
•	 National Hospital — Toxicology and Data Department;
•	 Malta Medicine Authority;
•	 Malta National Forensic Laboratory.
In the case of the Local detection of a new synthetic drug, the 
notification is received by the NFP, either from the 
National Forensic Laboratory or the Malta Police Drug 
Squad. The NFP in turn disseminates the information to the 
rest of the local network and to the EMCDDA. 
The NFP is also responsible for notification to the local 
network regarding reporting by other Member States which 
is received through the EMCDDA.
The following communication system for an early warning 
system for new synthetic drugs has now been put in place to 
be able to deal better with the expected following scenarios.
In cooperation between the NFP and the Europol National 
Unit of Malta a communication network for the reporting of 
new synthetic drugs in order to be able to handle the 
following three scenarios.
Scenario 1: A new drug is detected by the Malta Police Force
The Drug Squad Unit (DSU) informs the ENU who informs 
other law enforcement agencies (Les). The ENU informs NFP 
who in turn informs the EMCDDA and care agencies (CAs). 
The ENU also informs the European liaison officer (ELO) who 
then informs Europol.
Scenario 2: A new drug is detected by a Care Agency in 
Malta
The CA informs the NFP who informs the ENU/DSU and the 
EMCDDA. The ENU informs the ELO, who informs Europol.
Scenario 3: A new drug is detected by another Member 
State.
Case study
The network of experts involved in the EWS come from the 
different sectors. This contributes to assuring that all areas 
directly affected by changes in drug use trends and by the 
emergence of new synthetic drugs have such important 
Malta — early warning system
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Figure 16 — Communication network for the reporting of new synthetic drugs
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information made available to them through the 
collaboration that this network supports. Contributions by 
the Maltese EWS network, together with information sharing 
with other Member States and the EMCDDA have resulted 
in the scheduling of a number of new synthetic drugs which 
emerged in recent years. A typical example in the local 
context was the addition of mephedrone to the list of drugs 
scheduled under Maltese laws in September of 2010.
The Forensic Laboratory is responsible for the analysis of all 
the illicit drugs that are seized in Malta by the Police Drug 
Squad and hence all new synthetic drugs are reported by this 
laboratory. Although as a laboratory it is part of the 
local EWS network, though no official appointment as yet 
has been made. Since 2005, a number of synthetic 
compounds have been reported to the NFP (Table 1) who 
then reported on to the EMCDDA.
Though there is a good working relationship between the 
Forensic Laboratory and the NFP, there is no official 
so-called appointment and hence the network that links 
together the other members of the local EWS network is 
based on the good will of those that make up the relevant 
bodies of the said network. 
This in turn could be remedied by the provision of an official 
appointment. At present, any general sharing of information 
about new synthetic substances between members of the 
network is done on an individual basis and then the NFP 
informs the relevant bodies. 
In addition, when in 2010 a batch of bad heroin, found to 
be cut with Alprazolam was identified, the Forensic 
Laboratory also informed Sedqa, Malta’s National Agency 
Early warning system — national profiles
103
Table 1 — Reports to the EWS from 2005 until 2011
Chemical Year/s Number of reports
GBL 2011 (still not included on the EDND) 1
Desoxy-D2PM 2011 1
MDPV 2011 1
JWH-210 2011 (still not included on the EDND) 1
JWH-018 2011 (09-2011 still not included on 2011) 2
Mephedrone 2011 and 2010 6 (4 reports in 2010 and 2 reports in 2011)
GHB 2010 1 — overdose
BZP 2006 5 (3 reports on tablets and 2 reports urine 
samples)
mCPP 2006 (one of the biggest seizures in Europe 
– > 50 000 tablets)
1
DPIA 2005 3
Malta — early warning system
Against Drug and Alcohol Abuse, to be able to better inform 
its clients.
Strengths, limitations and way forward
The National network is composed of forensic experts from 
the National Laboratory, law enforcement personnel from 
police, customs, hospital and the medicines authority. The 
network has a good level of communication which 
contributes to the swift communication regarding any new 
substances or emerging trends. Malta is represented in the 
annual EWS meeting held by the EMCDDA and the national 
focal point is kept informed of any developments. Early 
detection of new psychoactive drugs has contributed to the 
inclusion of new substances in the list of scheduled drugs in 
Maltese Law. Members of the Maltese EWS network were 
instrumental in Malta’s decision to schedule mephedrone in 
September of 2010.
The major limitation as highlighted above is the fact that the 
network has no formal status and thus depends entirely on 
the good will of the actors within each of the relevant 
entities. This in itself — the good relations between the 
relevant entities — is not the limiting factor but, to the 
contrary, is the major reason why the network has 
functioned so well so far. However, this needs to be 
strengthened so that in times when there may be a change 
in personnel that may lead to less communication, this does 
not disturb the overall functioning of the network. Thus, in 
the future to prevent such a situation, the introduction of 
formal ties such as MoUs between the relevant bodies should 
provide the means through which the network continues to 
function as foreseen. 
Links and references
Malta national focal point (2007), 2007 National report — 
Malta Drug Situation, ISBN-978-99932-688-6-4.
Ministry for the Family and Social Solidarity (2008), 
National Drugs Policy 2008. 
Ministry for the Family and Social Solidarity, Malta.
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Introduction
In practice, the daily monitoring, surveillance and the acute 
assessment of risks of new psychoactive substances is done 
by the Drugs Information and Monitoring System (DIMS). 
The DIMS was originally started as a local initiative in 
Amsterdam to give drug users the opportunity to determine 
the composition of their drugs. In 1992, it was decided to 
expand this system nationwide. This offered the possibility to 
gain insight into the various new drug markets. The 
monitoring task of the DIMS has become increasingly 
important in the course of the 1990s and forms the basis 
of the Dutch early warning system (EWS). The base is still 
the same: exchanging information. Drug users have their 
drugs analysed in order to know the exact composition and, 
in return, give information about observed effects, use and 
market. 
Signals pointing to the appearance of new drugs on the 
market could be picked up by the DIMS. But other 
organisations, e.g. law enforcement or customs could also 
detect such signals. However, there was no exchange of 
information between these organisations. In fact, the lack 
of cooperation fuelled an attitude of distrust and when new 
information was gathered, each organisation assessed the 
need for further action in their own way. For example, the 
detection of a large amount of 2C-B by customs led to the use 
of a rapid procedure provided by the Netherlands drugs law 
(‘Opiumwet’), resulting in a decree prohibiting this substance 
(Borst-Eilers and Sorgdrager, 1998). Yet the Minister of 
Health, Welfare and Sport, who is leading where the 
prohibition of drugs is concerned, did not have the 
possibility to assess the need for prohibition from a 
public-health perspective. Thus, it was felt that there was a 
need for a coordinated assessment at national level. 
This coincided with the need to nationally implement the 
Joint Action of 16 June 1997 concerning the information 
exchange, risk assessment and the control of new synthetic 
drugs (Council of the European Union, 1997). This resulted 
in 1999 in the foundation of the Coordination Centre for 
Assessment and Monitoring of New Drugs (CAM) 
(Borst-Eilers, 2000a).
Concomitantly, the Committee for Risk Assessment of New 
Drugs (CRAND) was installed (Borst-Eilers, 2000b). 
The principal tasks of this committee are to exchange 
information on drugs and drug use and to assess the risks of 
new drugs decisively, independently and multidisciplinary. 
By exchanging information and assessing the risks, CRAND 
supports CAM in its task to inform and advice the minister of 
Health, Welfare and Sport on the new trends in drugs and 
drug use and the associated potential risks.
Initially, CAM was placed at the Health Care Inspectorate, 
but in 2006 it was moved to the National Institute of Public 
Health and the Environment.
Organisational issues
DIMS
Since the start of the DIMS in 1992, the Ministry of Health, 
Welfare and Sport has financially supported the national 
activities of the DIMS. During the 1990s, the DIMS has been 
embedded in the official Dutch drug policy. In 1998, the 
Minister established an independent supervisory commission, 
the Begeleidingscommissie DIMS (Borst-Eilers, 1998a). The 
members of this commission are appointed by the Minister 
(Borst-Eilers, 1998b; Hoogervorst, 2004b; Klink, 2008). 
Since 1999, the DIMS is part of the National Drug Monitor 
(Borst-Eilers, 1999).
The main focus of the DIMS is to identify the compounds 
of (synthetic) drugs, to describe prevalence of drugs in the 
market and trends in drug use, and to identify health risks for 
drug-users (Keijsers et al., 2008; Vogels et al., 2009; Brunt 
and Niesink, 2011). Apart from its monitoring function, DIMS 
also has an important surveillance task. When a drug with 
extraordinary health risks appears on the market, the DIMS-
bureau starts and coordinates a national warning campaign 
(i.e. Red Alert) to prevent and reduce health risks. 
The DIMS functions under the authority of the Dutch Ministry 
of Health, Welfare and Sport and is supervised by the 
Netherlands — early warning system
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Figure 17 — Organisation chart of the Drug Information and Monitoring System (DIMS)
Netherlands Health Care Inspectorate. An organisation chart 
of DIMS is shown in Figure 17.
DIMS is a network of cooperating institutions which consists 
of the coordinating and steering centre at the Trimbos 
Institute, which is the Dutch Research Institute for Mental 
Health and Addiction, 30 ‘test-offices’, and numerous 
anonymous drug users. Most of the offices are part of the 
prevention departments of facilities for outpatient addiction 
care situated all over the Netherlands. Field workers 
(i.e. prevention professionals) working at these facilities 
subsequently inform the substance-user about the compounds 
of the provided drugs, based on laboratory analyses. The 
drug testing system enables scientists at the central DIMS 
office to monitor synthetic drug markets by gathering and 
interpreting the information from the offices.
About six people are working at the DIMS-Bureau. The head 
of the bureau is a toxicologist. The Begeleidingscommissie 
DIMS represents different disciplines. 
The DIMS network is organised around a closed website. 
The DIMS website is used both for rapid exchange of 
information on new drugs, for internal warnings, but also for 
the identification of drugs.
Every year there is a refreshment course and meeting with 
the partners. Three times a year there is a meeting with the 
representatives of the member institutions. The 
Begeleidingscommissie DIMS meets three times a year. 
The staff of the DIMS Bureau meets weekly on current affairs. 
The DIMS Bureau also organises courses for new testers of 
the member institutions. Communication within these bodies 
is in Dutch. Twice a year, the DIMS publishes an update on 
the monitoring results and once a year, a more glossy folder 
is published to inform the general public, both are in Dutch. 
The DIMS provides data to the National Drug Monitor, CAM, 
the European EWS and to the EMCDDA. Results of the DIMS 
are also published in international scientific journals.
CAM
CAM became operative in 1999. It was formally founded 
by a ministerial decree (Borst-Eilers, 2000a). Later, the 
managerial structure of CAM was adapted to secure the 
separation of independent assessment and advice from 
subsequent policy making (Klink, 2009a). It is the task of 
CAM to see that new drugs are subjected to a risk 
assessment, following established procedures and criteria. 
Based on the results of a risk assessment, CAM advises the 
Minister of Health, Welfare and Sport regarding 
appropriate measures. Furthermore, CAM has a 
coordinating task regarding the early signalling of new 
drugs, making use of already existing monitoring systems. 
In these matters, CAM reports to the relevant directorate of 
the ministry of Health, Welfare and Sport. When new 
psychoactive substances are involved, CAM will, on the basis 
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of a risk assessment, also report to the EMCDDA via the 
national focal point and to Europol.
CAM consists of a coordinator, his deputy and administrative 
support. The coordinator should have knowledge and 
experience in the field of drugs and drug use. Currently, 
CAM is located at the National Institute of Public Health and 
the Environment (RIVM), further securing the scientific 
independent performance of the risk assessments. 
CAM organises at least three meetings of CRAND each year, 
to facilitate the broad exchange of information on new 
drugs and drug use. When there is a need for a risk 
assessment, additional meetings might be necessary. Minutes 
of the regular meetings are reported internally and to the 
Ministry of Public Health, Welfare and Sports. When a risk 
assessment has been performed, a risk assessment report 
is written, which is made public on the website of the RIVM 
after the Minister of Health, Welfare and Sport has sent his 
reaction to the Parliament. All communications are in Dutch, 
but when a risk assessment report is written, an English 
summary is included.
CRAND
CRAND was installed concomitantly with the foundation of 
CAM in 1999 (Borst-Eilers, 2000b). Originally, two separate 
committees were installed, one for the exchange of 
information and one for the risk assessments. Yet, the 
members appointed were almost the same. This was changed 
in 2003 when both committees were replaced by a single 
one, executing both tasks (Hoogervorst, 2004a; 
Hoogervorst, 2007; Klink, 2009b). Later on, the 
managerial structure of CAM and CRAND was criticised in 
the Parliament, as the head of the department from the 
Ministry of Health, Welfare and Sport, who is responsible for 
developing and executing drugs policy was also the chair 
of CRAND and member of the board of CAM. This was 
changed in 2008 by appointing an independent chair of 
CRAND and abolishing the board of CAM (Klink, 2009a).
The tasks of CRAND are:
•	 to support CAM in its task to inform and advice the 
minister of Health, Welfare and Sport;
•	 to broadly exchange information on drugs and drug 
trends;
•	 to assess the risks of new drugs decisively,  
independently and multidisciplinary;
•	 to examine and evaluate the risk assessment procedure.
CRAND consists of an independent chair and a maximum of 
20 members. The members are appointed by the minister of 
Health, Welfare and Sport and represent organisations 
having expertise in the field of drugs, drug use and 
addiction. The organisations currently represented in CRAND 
are the National Drug Monitor (also chair), DIMS, the Public 
Health Service of Amsterdam, the National Poisoning 
Information Center, the Health Care Inspectorate, the Food 
and Consumer Product Safety Authority, SolutionS Center 
(clinic for addiction care), Tactus group (addiction care), the 
Bonger Institute for Criminology from the University of 
Amsterdam, the Netherlands Forensic Institute, the 
Netherlands’ Police Agency and the Public Prosecutor. 
Next to the expert members, representatives from the 
Ministry of Health, Welfare and Sport and the ministry of 
Security and Justice are appointed. The coordinator of CAM 
is the secretary of CRAND. When a risk assessment is 
performed, the representatives from the ministeries may take 
part in the discussions, but do not actually assess the risks. 
The representatives from the other organisations base their 
judgment on their own expertise, without the need for 
consultation with the organisations they represent.
Focal point
The national focal point is hosted by the Trimbos Institute. 
In practice, DIMS also functions as the Dutch contact for the 
European EWS on behalf of the Dutch NFP.
Core functions and information flow
The N-EWS in the Netherlands is a network of 
organisations with each having their specific expertise and 
role. The involvement of each of them may vary depending 
on the process/function of the N-EWS that is at hand. 
Basically, three main N-EWS-related functions/processes can 
be discerned: Monitoring, Red Alert System and Risk 
Assessment. Each of these processes will be described here 
and it will be indicated which organisations are involved in 
each of them.
Monitoring
In the Netherlands, multiple monitoring instruments are 
present, which may provide relevant information for the early 
signalling of new drugs or new drug trends. Many of these 
are represented in CRAND. Meetings of CRAND are 
organised by CAM. Thus, the organisations involved are 
often referred to as the CAM network (Table 2).
In principle, information on all kinds of drugs is exchanged 
within the CAM network. However, in view of the monitoring 
task of CAM and CRAND, there is a focus on new drugs. 
Information is exchanged on a regular basis in CRAND 
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Table 2 — Sources providing relevant information for the National early warning system incorporated in the CAM network
Monitor Location Coverage Drugs market Principal methods
National Drug Monitor 
(NDM)
Trimbos Institute National all Gathers and compiles  
information from all 
available sources
Reitox/EWS EMCDDA Europe New psychoactive 
substances
Depends on Member States, 
mostly seizures
Drugs Information and  
Monitoring System (DIMS)
Trimbos Institute National New psychoactive  
substances, ecstasy,  
amphetamine, cocaine, 
opiates
Sample analysis at user level
Monitor Drug Incidents (MDI) Trimbos Institute National all Information from healthcare 
professionals (ED-hospitals, 
ambulance, police)
National Poisoning 
Information Centre
National Institute of Public 
Health and the 
Environment
National all Information requests from 
professionals
Addiction care SolutionS Centre, Tactus 
group
National, Utrecht all Information from addicts, 
anecdotal
Antenne Bonger Institute for 
Criminology
Amsterdam all Urban anthropologic  
surveillance
National Forensic Institute National all Sample analysis of seized 
drugs; Toxicology of drugs or 
road traffic victims
Netherlands’ Police Agency National all Seizures, anecdotal
Health Care Inspectorate National all Drugs law-related 
inspections, anecdotal
Food and Consumer 
Product Safety Authority
National ‘legal highs’ Analyses of samples, 
inspections of smartshops, 
anecdotal
Public Health Service of 
Amsterdam
Amsterdam all Ambulance reports,  
anecdotal
Public Prosecutor National all Seizures
meetings organised by CAM. However, when there is a need 
for immediate exchange of information, information is shared 
through the CAM network using e-mail communication. A 
need for immediate exchange of information is only felt when 
there is concern regarding public health or an issue seriously 
affecting public order would arise. Also, information is 
disseminated through the national focal point to the EMCDDA 
when, after first assessment, a public health issue relevant 
for other Member States is at hand. Information gathered in 
this way can be used by the Ministry of Health, Welfare and 
Sport as a basis for a decision to request CAM to start a risk 
assessment. If the information is insufficient to make a 
decision, CAM can initiate a so-called quick scan to 
retrieve and compile the available information from the 
CAM network.
Starting in January 2012, the DIMS will also operate as the 
national reporting centre for new drugs. By more actively 
and systematically sharing information on new psychoactive 
substances found by Netherlands Forensic Institute (NFI), 
customs and police labs it is tried to get more quickly 
reliable information about ‘legal highs’ and other new drugs 
on the Dutch drug market.
Red alert system
Substance use implies health risks. Dutch drug policy aims to 
discourage substance use and to reduce the harm involved 
(De Kort and Cramer, 1999). Sometimes, additional health 
risks emerge when drugs are contaminated with other 
substances, or when drugs do not contain what they pretend. 
If such additional risks are noted, a warning campaign is 
conducted by the DIMS to reduce the number of 
hospitalisations and to prevent fatal drug incidents. The
campaigns aim to timely inform (potential) substance users 
about these additional health risks. To determine acute risks 
for the Red Alert procedure a network of different experts can 
be consulted; e.g. toxicologists, the National Poison Centre, 
the National Forensic Institute. Several actors, namely field 
workers (i.e., prevention professionals), policymakers and 
scientists participate in these campaigns (Keijsers et al., 
2008). 
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A quick and adequate response to a contaminated drug on 
the market is of vital importance for drug users. To anticipate 
this, required actions of those involved has been laid down in 
a protocol based on past practical experiences. This protocol 
includes the aims of a warning campaign, background of 
the organisational structure, list of professionals involved and 
their contact information, responsibilities and tasks of policy 
employees, and a decision tree. The protocol also contains 
a checklist to make it possible to control whether all activities 
have been executed and all authorities have been informed. 
A Red Alert is closely watched and steered by policy 
employees of the Ministry of Health, Welfare and Sport and 
the Netherlands Health Care Inspectorate. Scientists at the 
DIMS-Bureau communicate with both these policy officials, 
the field workers at the test-offices and the press. The 
protocol also describes how the Red Alert campaign should 
be evaluated.
Risk assessment
On the basis of serious signals indicating public health or 
public order may be affected, the Ministry of Health, Welfare 
and Sport can request CAM to initiate a formal risk 
assessment [1] (numbers in square parentheses refer to 
numbers in Figure 18). CAM requests the members of 
CRAND to gather and send relevant information to CAM 
[2]. CRAND members send the relevant information to 
CAM. CAM gathers information from the literature and other 
relevant sources. Also, when there is a need, external experts 
can be involved, who may be invited for a special meeting of 
CRAND [3]. Based on all information that has been 
gathered, CAM compiles an information report and sends 
it to CRAND members [4]. The expert members of CRAND 
assess the risks individually and send the scoring forms with 
remarks back to the CAM. CAM compiles the risk scores and 
a risk assessment meeting of CRAND is convened where the 
results of the initial individual risk assessment are discussed. 
In a second scoring round during this meeting CRAND 
members can adjust their scores when there is a need. 
Subsequently, measures for further action are discussed 
including the consequences of these measures. On the basis 
of the risk assessment and the discussions during the 
meeting recommendations are made [5]. CAM now 
Ministry of Health,
Welfare and 
Sport
Minister
Interdepartmental Steering
Group Drug Policy
CAM CRAND
Other sources
External experts
(hearing)
1. Request risk assessment 2. Request information
3. Information
4. Information report
5. Risk assessment
+ recommendation
6. Risk assessment
 report
7. Policy advice
8. Policy advice
9. Decision
Risk assessment process
Figure 18 — Risk assessment process of the Coordination Centre for Assessment and Monitoring of New Drugs (CAM)
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produces a draft risk assessment report, which is commented 
by CRAND members (by e-mail) and subsequently, a final risk 
assessment report, which is sent to the Minister of Health, 
Welfare and Sport and the relevant department at the same 
ministry [6]. A policy advice is prepared by this ministry [7] 
which is discussed in the Interdepartmental Steering Group 
Drugs Policy. In this group, representatives from other 
ministries are present as well, including those from the 
Ministry of Security and Justice, the Ministry of Interior and 
Kingdom Relations, the Ministry of Foreign Affairs and the 
Ministry of Economic Affairs, Agriculture and Innovation. 
The comments from this group are sent to the Minister of 
Health, Welfare and Sport [8], who finally decides which 
further action will be taken [9].
Once the minister has sent his decision to the Parliament, the 
risk assessment report is released by placing it on the website 
of the National Institute of Public Health and the Environment. 
The report is written in Dutch. When the risk assessment 
concerns a new psychoactive substance, an English summary 
is sent to the EMCDDA and Europol.
Case study
PMMA warning on 11 November 2010
On 10 November 2010, the DIMS Bureau at the Trimbos 
Institute was informed by the NFI about ecstasy (‘XTC’) pills 
containing dangerously high amounts of PMMA. The pills 
were obtained from a police case in which a young man 
died after ingestion of these pills and some other drugs. 
The pills had been found in the surroundings of the victim. 
Because it was suspected that these pills might also be 
around in other places in the Netherlands, it was decided to 
make a general warning for these specific pills. The DIMS 
partners were informed and instructions were given which 
information should be given and in what way.
In addition, other Member States were informed through the 
EWS at the EMCDDA. Via the public relations official of the 
Trimbos Institute, a press communication was released and 
information was put on the website of the Trimbos Institute 
and on websites for drug users. Other relevant agencies 
were informed via specific e-mails and via the website of the 
Monitor Drug Incidents. The information was quickly received 
by national newspapers, radio and television. The news from 
the Trimbos website was also quickly spread via Twitter.
Strengths, limitations and way forward
Strengths 
The network structure of the national EWS in the Netherlands 
ensures a flexible approach, where the relevant participants 
take action. Implicitly, responsibilities are decentralised to 
ensure a rapid response. Yet, feedback to other partners and 
the Ministry of Health, Welfare and Sport ensures 
accountability. Weighing the relevance of new findings for 
public health and public order prevents premature actions, 
which would generate an unnecessary workload and — in 
the case of public warnings — a desensitisation of the public. 
Embedding in a network structure with DIMS and CAM as 
coordination centres supports the broad exchange of 
information. The regular meetings and exchange of 
information has created an atmosphere of trust. The use of 
a standardised risk assessment procedure ensures that risks 
from new drugs are assessed in a comparable way. The 
results from risk assessments provide a basis for a rational 
decision-making process. 
Limitations
The participants in the national EWS have fixed budgets and 
therefore are constrained in their activities. For example the 
CRAND may have the opinion that research on a specific 
substance is needed, but does not have the opportunity to 
initiate independent research. Yet, it should be said that 
the ministry of Health, Welfare and Sport always considers 
recommendations from CRAND, CAM, or other partners 
seriously.
In drug-related incidents, usually little toxicological data are 
gathered. Often, analyses are limited to confiscated drugs. 
When toxicology is performed in the hospital, case-related 
data are not released due to medical confidentiality 
constraints. Consequently, it is not always possible to 
confirm the contribution of a specific drug in an allegedly 
drug-related incident by toxicology data.
Way forward
Currently, no major changes to the structure of the N-EWS in 
the Netherlands are foreseen.
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Introduction
Norway has been part of the European early warning system 
(EWS) since it became a member of the EMCDDA in 2001. 
At the beginning of 2002, with a view to establishing a 
National early warning system (N-EWS), the Norwegian 
focal point embarked on a collaboration with the two most 
important players with regards to discovering new drugs in 
Norway, namely the National Criminal Investigation Service 
(Kripos) and the Norwegian Institute of Public Health (NIPH). 
The collaboration with these two institutions has been 
formalised. Initially, meetings were held every six months, but 
it was later decided that communication should primarily take 
place via e-mail. Since then, collaboration with other key 
players and individuals who are interested in the discovery 
of new drugs has also been established. This is described 
under the section Core functions and information flow. The 
first early warning report on the identification of new drugs 
in Norway was submitted in December 2001 for the year 
2001. 
In 2004, Norway joined the network for the current drug 
situation in Scandinavia (NADiS). The network, which was 
originally established as a Swedish network in 2000, 
became a Scandinavian collaboration when Norway and 
Denmark joined. In 2006, Finland became a member, as 
well as Iceland in 2011. NADiS is a closed network that 
largely involves institutions that analyse new drugs. The 
Norwegian Institute for Alcohol and Drug Research (SIRUS) 
is the administrator for the Norwegian part of NADiS. The 
Norwegian NADiS network consists more or less of the same 
agencies as the Norwegian EWS.
Organisational issues
The Norwegian EWS has no formal remit or regulation. 
It is based on voluntary participation and on Council 
Decision 2005/387/JHA, even though Norway is not 
formally bound by this decision. The Norwegian EWS is part 
of the Norwegian focal point and it is based at SIRUS. It has 
no links to EU institutions. The Norwegian EWS is a national 
system, with agencies in big Norwegian towns and cities. 
One person (a sociologist) works part-time as a national 
correspondent, and the head of the focal point is also 
involved in the work. Most of the communication takes place 
via e-mail. The language used in the national network is 
Norwegian, and information about new drugs is translated 
into English before it is sent to the EMCDDA EWS. The work 
of the Norwegian EWS is both scientifically and politically 
independent.
Core functions and information flow
The Norwegian EWS comprises 15 agencies, but the core 
of the work is the collaboration with Kripos, the NIPH and 
the Norwegian Medicines Agency. As a matter of routine, 
e-mails from the EMCDDA about new drugs that have been 
identified in Europe are sent to all members of the 
Norwegian EWS, and information that is submitted to the 
EMCDDA by other Member States is received in return. 
We also submit forms for drugs that have been discovered in 
Norway for the first time. It is mainly the Drugs Analyses 
Section at Kripos that fills out these forms when new drugs 
are seized, but the national customs laboratory has also 
identified drugs for the first time in Norway and submitted 
forms. SIRUS is responsible for maintaining a system whereby 
partners in the collaboration fill in forms when new drugs are 
identified, since this information is usually not available. The 
collaboration is often dependent on individuals. Norway has 
not established a separate database for the identification of 
new drugs, but uses the European database on new drugs 
(EDND). 
In addition to persons from Kripos, NIPH, the Norwegian 
Medicines Agency and SIRUS, the network consists of people 
from two sections at the Directorate of Customs and Excise 
(the national customs laboratory and the section for border 
controls), the ‘Føre Var’ (early warning) project at the Bergen 
Clinics Foundation, the Directorate of Health’s Poisons 
Information Department, the National Police Directorate, 
St. Olav’s Hospital’s Department of Clinical Pharmacology, 
Ullevål University Hospital’s Department of Clinical 
Pharmacology and Toxicology, the Institute of Forensic 
Medicine at the University of Oslo, Oslo Police District, the 
Health and Overdose Team in Trondheim and City of Oslo 
Alcohol and Drug Addiction Service. At present, the 
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Norwegian network comprises of 21 persons. There have 
been four meetings held in the Norwegian network. Since 
2010, the intention is to hold meetings once a year for 
members of the Norwegian network.
In addition to meetings of the Norwegian network organised 
by the focal point, other forums are also organised. Amongst 
other matters, collaborative meetings for analyses of drugs 
are organised by Kripos and SIRUS, and a collaboration 
group appointed by the Norwegian Medicines Agency for 
the continuous assessment of new drugs that should be 
included on the Norwegian list of narcotic substances is 
organised. The focal point is responsible for sending regular 
reports from the Norwegian EWS. The reports primarily 
contain information from the three main partners. For 
practical reasons, the reporting is limited to an annual EWS 
report. The Norwegian focal point and the EWS do not carry 
out risk assessments at the national level.
Case study
Example of PMMA and fatalities in Norway 
As a case study, the process concerning the incidence of 
PMMA in Norway during 2010/2011, and fatalities 
connected to the drug in the period is described. From 
summer to September 2010, the NIPH found PMMA 
(para-methoxymethylamphetamine) in blood in four 
autopsies. This information was communicated to Nordic 
contacts through the Nordic network on 27 September 2010. 
At the same time, Kripos reported a number of seizures of 
PMMA in the preceding weeks.
On 6 October, the NIPH published a warning on its website 
(www.fhi.no) about fatalities relating to the use of PMMA 
in combination with amphetamine/methamphetamine in 
Norway. The number of fatalities had now risen to six. In 
addition, the drug was found in several persons suspected of 
driving under the influence, which showed that PMMA was in 
circulation. 
The EMCDDA asked for more information with a view to 
issuing an alert to the Member States. The focal point 
contacted the NIPH, which wrote an updated text the same 
day. This was used in an alert about PMA and PMMA issued 
by the EMCDDA on 29 October.
On 12 November, following a very short consultation 
procedure, the Norwegian Medicines Agency included 
PMMA on the Norwegian list of narcotic substances that are 
prohibited pursuant to section 4 of the Regulations on 
narcotics. 
On 16 November, the EMCDDA sent an e-mail to Europol 
and the European Commission (the Directorate-General for 
Justice), in which it was pointed out that major seizures of 
the precursor 4-methoxy-BMK had been made, especially in 
Lithuania. It also stated that lack of control of the precursor, 
which is used to manufacture PMMA, can lead to increased 
amounts of PMMA and possibly also PMA on the illegal 
market in the time ahead. The concerned report originally 
came from the Technical Department at Kripos. It was 
forwarded to the EMCDDA by the focal point. 
On 12 January 2011, the NIPH informed the Nordic network 
of a total of 11 fatalities in Norway. Most had high 
concentrations of PMMA in their blood. On 31 January, a 
new warning was issued on the NIPH website about the fatal 
consequences of using PMMA. The number of fatalities had 
now risen to 12. In addition, PMMA had been found in the 
blood of 22 persons suspected of, among other things, 
driving under the influence. Furthermore, the police had 
made more than 80 seizures of PMMA since summer 2010, 
in the form of powder, either alone or mixed with 
amphetamines. The number of deaths was also reported to 
the Nordic network.
The example primarily shows that the NIPH has provided 
good and up-to-date information, both on its own website 
and through the Nordic network. Kripos also used the Nordic 
network actively as a distribution channel. From the focal 
point’s point of view, the collaboration with the two key 
analysis agencies worked well. The information and warning 
about the fatal consequences of taking PMMA were quickly 
communicated to Norwegian and Scandinavian partners, 
although it took more time before the EMCDDA was 
informed. 
Strengths, limitations and way forward
The Norwegian EWS has both strengths and weaknesses. 
One limitation of the system is that it often depends on 
individuals and personal relations, which means that changes 
in the agencies that cooperate with the system can lead to 
changes in the collaboration. Another challenge is that it 
has been difficult to decide how often a meeting should be 
convened. One strength of the Norwegian EWS is that the 
network is relatively small and transparent. This makes it 
easier to establish new relations in the network.
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It is a continuous challenge to get more agencies and people 
involved in the work on early warning in Norway. It is also 
a challenge to ensure that the system works satisfactorily. 
In 2010, a small-scale questionnaire survey was carried out 
in the Norwegian network, among other things about what 
can be done to increase activity in the network. It emerged 
that, for several of the participants in the network, pressure 
of time is a challenge in relation to giving priority to work on 
the EWS. It also emerged that more regular meetings were 
desirable.
 
Flexible and non-bureaucratic good cooperation exists with 
Kripos and the NIPH for many years. It could also be an 
option to extend the collaboration to include more agencies, 
although most of the relevant ones are already part of the 
Norwegian network. This is a continuous process. The goal 
is to monitor developments closely and have as many and as 
good sources of information as possible about new drugs in 
circulation in Norway.
Links and references
Norwegian Institute for Alcohol and Drug Research — 
http://www.sirus.no
Norwegian Institute of Public Health (NIPH) — 
http://www.fhi.no
National Criminal Investigation Service (Kripos) — 
http://www.kripos.no
Norwegian Medicines Agency (NoMA) — 
http://www.slv.no
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Introduction
Before Poland acceded to the European Union (in May 
2005), the Polish early warning system (EWS) was quite 
different from the present one. The flow of information was 
limited and the number of institutions within the system was 
restricted. Over the years, partners and the whole idea of the 
system changed. After 2005, the implementation of the EWS 
became an obligation, not only a recommendation. 
At the beginning, the system focused only on identifying new 
drugs on the market. There were, and still are, many 
limitations for active monitoring of new substances present on 
the Polish drug market. At present, an equally important 
factor is active identification of available information and 
alerts concerning new substances which may pose a serious 
threat to public health, especially to drug users. 
From the beginning, there was a need to extend the network 
of laboratories capable of identifying new drugs. In 2005, 
the Central Forensic Laboratory of Police Headquarters (CLK) 
was included in the network as a major partner. Other 
institutions that have been playing a very important role in 
the system include the Institute of Forensic Research with 
which a written cooperation agreement was signed in 2005. 
In late 2005, a decision was made to extend the network 
and start cooperation with toxicological wards. The 
cooperation started and has been developing until today. 
In 2007, the cooperation with Central Laboratory of the 
Agency of Internal Security has started. In 2010, the 
cooperation with the National Medicines Institute (NIL) 
was started, as the leading scientific facility specialised in 
analysing contaminated medicines. It was caused by the fact 
that the NIL started analysing new drugs present on the ‘licit’ 
market.
Since the launch of the system, a number of meetings have 
taken place. One of the most important was the conference 
organised in Autumn 2005, during which the whole idea 
of the EWS was presented and new partners (such as 
representatives of the Ministry of the Interior and 
Administration, NGOs and toxicological wards) were invited 
to cooperate. The cooperation with outreach programmes 
was initiated as they are very important partners in the 
network and the main actors in the development of the Polish 
EWS, i.e. active and precise dissemination of information. 
The outreach programmes with time started to play an 
equally important role as key informants concerning changes 
and new developments at the Polish drug scene in major 
Polish cities. The contact with outreach workers has also 
become a powerful tool to obtain in-depth information on 
new trends on the drug scene which is now becoming an 
important part of the Polish EWS.
Organisational issues
Development and implementation of the EWS is generally 
provided for in the Act of Law of 29 July 2005 on 
Counteracting Drug Addiction with the following tasks of the 
National Bureau for Drug Prevention (Kidawa, 2007):
•	 cooperating with international organisations concerned 
with counteracting and repairing damage caused by 
drug addiction;
•	 operating the national system of information on drugs 
and drug addiction as well as monitoring actions of 
counteracting drug addiction at national and  
international level, including:
 (a) acting as the national focal point of the 
 EMCDDA;
 (b) participating in the reporting activities for the  
 benefit of the national organisations;
 (c) cooperating with the EMCDDA and the 
 European Reitox Network on Drugs and Drug 
 Addiction.
The obligation of creating and further improving of a 
national EWS is also present in action 1.3 of the Ordinance 
of Council of Ministers of 22 March 2011 on the National 
Programme for Counteracting Drug Addictions 2011–16 
under the section devoted to supply reduction. The 
programme serves the role of the national action plan and 
the national drug strategy. 
The basic aim of the Polish EWS is to fulfil the obligation 
imposed by the Council Decision. Polish EWS plays a wider 
role than only fulfilling those obligations. The system is based 
on 3 pillars: (1) substance identification; (2) collection and 
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dissemination of information on possible health threats; and 
(3) identification of new trends and phenomena on the drug 
scene. 
At the national level, one of the main challenges is to warn 
drug users against the potential danger connected with 
using new, not well-known substances or combinations of 
several substances. Furthermore, the N-EWS focuses also on 
contaminants/adulterants of known psychoactive substances 
(e.g. cannabis with glass, cocaine with atropine, heroin with 
anthrax) as well as some medicinal substances (e.g. drugs 
containing benzydamine, dextrometorphane, ephedrine/
pseudo-ephedrine). Additionally, the Polish EWS collects 
qualitative data on drug scene in the framework of 
periodical meetings with outreach workers in order to have 
in-depth information on current drug scene developments. 
Since the beginning the Polish EWS has been installed in the 
national focal point — a department of the National Bureau 
for Drug Prevention (NBDP), which operates as an agency of 
the Ministry of Health. Two employees of the National Bureau 
for Drug Prevention with the background in political and 
social sciences work part-time on the EWS. Other duties are 
connected to regular activities of the NFP and the Prevention 
Unit of the NBDP. Technical support is provided by scientific 
laboratories (mainly NIL, IES), which provide sound 
knowledge in that field and consult the remaining partners. 
The NFP plays a central role in the system. It is responsible 
for data collection and dissemination as well as coordination 
and further development of the EWS. 
The coverage of the EWS is strictly dependent on sources of 
information. Almost all laboratories cooperating in the 
framework of the EWS operate as central laboratories 
collecting results from provincial laboratories (e.g. CLK) and/
or analyse samples from all over the country (e.g. NIL, ABW, 
IES). The toxicology department serves the role of Poisonings 
Information Centres for different regions, so they also collect 
data and information from other institutions. The outreach 
programmes are located in big cities simply because there 
is a concentration of clients seeking this form of help. So the 
coverage can be considered nationwide, but the number 
of partners is limited and therefore it is hard to precisely 
estimate the coverage. 
There are no meetings of all the network partners. The 
meetings are organised with smaller groups for particular 
‘categories’, e.g. NGOs and laboratories. There are regular 
meetings with harm/risk reduction programmes providers. 
The meetings are organised annually. The meetings with 
partners from laboratories are organised more often there 
are some urgent issues to discuss.
Core functions and information flow
At present, data are collected from the following partner 
institutions:
•	 Central Forensic Laboratory of the Police Headquarters 
(CLK) — responsible for forensic analyses for the Police. 
The CLK analyses more complicated samples (including 
samples of drugs) and collects data from 16 provincial 
police laboratories. 
•	 Institute of Forensic Research (IES) — responsible for 
conducting research within forensic science, as well as 
preparing expert reports for courts and prosecutor’s  
offices in criminal and civil cases. They conduct  
analyses of both body fluids and drugs seized. As a 
leading forensic institute in Poland they collect samples 
from all over the country.  
•	 National Medicines Institute — responsible for the  
quality, safety and efficacy of medicinal products and 
medical devices available on the Polish market. The 
Institute specialises in analysing contaminated drugs. 
Recently it has also been involved in analyses of new 
drugs on the legal market (legal highs). 
•	 Central Laboratory of the Agency of Internal Security — 
responsible for conducting forensic analyses (including 
drugs) in the course of the Agency’s investigations. 
•	 Six toxicological departments — Poisoning  
Information Centres — responsible for providing  
toxicological information for doctors and hospitals. In all 
cases, the centres are located in toxicological wards. 
•	 NGOs providing harm reduction and risk reduction 
(outreach) programmes. 
All communication within the system is done via e-mail. There 
is no special communication platform or database within the 
system. All partners from laboratories, who conduct analyses, 
have access to the EMCDDA (EDND) database. Substances 
are reported on EMCDDA reporting forms as all partners 
are fluent in English. The cooperating institutions fill out these 
forms with analysis results on an ad hoc basis. They send the 
information to the N-EWS. The information is verified and 
forwarded to the EMCDDA as well as the Polish network 
partners. Not all information is sent to outreach programmes. 
They receive information on new substances where there is 
more evidence of possible threat to users. They also receive 
information concerning all alerts received both from the 
Reitox network and the Polish network. 
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Additionally, outreach programmes serve the role of insiders 
and key informants in gathering information on the current 
situation and the latest developments on the drug scene. 
In the regular meetings with outreach programmes a focus 
group interview or a structured discussion is organised in 
order to get information on the current situation on the drug 
scene. The topic guide is similar on each with slight 
differences in emphasis on certain issues regarding recent 
developments. Data collection in this manner has started 
just recently (in 2008) but such simple analyses are planned 
every two years as they have proved effective. 
As for substance identification, different techniques and 
approaches are used in different laboratories for 
identification of new substances. 
The following identification techniques are used:
•	 Gas Chromatography–Mass Spectrometry (GC-MS) 
•	 Liquid Chromatography–Quadruple Time-Of-Flight Mass 
Spectrometry (LC-Q-TOFMS) 
•	 Nuclear Magnetic Resonance spectroscopy (NMR) 
•	 X-Ray Powder Diffraction (XRPD)
•	 High-Performance Liquid Chromatography with Charged 
Aerosol Detector (HPLC-CAD)
•	 High-Performance Liquid Chromatography with  
Electrochemical Detection (HPLC-EC).
For quantitative analysis, the following techniques are used: 
•	 High-Performance Liquid Chromatography with  
Diode-Array Detector (HPLC-DAD)
•	 High-Performance Liquid Chromatography with Charged 
Aerosol Detector Corona (HPLC-CAD).
 
To identify conformation, the following techniques are used: 
•	 Near Infrared Spectroscopy (NIR) 
•	 Fourier-Transformed Mid-Infrared Spectroscopy (FT-IR)
•	 X-Ray Powder Diffraction (XRPD).
Data on new substances analysed are reported to the 
EMCDDA and then to the Reitox network. Additionally, all 
information concerning new substances is disseminated to the 
national network of laboratories. If a possible threat 
connected to the use of a substance has been identified, 
outreach programmes are informed. Warnings and alerts 
are also sent to outreach workers. In cases of alerts going 
beyond the capacity of the EWS network, the alerts are sent 
to other institutions and organisations. For example, the 
information concerning anthrax in heroin was translated, 
filled with additional information concerning anthrax and 
sent to substitution treatment programmes, as well as 
detoxification units, both of which are in close contact with 
heroin users. 
There are no national guidelines and risk assessment 
procedures currently present in the national legislation. Work 
on national guidelines and the concept of restructuring the 
whole system, along with providing a clearly defined basis 
for the system has just started. 
Case study
Since 2008, the EWS activities have been dominated by 
‘legal highs’ (dopalacze — ‘boosters’ in literal translation). 
Especially the years 2009 and 2010 were the ‘years of 
legal highs’ (in 2008: about 40 shops all over the country, 
in October 2010: over 1 300 shops over the country were 
operating). The presence of the EWS and the possibility to 
exchange information both of new drugs and legal solutions 
concerning new drugs not only within the National network, 
but also with the EMCDDA and the Reitox network proved 
to be very effective to address this phenomenon. Analytical 
data available within the network facilitate the process of 
identifying new drugs present on the market. On the other 
hand, available knowledge of the existence of different legal 
solutions in other countries helped to prepare a basis for 
possible options for changes to the Polish law for the 
government, in order to respond to that phenomenon. 
Strengths, limitations and way forward
The strong point of the Polish EWS is the establishment of 
cooperation with most institutions and laboratories capable 
of identifying new drugs. Also, the precise distribution of 
information gathered by the EWS seems to work. Good 
cooperation with outreach programmes and toxicology 
departments and the likely use of these partners as data 
sources on health threats and new trends seems to be an 
optimistic sign of the further extension of the system’s 
application. 
A major task for the future is to create a more integrated 
system. A vital thing here is the development of national 
guidelines and building strong legal grounds for the EWS. 
The concept of such procedures, along with draft 
guidelines and legislative solutions is currently being 
prepared. To achieve that, there is also a need to secure 
sustainable financing for the analyses of new drugs in 
general and make legal changes. 
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The main downside of the Polish EWS system is many legal 
procedures to be followed in order to place new substances 
under legal control and the lack of risk assessment 
procedures foreseen by law, which would include a 
scientific risk assessment of substances by interdisciplinary 
teams of experts. In the long term, legal solutions are planned 
to establish a Committee comprised of interdisciplinary 
scientists who would conduct risk assessment and would 
recommend control measures for the government. Before that, 
it is planned to create an advisory body of such sort within 
the Council of Counteracting Drug Addiction. The Council of 
Counteracting Drug Addiction operates at the Prime 
Minister’s office and functions as a coordination and 
advisory body for counteracting drug addiction. Its main 
duties are to monitor and coordinate the actions within state 
policy in the field of narcotic drugs, psychotropic substances 
and drug precursors.
Another problem within the system is limited information 
concerning both the number of cases and the substance 
identified in body fluids coming from the toxicology branch. 
Additionally, the limitation is the lack of laboratories in 
poisoning centres capable of identifying new substances.
In the long term, there are plans to create three or four 
laboratories nationwide, which would provide analyses 
of poisoning cases where there is no clear evidence what 
caused the condition. Those laboratories would serve the 
role of analytical base for hospitals from regions allocated to 
them. They would also be responsible for collecting data from 
hospitals. The system would be connected with the 
development of toxicological information exchange and the 
monitoring system of toxicology and toxicity of products and 
goods. The draft concept of the whole system has been 
prepared by the National Consultant in Clinical Toxicology 
and presented to the Minister of Health. 
Further development of the EWS should also include a 
scientific approach to new phenomena emerging on the drug 
scene the monitoring of new trends. The case of ‘legal highs’ 
in Poland showed that in-depth information concerning the 
population of users of new substances, along with their 
characteristics is equally important in identifying new 
substances in order to provide effective measures to address 
the threat that these new substances might cause to the public 
health. 
Links and references
Chojecki, D. and Kidawa, M. (2006), ‘Szybka informacja, 
skuteczne działanie’, Serwis Informacyjny Narkomania nr 1 
(32).
Kidawa, M. (2007), ‘System Wczesnego Ostrzegania o 
Nowych Narkotykach’, Remedium, nr 5.
Legal acts in original language:
Ustawa z dnia 29 lipca 2005 r. o przeciwdziałaniu 
narkomanii (Dz. U. Nr 179, poz. 1485)
Rozporządzenie Rady Ministrów z dnia 22 marca 2011 roku 
w sprawie Krajowego Programu Przeciwdziałania 
Narkomanii na lata 2011-2016 (Dz. U. z 2011 r. Nr 78, 
poz. 428)
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Introduction
In Portugal, the main law on control, use and traffic of 
narcotic drugs, psychotropic substances and precursors is 
the Decree Law 15/93 of 22 January (republished as Law 
18/2009 of 11 May), which regulates aspects regarding 
penalties, medical prescriptions, authorisations, certification 
and control activities, as well as governmental responsibilities 
concerning treatment, prevention, criminal investigation and 
money laundering. In the annexed tables of the mentioned 
Decree Law are included the list of controlled substances 
in Portugal, following a national decision, a World Health 
Organization recommendation, a Commission on Narcotic 
Drugs decision or an EU Council Decision. 
On 16 June 1997, the European Union Council approved 
the Joint Action related to exchange of information, risk 
assessment and control of new synthetic drugs. In the 
following up of this initiative, the European Monitoring Centre 
for Drug and Drug Addiction (EMCDDA) and the Unit Drug 
of Europol (UDE), established their respective mandate and 
action fields in the context of new synthetic drugs and 
approach forms to start as early as 1997. The information 
collected and analysed by the UDE is mainly from forensic 
structures and law enforcement agencies, while data 
collected and analysed by the EMCDDA covers demand 
reduction area and is provided by the national focal points 
of each Member State.
In Portugal, the General Direction of Communitarian Affaires 
of the Ministry of Foreign Affairs organised a meeting with 
all the partners in this area, on 6 November 1997, to 
delineate the national implementation of the referred Joint 
Action. The meeting conclusions permitted the establishment 
of an exchange of information between the different 
institutions involved. The national system was created to 
ensure the fast gathering and analysis of information, 
feasible and relevant, on new synthetic drugs to contribute 
with relevant recommendations for legislative instruments 
and disseminate information for interventions in prevention 
and public health.
In 2003, the Portuguese Institute on Drugs and Drug 
Addiction (IPDT) was merged with the Service for Drug and 
Addiction Prevention and Treatment (SPTT), resulting in the 
Institute on Drugs and Drug Addiction (IDT). In Portugal, 
as the Portuguese focal point is located within the Institute 
on Drugs and Drug Addiction (IDT, I.P.), being the focal 
point tasks carried out by International Relations Unit of the 
Institute, the transmission of relevant information of the EWS 
is done by the IDT, I.P. to the EMCDDA and by the National 
Unit of Europol to the UDE. This double procedure allows the 
collection of information from different sources and partners 
working in the drugs field and its regular transmission to the 
European agencies. Since the implementation of this 
mechanism, the IPDT responded, in cooperation with its 
national partners, to EMCDDA official requests and to 
punctual requests, namely from other Member States. 
In December 2000, three years after the entry into force of 
the Joint Action, a national meeting of the early warning 
system was organised with the participation of all relevant 
partners, to promote a reflection on the work done and make 
suggestions for the future.
The main conclusion on the work undertaken indicated 
a positive evaluation of the articulation and exchange of 
information between national partners, improving each one’s 
work quality, in the context of the EWS, as in other projects 
and collaborations involving different bodies and the NGOs. 
With the purpose of guaranteeing a higher normalisation of 
this mechanism at European level, the National Network of 
Alert Mechanism proposed the EMCDDA to prepare and 
disseminate implementation guidelines, as the solutions 
founded by the Member States to reply to this Joint Action 
differ, in this moment, in the ambit and results. Also, a clear 
definition of new synthetic drugs was needed, as well as the 
definition of common procedures to use in the context of this 
mechanism.
In 2005, after the entry into force of Council Decision 
2005/387/JHA, another meeting of the National early 
warning system (N-EWS) was held, under the patronage 
of IDT, I.P., which gathered all the national partners of this 
network and also representatives form the European 
Commission and the EMCDDA. This was an opportunity 
to strengthen the debate on new synthetic drugs and the 
achievements of the network under the Joint Action. The new 
mandate on new psychoactive drugs, the procedure and 
deadlines established by the Council Decision were also 
discussed, especially the ways to adapt to the N-EWS to the 
European objectives.
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Organisational issues
•	 The N-EWS is an informal network that gathers  
representatives of IDT, I.P. national structure  
(prevention, treatment units and help line  
representatives), law enforcement agencies, forensic 
laboratories, national emergency help line, among  
others, coordinated by IDT, I.P. staff members. Along 
with these professionals, researchers that work closely 
with drug addicts, in the field can be pointed out;
•	 its main objective is to disseminate at national level all 
relevant information regarding the new psychoactive 
substances and patterns of use;
•	 the coverage of the N-EWS is national and guaranteed 
by the sharing of information by the several IDT, I.P. 
regional delegations;
•	 the staff involved in this structure belongs to the national 
focal point;
•	 this network communicates basically by e-mail and 
telephone; using both Portuguese and English.
Core functions and information flow
Information exchange is mainly based on the alerts sent by 
the EMCDDA that IDT, I.P. disseminates within the N-EWS, 
Figure 19 — National partners and information flow of the EWS for new psychoactive substances
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within a maximum delay of 48 hours, as shown above. 
The national mechanism envisages the coordination and 
exchange of information between both demand and supply 
sides of drug phenomena. One of the core functions of the 
N-EWS is to ensure the recollection and analysis of fast, 
reliable and relevant information concerning the new 
psychoactive drugs and the new patterns of use. This 
includes sharing this kind of reliable information with 
professionals, experts, policymakers, media and general 
population.
The information gathered through this mechanism is mainly 
focused to field interventions and public health protection.
Case study
As mentioned above, each time a new psychoactive 
substance is submitted to control measures, it is added to the 
annexed tables of the Decree Law 15/93. The lists annexed 
to this Decree Law have been amended several times as 
follows: 
•	 4-MTA through decree-law 214/2000, 2 September 
2000, included under list II-A, annexed to decree-law 
15/93, 22 January 1993;
•	 PMMA through Law 47/2003, 22 August 2003, list II-A 
annexed to decree-law 15/93, 22 January 1993;
•	 GHB through Law 17/2004, 11 May 2004, list II-A, an-
nexed to decree-law 15/93, 22 January 1993;
•	 2C-I, 2C-T-2, 2C-T-7, and TMA-2 14/2005, 26 January 
2005;
•	 Oripavina and BZP through Law 18/2009, 11 May 
2009.
Strengths, limitations and way forward
The N-EWS is an informal network within an institutional 
framework granted by the IDT, I.P. One of the strengths of the 
N-EWS is that since it is a rather small network it is very easy 
and fast to disseminate the information periodically sent by 
the EMCDDA. At a distance of an e-mail or a phone call, the 
alert is sent to all national partners.
One of the limitations of the system is that not all the seizures 
of all substances can be tested at the scientific laboratories 
with the desirable rapidity needed for the complete 
functioning of the N-EWS. 
The way forward is to strengthen the national capacity of 
gathering data regarding the new patterns of using new 
substances and disseminating validated and evidence-based 
knowledge through, e.g., street teams.
In 2010, following the need to create rapid responses to a 
new reality in the streets, an information network was 
created involving IDT, institutional partners and the NGO in 
the field. This informal and very flexible mechanism has the 
purpose of monitoring the evolution of the drugs phenomena, 
collecting information on three main priorities: use of new 
psychoactive substances, new patterns of consumption and 
over use. A field assessment, namely including the 
notification of new substances and/or new patterns of use is 
gathered by the street teams’ NGO and sent to IDT, I.P. — 
Harm Reduction Unit. This unit sends the collected information 
to the national focal point of the EWS which disseminates the 
relevant information among the network partners.
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Introduction
National drug policy
Shortly after 1991, most illicit known drugs have emerged on 
the Romanian black market and the number of drug 
trafficking offences increased considerably, as did the 
number of drug users and mainly injecting drug users (IDUs). 
In line with the European drug strategy, the national policy 
has tried to strike a balance between drug demand and drug 
supply reduction. Because of the missing links in the 
assistance chain and the alarming level of problem drug use 
that called for substitution treatment, higher emphasis was 
placed on demand reduction, which included preventive 
interventions and integrated care for addicted drug users. 
The national drug policy was managed from 2001 by an 
Inter-ministerial Commission composed of eight ministries 
instrumental in the field of drugs. A preventive touch was 
added, once the Inter-ministry Commission for Drug Use 
Prevention joined the health, public administration, youth 
and education approaches in one body. These early models 
of coordination ended with the setup of the National 
Anti-drug Agency (NAA) in 2002, in which the Spanish 
model of coordination in the field of drugs was transferred 
in Romania. With the creation of the NAA, it has become 
possible to tackle drugs in a systemic, integrated, coherent 
and continuous manner, from the perspective of inter- and 
multidisciplinary teamwork.
Organisational issues
The organisation and functioning of the national early 
warning system (EWS)
The establishment of the Agency also meant the 
institutionalisation of the national focal point (NFP) in charge 
of monitoring the drug phenomenon. Thus, drug demand 
reduction, drug supply reduction, drug monitoring and 
training became the pillars of the national policy on drugs 
in Romania, implemented in a centralised manner. The 
‘philosophy, main actors, general actions and initiatives of 
the Government in the field of drugs’ have been translated 
into practical terms into instruments following the main 
European guidelines and recommendations. The Romanian 
national focal point is a member of the European Reitox 
network coordinated by the EMCDDA. The Romanian EWS 
is coordinated by the NFP at national level. 
Objectives of the early warning system:
•	 to provide primary data on new psychoactive  
substances
•	 to provide public-health related information. 
The Romanian EWS acts both at European and national 
level.
One of the Romanian EWS’ main activities is the 
participation to the European early warning system 
coordinated by the EMCDDA, where it collects and 
disseminates the information available regarding new 
psychoactive substances and supports the assessment 
procedures available at EU level.
At national level, the Romanian EWS is entitled to support 
the response interventions elaborated by the drug demand 
reduction structure of the Romanian National Anti-drug 
Agency. Also, it supports the legislative and informative 
initiatives elaborated by the staff of NAA and submitted to 
the different parliamentary and governmental structures, 
working groups, etc. involved in drug demand and supply 
reduction legislation and regulation endeavours. 
The organisation and functioning of the EWS at national 
level is a national responsibility. The national EWS is 
coordinated by NFP. The national network is comprised of 
one national coordinator, members of the NFP (all 11 
members) and National Anti-drug Agency (drug demand 
and supply reduction departments), Romanian Europol 
National Unit, Forensic Science and Toxicology Laboratories 
from the Police, main hospitals and emergency units, 
University of Pharmacy, Institute for Legal Medicine and 
National Medicine Agency, NGOs involved in drug-related 
harm reduction programmes, public and private treatment 
centres. The coverage of the EWS is ensured at national 
level. The exchange of information is ensured by e-mail 
networking and information exchange, written institutional 
reports, and two annual workshops on new emerging 
psychoactive substances.
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Outcomes example
In the 2011 workshop of the National early warning network 
of experts, a bureaucratic barrier in identifying drug-related 
deaths and emergencies was identified and surmounted. 
Accordingly, the paraphernalia often is taken by the police 
and there is lack of communication between the Forensic 
Medicine Institute (IML) and police. 
The Romanian EWS has owned its scientific and political 
independence. The assessment performed with the help of the 
members of the network are carried out with participation of 
a wide range of experts: sociologists, toxicologists, chemists, 
psychologists, social workers and criminal police 
specialists. The reports are written at a high level of expertise 
and objectivity.
Core functions and information flow
The main sources of information are: 
Healthcare system — specialised and non-specialised 
treatment centres, hospitals’ emergency rooms, poisoning 
centres, psychiatric departments, outreach and street work 
agencies, drug prevention and harm reduction 
establishments, low threshold services, drug helplines, 
general practitioners, etc., as well as the laboratory 
networks of the various healthcare establishments 
(toxicological analyses of specimens from deceased or living 
individuals, etc.);
Law enforcement agencies — police, specialised drug units, 
customs, border guards, prosecutors’ offices, etc. and their 
laboratory networks (forensic analysis of seized drugs); 
Legal Medicine Institute:
•	 national medicines agencies and the national  
pharmacovigilance systems;
•	 universities and research establishments;
•	 scientific publications and grey literature in national 
languages;
•	 key informants — users (including discussion groups and 
forums), organisers of youth events (festivals, concerts, 
raves, etc.), owners and staff of clubs, etc.;
•	 media sources — printed and electronic media, the 
Internet, etc.
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Figure 20 — Information flow in the framework of the Romanian EWS
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Methodological diversity and triangulation of different 
approaches — the tools used in data collection of new 
emerging trends in substance use are diversified and most of 
them are having a low degree of standardisation.
Qualitative tools — Internet websites forums, social networks 
and media monitoring, interviews with key informants, drug 
users, etc.
Quantitative instruments:
•	 online surveys; 
•	 Behavioural Surveillance Survey among Injecting Drug 
Users using Respondent driven sample (RDS);
•	 risk assessments (for assessing the scale of the emerging 
trend, market, the medical, social, and crime involved 
associated risks for new substances);
•	 emergency cases monitoring.
Case study
Pilot survey on drug-related medical emergencies
The Romanian national focal point conducted a pilot survey 
on drug related medical emergencies which is largely
described in the National report on drugs 2010. 
This study presents an efficient way of assessing new treats 
in psychoactive substances use trends together with the data 
from drug-related deaths. Data was required from 56 
emergency hospitals from the administrative territorial units 
of Romania, of which 41 are located in counties and 15 in 
the Municipality of Bucharest. Of these, 45 medical units 
have responded to the request: 34 at county level and 11 in 
the Municipality of Bucharest. Toxicological analyses were 
conducted to determine the presence of a licit or illicit 
substance in body fluids and a direct cause was established 
between the cause of the emergency and drug use for 275 
patients.
Online survey on drug use in recreational settings in 
2008 
Research project focusing on the lifestyle, attitudes, 
knowledge and practices referring to the use of licit and 
illicit substance use among young people in recreational 
setting activities in Bucharest. The study was carried out from 
20 September to 5 December 2008 in partnership with a 
group of websites and online social networks usually involved 
in promoting recreational events.
Methodology of the online survey 
•	 The target population was made up of Bucharest-based 
young people aged 15 to 34 who attend recreational 
settings; 
•	 online questionnaire applied in websites and online 
social networks that promote recreational events e.g. 
afterhours.ro, nights.ro, clubbingradio.ro, metropotam.
ro, beatfactor.ro, pubbing.ro, anyplace.ro, hi5.com on  
a selfnominated sample of 1 511 subjects; 
•	 online portals in the study were chosen by  
representativeness criteria according to promoted music 
style, popularity/notoriousness among night life goers in 
Bucharest; 
•	 recreational drug use in the online sample (1 511 
respondents). 
Results: Bucharest recreational setting is a complex picture, 
well segmented by criteria such as age, price, and musical/
cultural options. Recreational drug use has become a reality 
at all levels categories participating in pastime activities, 
marked by psychotropic content substance use in a large 
variety: marijuana, ecstasy, amphetamines, cocaine, LSD, 
magic mushrooms, ketamine, bromomescaline, etc. 
The subjects reported the use of several substances not 
usually in the previous surveys. The prevalence rate of these 
substances use is as follows: 
•	 1 % of the respondents reported lifetime ketamine use;
•	 0.4 % bromomescaline (2cb)-phenethylamine;
•	 0.3 % salvia divinorum — plant inductive of  
hallucinogenic effects, usually sold in ethno-botanical 
plant shops. 
Other substances mentioned less frequently: DMT 
(dimetiltriptamina), DXM (dextrometorfanul, substance found 
in the pharmaceutical product Tusin), ice — crystal meth, 
datura — garden plant containing very toxic alkaloids for 
humans, ethnobotanical plants, medicines such as Regenon, 
Romparkin. 
Specificities of synthetic drug use 
Respondents of the survey were asked to provide details on 
the commercial names used for ecstasy pills/synthetic drugs 
on the market. Following database analysis, it was noticed 
these names are sub-types of pills with different concentration 
and prescription belonging to the designer drugs category — 
synthetic drugs (ecstasy/MDMA/amphetamine or 
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bromomescaline, etc.) As noticed also within the qualitative 
component of the research, names come from logos printed 
on the pills and usually rely on the notoriousness of brands 
known to young people (for cars, clothing etc). The most 
frequently mentioned names were: ‘Armani’, ‘Rolex’, ‘Puma’, 
‘Mitsubishi’, ‘Heart’, ‘Butterfly’, ‘Dollar’, and ‘Smiley’. 
Risk assessment on new psychoactive substances sold 
as ‘legal highs’ 
The Romanian national focal point, together with UNICEF 
Romania and Romanian Harm Reduction Network, started at 
the beginning of 2011 a qualitative research and evaluation 
project: ‘Risk assessment on the use and abuse of 
psychoactive substances sold as legal highs’, in order to 
assess the risk posed by this new drug use phenomenon and 
to make recommendations for building up of a harm 
reduction network of services addressing this specific 
category of addiction. The conceptual framework of data 
collection and analysis followed the published EWS 
Operating guidelines on Risk assessment of new 
psychoactive substances and the following key variables: 
•	 dose and frequency of use 
•	 short-term and especially long-term effects
•	 interactions with other substances (including alcohol and 
medicines)
•	 individual characteristics (e.g. genetic susceptibility,  
presence of interacting risk factors)
•	 characteristics of the social and cultural environment
•	 involvement of organised crime.
The methods of data collection involved online monitoring, 
focus groups and interviews conducted on key informants 
and questionnaires conducted on heavy ‘legal highs’ users 
and persons involved in ‘legal highs’ retail commerce 
activities.
Physical, chemical and pharmacological content 
This component included searches of substance mixtures 
that have proved to be most searched for and used among 
children and young people included in searches, and 
testimonials detected on-line, on different forums that tackle 
these specific topics. 
Mixtures of plants and chemical substances intended for 
smoking
The ‘spice’-type substances are the most common categories 
of psychoactive substances sold as ‘legal highs’. A large 
number of products designed for inhaling/smoking branded 
as ‘spice’ was detected such as ‘Spice Silver’, ‘Spice Gold’, 
‘Spice Diamond’, ‘Spice Arctic Synergy’, ‘Spice Tropical 
Synergy’, ‘Spice Egypt’, ‘Spice Maraciuca’, ‘Ganja’, ‘M6’, 
‘Diesel’, ‘Katana’.
Spice mixtures started to be searched for in the last 4–5 
months of 2008, with a rapid increase in 2009, followed by 
a decrease once the Emergency ordinance appeared and 
placed 36 plants and psychoactive substances under national 
control. Soon after the effect of the ordinance, a new type of 
‘Spice’ emerged fast on the market, namely ‘Spice 
Maraciuca’ that might not have contained a synthetic 
cannabinoid incriminated by Romania law. Additionally, the 
term ‘spice’ has been used for psychoactive plants before the 
term ‘ethno-botanicals’ became largely accepted.  
Another category is made up of plants such as Kratom and 
Salvia Divinorum, defining a category of plant mixtures 
destined for smoking. These substances were banned and the 
current information does not reveal any demands. Salvia 
Divinorum is probably the first psychoactive substance 
included among ‘ethno-botanicals’. Online interrogations in 
Romania show the interest for this plant at the end of 2006 
and beginning of 2007. 
Mixtures of energising chemical powders (amphetamine type 
stimulants)
Mixtures of chemical powders that are synthetic psychoactive 
substances, have energising or hallucination effects, and are 
traded under different names and mixed with known 
energisers: caffeine, creatine, etc. Most psychoactive 
compounds detected in these mixtures fall within the category 
of cathinones and piperazines. The data of the Central 
Analysis Laboratory within IGRP referring to the time period 
from January 2009 to February 2010 showed they 
generally contained cathinones. The most popular products 
were sold under the brands ‘Special Gold’ and ‘Magic’. 
A similar content has products such as ‘Flower Magic 
Powder’, ‘Flower Magic Powder+’, ‘Charge+’, ‘Flower 
Power’, ‘Crush’, ‘Crystal bath’, ‘Dark+’, ‘Special Diamond’, 
‘Special Original’. Other products with a similar content are 
mephedrone and some of its derivatives partially vanished 
from the ‘legal highs’ shops once the first ordinance took 
effect and placed legal highs under national control. 
A product sold as ‘White Sensation’ and promoted as a 
substitute for ‘Special Gold’ became the most popular drug in 
the second half of 2010, after the ban on MDPV and 
5-MeO-DALT, according to the forum ‘droguri101.ro’. 
There is no accurate information on the active substance 
but according to the online forum, this product contains the 
cathinone 4-MEC. 
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Another mixture of energising substances called ‘Pure by 
Magic’ was probably more popular among drug users after 
the effect of the two legal documents. No accurate 
information is available for the active substance, but 
empirical evaluations make it similar to a relatively new 
product NRG1, that might, according to the mentioned 
source, consist of naphyrone. The product gained in 
popularity in the second half of 2010, peaked at the end of 
the year, after which it declined, showing a trend similar to 
‘ethno-botanical plants’. 
The psychoactive substances described in the study are just 
a part of those present on the market. These products are 
changing from one day to another as does the concentration 
and ingredients that compose the sold brand. In addition, 
the trade name changes rapidly, which make the association 
between a substance and a certain brand difficult. Some of 
the most relevant findings of the Risk assessment of the use 
of new psychoactive substances among children and young 
people in Romania illustrated the following. 
Strengths, limitations and way forward
The Romanian early warning system continues to develop 
by enlarging its network and strengthening its research 
capabilities. The main advantages of the Romanian EWS 
are related to the fact that the EWS involves a 
multidisciplinary network of professionals, involved in drug 
demand and supply reduction but also in treatment, harm 
reduction, etc. Because sometimes the data regarding new 
substances is received in isolated spots and many times 
ignored, the emergence of the network provided a very 
efficient tool of data integration and dissemination of the 
most efficient means of coping with emerging trends on new 
substances use, a way of providing evidence-based 
information to legal stakeholders and intervention-focused 
professionals. 
Also, the network is constructed to work in a fast pace of 
information exchange, mainly by e-mail, telephone and 
expert meetings information exchange and debate and less 
based on bureaucratic institutional dialogue (such as written 
official requests, etc.).
The disadvantages are mainly related to the economic 
dimension. There is a lack of existing infrastructure for testing 
the biological samples in the toxicological units of emergency 
hospitals; a general problem with the new substances library 
updates for all the units involved in testing activity (including 
the Police laboratory and the Forensic institute laboratory). 
For example, according to the Institute of Legal Medicine 
representative ‘we do not have a toxicological 
confirmation of drug-related deaths for mephedrone (the 
5th cases mentioned in media), but there are problems with 
acquiring standard samples used for analysis of such 
substances.’ Also, there is a strong need for professional 
training in order to be able to obtain accurate empirical 
information about drug-related emergencies at national level. 
There is also a strong need for professional training in order 
to be able to obtain accurate empirical information about 
drug-related emergencies at national level.
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Introduction
The early warning system on new psychoactive substances 
was implemented in Slovakia in 2005 on the basis of EU 
Council Decision 2005/387/JHA on information exchange, 
risks assessment and control of new psychoactive substances 
in order to create an effective tool which could flexibly react 
and resolve issues of new psychoactive substances and 
provide early exchange of information regarding their 
appearance in all EU Member States. 
In the Slovak Republic (SR), the EWS functions at national 
level. Its activities are organised by the Government Office 
of the Slovak Republic who is manager for addressing drug 
issues. Administratively and technically, EWS activities are 
provided by the General Secretariat of BMDADC (since 
November, the Department for Drug Strategy Coordination), 
via the NMCD department. 
At national level, the EWS was established under the NMCD 
(NFP) by the establishment of the EWS working group which 
imply experts acting in various fields of drug phenomena 
(law enforcement, healthcare authorities, toxicology, forensic 
laboratory as well as the NGO and ENU. At present, the 
EWS group has 15 members who act in institutions and 
leading departments of the Ministry of Health, Interior, 
Justice, Economy, in low-threshold agencies (NGOs), NTIC 
and also specialists in the area of toxicology, forensic 
medicine and the provision of healthcare.
Organisational issues
Functioning of N-EWS 
The EWS group regularly meets once in a year (in November 
or December). In practice, they mainly address and discuss 
measures leading to reducing the demand for new 
psychoactive substances and, if necessary, recommendations 
for their control under the relevant drug laws. An initiative 
for legal restriction of new drugs most often arises from the 
police via their special units which act in the area of reducing 
the availability of drugs (National Drug Service), or from the 
Europol national centre. Before the EWS group recommends 
listing a new psychoactive substance in the list of controlled 
substances, they collect and verify all available data 
regarding the new substance (physical-chemical description 
of the substance, seizures, identification of a new substance 
and its admixtures, cases of intoxication and mortality in SR, 
its use in human and veterinary medicine, its distribution and 
methods of use and the involvement of organised crime). 
Key information sources are EMCDDA–Europol Joint Report 
as well as EMCDDA reports on Risk assessment. A very 
useful and prompt source of information is also the European 
Database of New Drugs (EDND) which provides updated 
information on new psychoactive substances.
Core functions and information flow
Information exchange
At national level, information related to new psychoactive 
substances is most frequently exchanged via NFP Internet 
portal www.infodrogy.sk which allows the exchange of 
sensitive EWS data (e.g. regarding analytical data and mass 
spectra of NPAS) via a closed section of specialists, 
accessible only by N-EWS members. The public has access 
to information of a warning and official nature (e.g. adopted 
NPAS control measures and warning reports of their 
harmfulness) via publicly accessible and open sections. 
Mass communication means (printed media and mass media) 
are used for the distribution of publicly accessible 
information. 
Key EWS partners
A key EWS partner in the area of detection and discovery of 
new trends in the use of psychoactive substances at national 
level is the NDS BFOC PFH. Qualitative analysis and 
identification of seized new psychoactive substances is 
carried out by the IFS PF who is the second key partner in the 
EWS national network. 
(8) With collaboration of Andrej Bolf, specialist of the drug expertise, and Ivana Bučková, officer of the National drug service.
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Figure 21 — Scheme of the basic N-EWS organisational structure
Notes:  (1) Before 2 March 2011, the Board of Ministers for Drug Addictions and Drug Control (BMDADC).
 (2)  Before 1 January 2011 the General Secretariat of BMDADC.
Source:  DDSC, 2011.
Cooperation between National Drugs Service and N-EWS
Within the Ministry of Interior and the Presidium of Police 
Force, the fight against drugs is addressed by the Bureau 
of the Fight Against Organised Crime (hereinafter ‘BFOC’), 
mainly via the section of the National Drugs Service and the 
West, Middle and East anti-drug departments. The National 
Drugs Service within the BFOC structure is a department 
addressing the fight against organised crime activities at 
national level whilst its activities are also orientated towards 
international cooperation in the combat against drugs. 
Within the BFOC structure, the West, Middle and East 
anti-drug departments focus upon the detection of drug crime 
in the appropriate regions of eastern (Košice and Prešov 
regions), central (Žilina and Banská Bystrica regions) or 
western (Bratislava, Trnava, Trenčín and Nitra regions) 
Slovakia.
The National Drugs Service has cooperated within the EWS 
national network since 2005, mainly in the form of mutual 
exchange of information regarding the occurrence of new 
psychoactive substances in the Slovak Republic and EU 
Member States. Since 2007, the National Drugs Service has 
cooperated within the national EWS, not only in the 
provision of information about new trends in drug use, but 
also in initiating the inclusion of new psychoactive 
substances (which are increasingly being used in Slovakia) in 
the list of controlled substances. 
The National Drugs Service will provide the N-EWS 
coordinator with the following data structure:
•	 number of cases in which the substance was seized 
(data and time of seizure);
•	 persons who possessed, smuggled or traded the  
substance;
•	 the seized amount, form and name under which the 
substance is sold;
•	 the origin, method of production, distribution and sale of 
this substance;
•	 method of further processing, packaging of the  
substance in the area, its price if known (mainly in the 
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case of Internet sales);
•	 participation of criminal groups, characteristics of  
dealers, sellers or cooperation with international  
criminal groups.
Cooperation between IFS PF and N-EWS
The Institute of the Forensic Science of Police Force was 
established in 1991 within the Ministry of Interior as an 
organisation for providing criminal-technical and expertise 
activities for the needs of the Slovak Republic Police Force, 
bodies acting in criminal proceedings and the courts, as 
well as for providing scientific-technical development in this 
area. They most frequently carry out investigation in cases 
where prosecution (most frequently for drug possession or 
trafficking) is commenced and samples are seized by bodies 
acting in criminal proceedings (the police) or for the needs of 
criminal police or customs administration (where a sample is 
seized by a unit of the Bureau of the Fight against 
Organised Crime and the Customs Criminal Office).
From a structural viewpoint, the IFS PF is under the authority 
of the Police Force Headquarters as an independent part and 
performs its activities via three departments: 
(1) off shores in Bratislava — analyses samples seized in the 
area of Western Slovakia (Bratislava, Trnava, Trenčín and 
Nitra regions); 
(2) off shores in Slovenská Ľupča — analyses samples seized 
in the area of Central Slovakia (BanskáBystrica and Žilina 
regions); 
(3) off shores in Košice — analyses samples seized in the 
area of Eastern Slovakia (Košice and Prešov regions). 
The department in Bratislava maintains a central database of 
all seizures including new psychoactive substances which are 
not in the list of controlled narcotic and psychotropic 
substances in Slovakia (Act 139/1998 Coll. on narcotic 
substances, psychotropic substances and preparations). Data 
is compiled at annual intervals and processed for the 
purposes of statistics of the Ministry of Interior and further 
distributed at national level (for the needs of the NFP — 
Annual report on drugs, ad hoc reports and studies) at an 
international level for the UN and EU. 
Most frequently, powdered or crystalline materials are 
submitted for expert analysis if there is a suspicion of a 
presence of narcotic or psychotropic substances. Within 
forensic analysis, the IFS PF states the precise content of 
seized substances (active compounds + admixtures). Gas 
chromatography with mass spectrometry (GC-MS) detection 
and infrared spectroscopy (FTIR) are the standard methods 
used for identification of these substances. If new narcotic or 
psychotropic substances are discovered using these methods, 
definite identification depends upon the availability of 
referential spectra of these substances, which in most cases 
is a problem since many times these are substances which 
have not yet been ‘scientifically assessed’. Referential spectra 
are from specialist literature or via international cooperation 
within the European Network of Forensic Science Institutes 
(ENFSI), or from accessible EWS information (analytical 
data) from the EMCDDA or from information obtained via 
Europol. 
In cases of new psychoactive substances, the IFS PF does not 
perform determination of the concentration of the active 
compound as standard, since they do not primarily have 
official standards of such compounds at their disposal and 
do not have the capacity for the preparation of such 
standards (IFS PF) are able to determine the concentration of 
new psychoactive substances (e.g. in case of mCPP). 
In case of testing biological material (urine, blood) for the 
presence of narcotic or psychotropic substances and their 
metabolites, determination of the presence of new narcotic 
and psychotropic substances in samples is not routinely 
carried out (drugs are identified in cooperation with 
Toxicological Laboratory).
The main N-EWS outputs include:
•	 ‘Reporting form on NPAS’ — via the mentioned  
standard form, a summary of information regarding any 
NPAS seized and identified in the Slovak Republic is 
provided. Reports are sent by the IFS PF. Most  
frequently, the period for sending an official report is 
around 30 days. If a new psychoactive substance is 
definitely identified, a report is sent to the EWS within 
one week. 
•	 ‘Questionnaire on NPAS’ — more detailed information 
about an NPAS (their users, effects, production,  
distribution, etc.) which is provided to the EMCDDA 
upon request (e.g. in case of a discovery of ‘Spice  
phenomenon’ and mephedrone).
•	 ‘Final report’ (covering 12 months), ‘Progress report’ 
(covering the first six months of the year).
•	 ‘NPAS Central database’ — at national level, includes 
basic data about seizures of new narcotic and  
psychotropic substances since 2005. Seizures are  
recorded in individual years and in practice, they  
include all NPAS reports via ‘Reporting forms’. 
•	 ‘Presentations and minutes from EWS meetings’ — the 
N-EWS coordinator prepares a report from each EWS 
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meeting which contains the main conclusions, tasks and 
measures taken at the meeting and via the section of 
specialists, gives access to all presentations and  
materials from the meeting (by 10 working days from the 
date of the meeting). 
•	 Official suggestions for including NPAS in the list of  
controlled substances: to date, three suggestions were 
prepared for inclusion of new substances: mCPP,  
ketamine, synthetic cannabinoids identified in ‘Spice’ 
products (JWH-018, JWH-073, CP47,497, HU-210) into 
the act on narcotic substances, psychotropic substances 
and preparations. 
•	 Official statements to control measures issued by the EU 
Council in relation to NPAS (e.g. BZP, mephedrone).
Case study
Trends in terms of NPAS 
Via the N-EWS, for the period (2005–10), a total of 23 new 
psychoactive substances were seized and identified in 
Slovakia: mCPP, BZP, TFMPP, phenylpiperazine, 
diphenylpiperazine, dibenzylpiperazine, pFPP, 2-CB, 4-fluoro-
amphetamine, ketamine, JWH-018, CP 47-497, JWH-250, 
JWH-073, JWH-122, mephedrone, butylone (bk-MBDB), 
methylone, diphenylprolinol, N-ethylcathinone, 
dimethylcathinone, MDPV, and Salvia Divinorum. For the 
mentioned six-year period, the police, in cooperation with 
customs officers, reported 98 seizures of new psychoactive 
substances in the EWS, from which more than half were 
represented by seizures of piperazines (mainly mCPP). 
The most frequently seized new psychoactive substance in 
the Slovak Republic (2005–10) is mCPP with 44 seizures, 
followed by mephedrone (11), JWH-250 (8) and ketamine 
(8). The order remained unchanged in the proportion of most 
frequently seized groups of new psychoactive substances: 
piperazines (53 %), cathinones (23 %), synthetic 
cannabinoids (12 %) and other substances (12 %).
Strengths, limitations and way forward
The expansion of the network of certificated toxicological 
laboratories which provide information about the objective 
effects and health risks would be a great contribution to the 
functioning of the N-EWS in the area of exchange of 
information of serious intoxications, due to experimentation 
with NPAS. 
The low number of IFS workplaces and their employees who 
carry out analysis of all seized psychoactive substances in 
the Slovak Republic causes delays and significantly increase 
the time of expert examination and provision of timely 
reports about an NPAS notification via a Reporting form. 
The method for adopting control measures and including 
NPAS in drug law is also complicated and complex. 
Amendments to law must undertake inter-departmental 
discussion proceedings by the MH SR, the government, 
departments of the Parliament of the Slovak Republic and 
Parliament itself (which usually takes several months to a 
year). Since in the Slovak Republic the Act regarding 
narcotic substances, psychotropic substances and 
preparations is under the auspices of the Ministry of Health 
of the Slovak Republic, the main criteria for including such 
substances in the list are mainly their affect upon health and 
potential to induce drug addiction. However, in practice, 
substances are more often included in this list due to their 
social risks (their frequent seizure, use, production and 
trade). In the majority of cases, these are seizures of new 
substances, the effects of which there is very little valid 
information. Since application of legal consequences and 
measures is only possible if the substance has the status of 
a controlled substance, in accordance with the Drug Act 
No 139/1998 coll., the initiative for inclusion of an NPAS 
in the mentioned Act in the majority of cases came from 
law-enforcement authorities. At present, within the N-EWS, 
new options of how to effectively prosecute persons who use 
NPAS (mainly producers and traffickers) using other 
measures than an amendment to the law on narcotic 
substances, psychotropic substances and preparations are 
sought.
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Introduction
The problem of illicit drugs in Slovenia became a topic of 
discussion especially during the 1990s, when the epidemic 
of using illicit drugs started to rise. Initially, the epidemic of 
using heroin was in the foreground but later on, other 
synthetic drugs also gained importance. With the 
development of electronic music and the accompanying 
youth culture, the use of synthetic drugs also came to be in 
full swing in Slovenia.
Slovenia has taken a number of measures to effectively carry 
out a holistic and multi-disciplinary approach towards 
getting illicit drugs under control. In 2002, the system for 
early detection of new psychoactive substances (NPAS) 
began to establish itself with the help of the European Union, 
along with the information system on NPAS. Carefully 
following the legal orders and the European Union 
guidelines, an integrated system has been established in 
Slovenia, connecting the key institutions and non-
governmental organisations, which can have an important 
influence on the early detection and monitoring of NPAS, as 
well as on informing the experts and the general public about 
the appearance of NPAS and which can also offer 
suggestions for NPAS to be included on the list of illicit drugs. 
All this contributes to lesser risk for the health of drug users 
and it also gives the legislative and repressive bodies a 
chance to take appropriate measures in this domain. 
The beginnings of the preparation of the project of the early 
warning system (EWS) in Slovenia go back to the year 2002 
when a professional educational workshop was organised 
in Slovenia under the guard of the EMCDDA, in which 
representatives of the candidate countries for the EU have 
gathered, i.e. those who were supposed to cooperate in the 
EWS in the future. In the same year, the national unit of the 
European Police Directorate (the Europol section at the 
General Police Directorate) began to operate, which 
represented the basis for the functioning and upgrading 
of the EWS in Slovenia, along with the other units of the 
police. In 2003, the national correspondent of the EWS was 
appointed and he started to take part in the meetings of the 
European specialist in this field and he also made a draft of 
the Slovene model of the EWS. 
At first, only two partners took part in the model of the EWS, 
which were the National Institute of Public Health (NIPH) 
and the Europol Section at the Criminal Police Directorate. 
They exchanged information using two information paths. 
The first was through the European Information Network for 
Drugs and Drug Addiction (Reitox) and the other one through 
Europol. The other key partners joined the existing model in 
2004 and also the network of those receiving alerts from the 
EWS has been spreading since then. 
By adopting the Council Decision 2005/387/JHA from 
10 May 2005, Slovenia also regulated this domain in 
accordance with this document and appointed an 
inter-ministerial working group in July 2007, which has been 
observing the appearance of NPAS on a regular basis and 
proposed appropriate measures to the Ministry of Health. In 
September 2009, a new enlarged inter-ministerial working 
group was appointed by a decision of the Health Minister.
Organisational issues
Legal-legislative context for establishment of the early 
warning system 
The legal basis for the organisation of the EWS in Slovenia 
is represented by the legislation in the domain of illicit drugs; 
the Production of and Trade in Illicit Drugs Act, the Penal 
Code of the Republic of Slovenia, the Act Regulating the 
Prevention of the Use of Illicit Drugs and the Treatment of 
Drug Users, the Resolution on the 2004–09 National 
programme on drugs control and also EU legislation, 
respectively, the Council Resolution 2005/387/JHA from 
10 May 2005.
Regulation and tasks of the early warning system 
In Slovenia, the Minister of Health appointed an 
inter-ministerial expert group of the EWS with a resolution. 
(9) Technical review: Aleksander Pučko, Rajko Kozmelj, Tomo Hasovič.
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This group includes: the National Institute of Public Health, 
the Ministry of Health, The Europol Section at the General 
Police Directorate, the Section for Illicit Drugs at the General 
Police Directorate, the National Forensic Laboratory at the 
General Police Directorate, the Institute for Forensic 
Medicine at the Faculty of Medicine in Ljubljana, the Centre 
for Poisoning at the University Clinical Centre Ljubljana and 
the non-governmental organisations DrogArt and Stigma. 
The inter-ministerial working group has following tasks: 
•	 to prepare expert guidelines and recommendation for 
the work of the EWS;
•	 define the conditions and procedures for the analysis of 
new psychoactive substances;
•	 make suggestions to the Ministry of Health for including 
NPAS into the Regulation of the Illicit Drug Classification;
•	 actively cooperates in the European EWS;
•	 ensures appropriate exchange of information from the 
European EWS into the national territory. 
The inter-ministerial working group assembles in sessions if 
necessary; the sessions are organised by the group leader 
once or twice a year, especially if it is necessary to discuss 
more serious problems and if any measures need to be taken. 
There are also other institutes that cooperate with the EWS 
on a regional and local level: regional institutes for public 
health, community health centres, non-governmental 
organisations from the field of illicit drugs, emergency help 
services and a network of centres for prevention and 
treatment of illicit drug addiction. 
The Slovenian EWS is designed more widely than the 
European model, which gives it an added value. It also 
exchanges information about the appearance of illicit drugs 
with a high concentration of psychoactive substances, as well 
as illicit drugs with dangerous adulterants. 
The Slovenian EWS also includes experts who have been in 
contact with the field of drugs in their field of work and are 
familiar with the problematic of drugs, have valuable 
experiences and appropriate knowledge and are also 
professionally and politically independent at their work. 
The mutual communication is enabled by e-mails and by 
phone in both Slovenian and English language. The expert 
public is informed about the appearance of the NPAS in the 
form of notifications, which they receive by e-mail, while the 
general public and the media get the information from the 
notices for the public and the media, which are published on 
the Internet pages of the National Institute of Public Health 
and in mass media.
Core functions and information flow
Core functions of partners of the early warning system on the 
NPAS 
•	 the Ministry of Health in the Republic of Slovenia is  
competent for legislation in the domain of drugs, which 
also includes the Regulation on the Illicit Drugs  
Classification. This document is regularly complemented 
with new psychoactive substances based on relevant 
documents and suggestions, which are forwarded by 
competent institutions. The ministry also appointed an 
inter-ministerial working group of the EWS. 
•	 the National Institute of Public Health has the role of the 
coordinator within the EWS. It receives information from 
the EMCDDA and sends this information into the  
national system, it also takes care for the flow of  
different information between the members of the  
inter-ministerial working group within the system and 
also takes care of informing the wider group of  
participants. When a new or dangerous NPAS  
emerges, the Institute gathers information and takes 
care of its flow, when the information is received by the 
system’s partners and participants. Then the experts from 
the Toxicology Section at the Institute prepare an  
estimation of risk for drug users, the experts from public 
relations form a notification for the media and the 
general public. The Institute also needs to forward the 
relevant information to the European EWS. 
•	 the Europol Section at the General Police Directorate 
receives information from the European Police  
Directorate about the appearance of NPAS and  
forwards them to the national EWS. The information 
about the appearance of NPAS in Slovenia is  
forwarded to the European Police Directorate. 
•	 the Illicit Drug Section at the General Police Directorate 
gathers information about NPAS, which occur in the  
Slovene territory and also gathers samples of these 
NPAS. The information is then forwarded to the EWS. 
•	 the National Forensic Laboratory at the General Police 
Directorate, within which there are five operating  
laboratories (biology, chemistry, physics, dactiloscopic 
laboratory and a laboratory for document research)  
carries out also analyses of the confiscated NPAS,  
especial in the chemistry laboratory, which uses  
different analytical instrumental methods. The  
laboratory is equipped with four gas chromatographs, 
connected to mass spectrometers (GC/MS), with liquid 
chromatograph (HPLC), infrared spectrophotometer with 
a microscope (FTIR) and an ionic chromatograph (IC). 
The existing instruments are used to analyse and define 
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the sort of the drugs, the additives, active additions, the 
drugs are also profiled and the percentage of active 
components is also defined. The chemistry laboratory 
is also used to analyse a wide spectrum of substances, 
from colours, varnishes, explosives, to poisons, illicit and 
other (e.g. designer) drugs, which occur on the black 
market and also medicines. 
•	 The Toxicology laboratory of the Institute for Forensic 
Medicine at the Faculty of Medicine carries out  
toxicological analyses of mostly biological samples.  
The basic fields of work of this laboratory are forensic  
toxicology, clinical toxicology, determining drugged 
driving, therapeutical monitoring of less frequent and 
analytically challenging medicines. Within the 24-hour 
duty service, the toxicologists carry out urgent  
toxicological examinations as a support to the Centre  
for poisoning and other health institutes around  
Slovenia. The laboratory mainly carries out instrumental  
chromatographic analyses GC-MS. The laboratory  
forwards the information about the appearance of a 
NPAS in the samples of body fluids of its users to the 
EWS. 
•	 The Centre for Poisoning at the University Clinical  
Centre Ljubljana is treating all kinds of acute poisonings, 
including illicit drug poisonings and at the same time 
offers a 24-hour information consultant service from the 
field of clinical toxicology to all the doctors in Slovenia. 
The Centre also has a Register of poisoning of the  
Republic of Slovenia, which includes poisonings with 
illicit drugs. The centre forwards information about  
poisonings with NPAS to the EWS. 
•	 The non-governmental organisation DrogArt operates in 
the field of lessening the damage caused by stimulant 
drugs and alcohol, among other activities they carry 
out a field action of informing and giving first aid to 
the users of stimulant drugs at electronic music events, 
they also administrate a web forum, where users can 
exchange experiences about drugs, currently on the 
market. They forward information about the appearance 
of NPAS and their spreading to the EWS. They are often 
the first to detect the appearance of a NPAS and also 
get a sample of this substance for the analysis. 
•	 The non-governmental organisation Stigma also operates 
in the field of lessening the damage caused because 
of the consequences after using illicit drugs. The work 
is done in two drop-In centres, on field and in prisons. 
Among other activities they ensure free sterile set and 
replacement of needles, consultation concerning drug 
problems, help with social matters, employment and 
health services, information about the programmes of 
treatment. They forward the information about the  
appearance of NPAS to the EWS and also to the  
network of low-threshold programmes. 
Information flow 
The National Institute of Public Health, the Europol Section 
and the Illicit Drug Section get information about NPAS and 
then forward this information to the inter-ministerial 
working group. Within this group the information is 
exchanged about the appearance of NPAS, about the 
confiscated samples, analyses results, trafficking, use and 
risks for the users. Within the group, some confidential 
information is also exchanged. To be constantly updated, the 
information is exchanged using e-mail. 
After exchanging all available information, the
inter-ministerial working group appraises the risks for the 
users and makes a decision whether it is necessary to inform 
the wider group of participants and also the general public 
and the media in the future and which information these 
notifications should contain. If the group estimates that the 
risks of the psychoactive substance are very high, a press 
conference can also be made.
The wider group of participants includes centres for 
prevention and treatment of illicit drug addiction, 
non-governmental organisations operating in the domain of 
drugs, community health centres, emergency help services, 
institutes for health care and some centres for social work. 
When this group receives a notification about the 
appearance of a NPAS, in returns the information about this 
substance back to the EWS, i.e. the information concerning 
the appearance of this substance, the forms of the substance, 
the reported dangerous effects when using it, the price, etc. 
The feedback is also being gathered by the National Institute 
of Public Health, which forwards it to the members of the 
inter-ministerial working group. Based on all gathered 
information, which have been forwarded to the System from 
the members of the inter-ministerial working group as well 
as from the wider group of participants, joint information is 
formed for the EMCDDA. Some suggestions for necessary 
measures for the Ministry of Health are also prepared and 
the Ministry can then carry out the procedure of adding the 
NPAS on the list of illicit drugs. 
The national EWS gets the information about the NPAS also 
from the European EWS. The EMCDDA and Europol forward 
this information to the National Institute of Public Health or 
to the Europol Section at the General Police Directorate. The 
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received information is then forwarded to the members of 
the inter-ministerial working group to study and estimate. The 
members of the group then forward feedback to the network, 
each member for their field of expertise. This is followed by a 
consultation of the members, which is done by e-mails, where 
they discuss the level of risks of the new substance for the 
health of its users, about the appearance or the possibility of 
appearance in Slovenia, about availability of the substance 
etc. If the members estimate that the substance could have 
any risks, a notification for the expert public is made, 
including negative effects when using the substance, 
instructions for taking measures and other important 
information. This notification is then sent using e-mails to all 
the receivers of the notifications of the EWS. 
The time frame: When the information about the appearance 
of a NPAS gets into the EWS NPAS, a notification, along 
with the estimation about the danger for its users is sent to the 
wider group of participants, to the general public and media 
as soon as possible. This mostly means that this happens 
within a few hours, any other time delays occur when it is 
necessary to wait for the analyses results.
Case study
Mixture of atropine and cocaine in Slovenia 
In November 2005, the EMCDDA forwarded a notification 
about the appearance of a mixture of atropine and cocaine 
in several European countries to the National Institute of 
Public Health. The mixture first emerged in France, Belgium, 
Germany and Italy. The Institute forwarded the information 
to the members of the inter-ministerial working group of the 
EWS NPAS, who decided that it is necessary to inform other 
members of the system due to the immediate proximity of Italy 
and all other risks for the drug users in Slovenia connected 
to this fact. DrogArt was also among those who received the 
notification and therefore notified its users on their web page 
and on the web forum about the appearance of the new 
substance. 
On 2 February 2006, DrogArt received a call at their 
duty service about cocaine users, who reported eye sight 
problems after consuming cocaine. One of the users also 
wrote the same message on the web forum. Since eyesight 
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problems are a common symptom of atropine poisoning, 
DrogArt immediately considered the possibility whether it is 
possible that the substance is actually a mixture of cocaine 
and atropine, about which they had received a notification 
from the EWS NPAS a few months earlier. This is why they 
asked the user to bring a sample of the suspicious cocaine to 
the Organisation DrogArt. The user brought the sample and 
the employees at DrogArt immediately gave the sample to the 
National Forensic Laboratory at the General Police 
Directorate, in cooperation with the National Institute of 
Public Health. 
On 16 February 2006 the National Forensic Laboratory 
confirmed that the substance is a mixture of atropine and 
cocaine. The inter-ministerial working group of the EWS 
NPAS decided that it is necessary to immediately inform 
other participants in the system and the general public about 
this because of the risks this substance presents to the 
potential users. The National Institute of Public Health 
prepared a report for the public which was also forwarded 
to other participants in the system and to the media and the 
report was also published on the Institute’s website. 
The organisation DrogArt informed its users (mostly visitors 
of electronic music events) about the new mixture on their 
website and on the web forum.
Strengths, limitations and way forward
Strengths
The Slovenian EWS has a number of strengths, including 
covering the territory of the whole country, it is extremely fast 
and useful and serves to the public good. It is known for its 
extremely good cooperation between the key carriers of the 
system, which are the health sector and the police. 
There is a formally founded inter-ministerial working group, 
which has been appointed by the minister, which gives 
legitimacy to the operation of the system and at the same 
time enables quicker, faster and more effective operation. 
The strength of the system is also the fact that it includes 
non-governmental organisations operating in the field of 
illicit drugs, which have good connections with the drug 
users and are often the first ones to detect the appearance of 
a NPAS, what contributes greatly to the effectiveness and fast 
operation of the system.
The system includes all those key institutions and those in 
connection with illicit drug users on a regional and local 
level. This way, it is ensured that the workers in these 
institutions get the necessary information needed for working 
with drug users. On the other hand, these institutions also 
ensure a faster information flow to the end users — the illicit 
drug users. 
Limitations 
Although the EWS has been operating for several years, the 
protocol of operation still hasn’t been formally written down, 
there are also no written guidelines and procedures of 
informing when a new or/and dangerous NPAS appears, 
there are also no instructions of which information should 
or could a notifications for the expert public, for the general 
public and the media include and there are also no 
standardised forms. The operation of the system is therefore 
often based on verbal contracts and previous experiences. 
Further development 
Since the General Police Directorate (Europol Section, Illicit 
Drug Section, National Forensic Laboratory) and the 
National Institute of Public Health are still the bodies who 
carry the largest part of responsibility for proper operation of 
the EWS, it will be necessary to ensure bigger incorporation 
of other partners. 
It will be necessary to establish a common database about 
the NPAS on a national level, to which all the experts 
included into the system will be able to access. 
It will also be necessary to think about enlarging and 
upgrading the system, in the sense of including new 
receivers of the notifications as well as cooperating with 
the other early warning systems. The usefulness of such 
cooperation of the EWS has already been shown in the 
past in the field of infectious diseases. 
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Introduction
The EU Council Decision 2005/387/JHA required every EU 
country to rely on a national exchange and collection data 
system on new substances to report to the EMCDDA and thus 
comply with the objective of the Decision. 
As it was not an EU Directive but an EU Decision, the 
Spanish Government did not need to set up a  new 
regulation on this subject. Instead, a specific Spanish 
applicable regulation stemmed from the 1961 UN Single 
Convention on Narcotic Drugs and 1971 UN Convention 
on Psychotropic Substances was used as a legal framework 
for the EWS development: Ley 17/1.967, de 8 de abril, de 
normas reguladoras por las que se actualizan las normas 
vigentes sobre estupefacientes adaptándolas a lo 
establecido en el Convenio de 1.961 de Naciones Unidas 
and Real Decreto 2829/1.977, de 6 de octubre, por el 
que se regulan las sustancias y preparados medicinales 
psicotrópicos, así como la fiscalización e inspección de su 
fabricación, prescripción y dispensación.
National regulation on illicit drugs allowed the Spanish 
Ministry of Health, Social Services and Equality and several 
other ministerial departments to apply the necessary 
measures in compliance with the EU Decision. 
Nonetheless, the Spanish Government Delegation for the 
National Plan on Drugs (national focal point) has been 
regularly sending official reports on new drugs to the 
EMCDDA since 2001, although reports were mostly sent on 
the EMCDDA´s request during 1997–2001. Gradually, the 
Spanish NFP started devising specific protocols involving all 
the EWS partners to ensure data flow reached the 
appropriate target. 
Organisational issues
Administrative/legal basis/mandate:
As stated above, the Spanish Government Delegation for the 
National Plan on Drugs (Ministry of Health, Social Services 
and Equality) is responsible for complying with the EU 
Decision on the EWS. Spain relies on the necessary generic 
legal framework to carry out the EU Decision mandate, even 
though there is not a specific or detailed legislation on the 
EWS. 
Recently, a new national regulation establishing the protocol 
by which new narcotic drugs can be subjected to control 
measures, in accordance with Ley 17/1.967, has been 
approved (Real Decreto 1194/2011, de 19 de agosto, por 
el que se establece el procedimiento para que una sustancia 
sea considerada estupefaciente en el ámbito nacional).
Objectives
The Spanish EWS definitely serves the Council Decision. 
Moreover, it has turned out to be very useful to improve the 
drug reporting system and to speed up information flow with 
the 19 Spanish Autonomous Communities and Cities and 
with other agencies and entities (National Institute of 
Toxicology and Forensic Sciences, Spanish Drug Agency, 
etc.). Theoretically, EWS protocols could also be used to 
channel different types of drug-related information (data on 
epidemiological indicators, mortality, seizures, etc.)
Institutional basis
The Spanish Governmental Delegation for the National Plan 
on Drugs (DGPNSD) is responsible for the EWS-Unit right 
functioning. DGPNSD is located within the Spanish 
Ministry of Health, Social Services and Equality. The EWS 
unit comprises:
1. Agencies located within the Spanish Ministry of Health, 
Social Services and Equality: 
•	 Governmental Delegation for the National Plan on Drugs 
(DGPNSD) — Spanish Observatory on Drugs,  
responsible for epidemiological data on drugs: surveys 
and drug-related problems key indicators (admission to 
treatment, emergencies and mortality); 
•	 Spanish Agency on Drugs (Agencia Española de  
Medicamentos y Productos Sanitarios);
•	 Drug Analysing Labs network (which is mostly  
responsible for seized derived samples) (Public Health 
Department); 
•	 Secretariat of National AIDS Strategy;
•	 Public Health Alert System (Public Health Department). 
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2. Agencies located in several other departments: 
•	 Intelligence Centre against Organised Crime/CICO, 
(Ministry of Interior); The Spanish Cuerpo Nacional de 
Policía and Guardia Civil are responsible for drug  
seizures throughout the whole country, control  
measures, etc. 
•	 National Institute of Toxicology and Forensic Sciences 
(Ministry of Justice) which is mostly responsible for  
biological samples of drug analysis. Seized derived  
samples are subject to analysis at the INTCF only if 
cases are under the Law 38/2002, de 24 de octubre 
regulating express trials; 
•	 Customs (Ministry of Treasury and Public  
Administrations).
3. Autonomous Communities and Cities (19) 
•	 Autonomic drug-specialised treatment network  
(outpatient, inpatient and emergency premises which 
are the data source of the drug-related problems key 
indicators);
•	 Autonomic Police Force in some specific Autonomous 
Communities (working in collaboration with the Spanish 
Cuerpo Nacional de Policía and Guardia Civil).
Links to EU institutions
Contact with EU institutions is made through the Spanish NFP 
(DGPNSD). Although reports are almost exclusively sent to 
the EMCDDA, there is a Spanish NFP for Europol which is 
contacted occasionally for specific purposes and the Spanish 
Drug Agency maintains close contact with the EMA 
(European Medicines Agency).
Coverage
The Spanish EWS unit has national coverage.
Administrative/legal basis/mandate
It is very difficult to figure out the exact size of the EWS unit 
in terms of staff. The EWS relies on a basic structure within 
the DGPNSD and CICO, which is made up of five people 
from different backgrounds (civil servants, lawyers, 
medical doctors, members of the Spanish Cuerpo Nacional 
de Policía/Guardia Civil, etc.) in charge of EWS-related 
issues, among many other tasks. Besides, there are many 
other people throughout the country whose work is devoted 
to the EWS correct functioning (drug-treatment professionals, 
laboratory technicians, Cuerpo Nacional de Policía, 
Guardia Civil and autonomous police staff, etc.) 
Communication tools (information technology,  
meetings, periodicity of meetings)
Communication among the different actors and levels of the 
EWS process is based on e-mails, fax and phone calls. The 
SENDA (Sistema Estadístico de Análisis y Evaluación sobre 
Crimen Organizado y Drogas) database in CICO and the 
Drug-related problems Key indicators information system in 
the Spanish Observatory on Drugs (DGPNSD) are used as 
the main sources of information for reporting. However, the 
Spanish Observatory on Drugs is currently working on a 
web-based drug problems indicators system that will 
facilitate the reception of timely and updated information.
Lately, the Internet has demonstrated to be a good 
information source to detect new drugs and new drug 
consumption patterns. The possibility of conducting 
web-based monitoring activities on a regular basis has been 
considered. Meetings of the involved departments are 
convened at the request of any of them when necessary, but 
with no fixed periodicity. 
Language
The official working and reporting language is Spanish, 
except for reporting activities to the European institutions, 
for which English is used.
Scientific/political independence
The EWS unit reports and opinions serve no political 
purposes, since the EWS works as a national new drug 
(or a new pattern of drug use) surveillance national system. 
EWS reports are entirely based on technical expertise and 
therefore political independence is guaranteed. 
Core functions and information flow
On one hand, the Intelligence Centre against Organised 
Crime (CICO) starts collecting data on the controlled 
substances seizures on a regular and standardised basis from 
the Police and Guardia Civil forces and from the Customs 
Corps. This information is loaded up in a computerised 
information and communication system called SENDA (see 
‘Communication tools’). Information is then analysed and 
assessed to produce reports on the actual and current 
situation of drug supply and on new trends, which is 
regularly sent to the Spanish national focal point.
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Figure 23 — Information flow in the framework of the Spanish EWS
On the other hand, and regarding both controlled and 
non-controlled substances, there is a nationwide net-like 
laboratory system which has the mandate to analyse and 
report to CICO on the exact composition of drug seizures. 
Information on those identified controlled and non-controlled 
substances is regularly sent to CICO.
If the alert is referred not to seizures but to a new pattern of 
drug use or to the detection of contaminants within drugs, 
etc., the responsibility of reporting to the DGPNSD falls on 
the correspondent autonomous communities authorities who 
will establish the necessary control measures and responses. 
There is no standardised procedure to carry out a risk 
assessment of a new drug but decisions to set up control 
measures on a specific substance may be proposed by any 
of the agencies involved in the EWS, provided that a 
justified and well-reasoned request is made and an 
agreement among them is reached. Ad-hoc committees are 
convened when necessary.
The DGPNSD regularly allocates public funds to several types 
of drug programmes (prevention, treatment, rehabilitation, 
etc.) to be developed by the autonomous communities, local 
entities, research institutions and NGOs. Some of the NGOs 
are running prevention and harm-reduction programmes 
offering drug users the possibility to analyse (field testing) 
purity or composition of illicit drug pills they will be abusing 
soon after. The number and composition of the analysed pills 
are not systematically reported to the Spanish EWS. Only 
occasionally, the Spanish EWS becomes aware of the results 
of these interventions through the EMCDDA or the press.
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Case study
Cases follow the above included diagram.
Strengths, limitations and way forward
Strengths
•	 The Spanish EWS belongs to the Spanish Public  
Administration and has a nationwide structure with a 
fairly good coverage. 
•	 Drug-related problems information system (Spanish Key 
indicators: Admission to drug treatment, Drug-related 
mortality, Drug-related emergency episodes). The well 
functioning of this information system ensures a correct 
surveillance of drug-related clinical issues. 
•	 In relation to the drug analysing laboratories network:
•	 the fact of counting on a network of drug seizures  
analysing laboratories (Ministry of Health, Social  
Services and Equality) throughout the country and that 
they draw on the same common guidelines promotes 
and ensures homogeneity of analysis results and reports;
•	 the fact that these laboratories are widely distributed 
throughout the country and that they take care of almost 
100 % of the seized drugs in Spain, places an added 
value and significance to the results and reports; 
•	 every drug seizures analysing laboratory works with and 
follows the United Nations best practice drug-analysis 
recommendations. However, technical resources, well-
trained staff and burden of work are not distributed 
evenly.
Limitations
•	 Since several Ministerial Departments as well as the  
autonomous communities are involved in the EWS, a 
very close collaboration among them is required to make 
further progress. Thus, coordination efforts are  
necessary.
•	 Risk assessment protocols and procedures are neither 
well established nor standardised yet, thus affecting  
decisions’ timing and deadlines, if those are to be made.
•	 The lack of EWS-specifically devoted staff makes work 
less efficient.
•	 In Spain, the large number of seizures and the amount 
of seized drugs pose a considerable burden on drug 
analysing laboratories and makes analysis and  
reporting a rather difficult and time-consuming process.
•	 Storage, custody and destruction of such an amount of 
seized drugs often entails difficulties, and delays  
analysing and reporting, thus preventing the NFP to 
report on time. 
•	 Laboratories complain about technical problems to 
identify new not-well-known, non-controlled substances 
without having previously been provided with technical 
guidance or at least some information on them. 
•	 It is the policy of the Spanish EWS that national data 
should be reported to European institutions only by the 
NFP. 
Way forward
•	 Promote a better coordination among the different  
departments and actors involved in the EWS. 
•	 Setting up a standing committee, made up by  
representatives of every involved sector to meet on a 
regular basis.
•	 Strengthen coordination and work relations between 
the EWS and the Public Health Alert System (Ministry of 
Health, Social Services and Equality).
•	 Devise a specific procedure for the risk assessment of 
new substances, including flow information and  
decision-making protocols, scientific workgroup and 
standing committee composition and timing/deadlines of 
the whole process.
•	 As stated above, it would be advisable to provide drug 
analysing laboratories with updated information and 
new drugs identifying patterns to allow them to be  
proactive in looking for new substances before  
intoxications or deaths have occurred, or big amounts of 
those new drugs have been seized. 
•	 The use of the Internet as an additional source of  
information for new drugs and drug consumption trends 
surveillance purposes should be promoted. The  
possibility to use it as a means to counteract new drugs 
marketing and promoting activities should be explored. 
Links and references
Ministerio de Sanidad, Política Social e Igualdad  
— http://www.mspsi.es
Plan Nacional sobre drogas, Ministerio de Sanidad, Política 
Social e Igualdad — http://www.pnsd.mspsi.es
Laws and regulations: 
http://www.boe.es/boe/dias/2002/10/28/pdfs/A37778-
37795.pdf
http://www.pnsd.msc.es/Categoria2/legisla/pdf/15.pdf
http://www.pnsd.msc.es/Categoria2/legisla/pdf/26.pdf
http://www.boe.es/boe/dias/2011/08/23/pdfs/BOE-
S-2011-202.pdf
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Introduction
The Swedish National Institute of Public Health (SNIPH) is 
a focal point of the Reitox network and accordingly has the 
responsibility of reporting to the European Monitoring Centre 
for Drugs and Drug Addiction (EMCDDA) on the drug 
situation.
The Swedish Government has commissioned SNIPH and the 
Medical Product Agency (MPA) to collect and assess 
information on new drugs and consider if there is a need to 
regulate them as narcotic substances at a national level. 
The mission is divided between the two authorities, whereby 
the MPA investigates medicinal substances/substances with 
potential medical value and SNIPH investigates other 
psychoactive substances with a potential for misuse. The 
SNIPH also has the task of guarding and investigating 
whether there is a need for a substance to be regulated 
under the Act on the Prohibition of Certain Goods Dangerous 
to Health. The easiest way to explain this act is to say that it 
focuses on health issues, but does not criminalise personal 
use.
This joint effort provides for the establishment of an early 
warning system (EWS) to identify new synthetic drugs as 
they appear on the European market. It also incorporates a 
mechanism for assessing the risks of these drugs and 
comprises a decision-making process, through which these 
products may be placed under control in the EU Member 
States. 
Swedish Customs, the National Criminal Investigation 
Department of the National Police Board, social services and 
the healthcare services are required by Swedish law to report 
to SNlPH without delay if in their work they notice anything 
that indicates that a new psychoactive substance is unsuitable 
or if there is a change in patterns of use. Other involved 
organisations are the National Laboratory of Forensic 
Science which carries out analyses on seizures made by 
the Swedish Police. For the seizures made by Customs, the 
majority is analysed by Customs’ own laboratory, although 
in exceptional cases, some are analysed with help from the 
National Laboratory of Forensic Science. The Department of 
Forensic Chemistry of the National Board of Forensic 
Medicine provides information about drugs detected in 
bodily fluids or specimens, performs toxicological analyses 
of specimens collected post-mortem and analyses blood and 
urine samples from individuals suspected of driving under the 
influence of drugs. The department also analyses samples 
from correctional care, the Police, healthcare services and 
social services to verify suspected use of narcotics. 
The Swedish Council for Information on Alcohol and Other 
Drugs (CAN) is an independent organisation that delivers 
statistics on ‘Drug trends in Sweden’, CAN’s annual report 
and the widest statistical resource within the drug field.
There is also a collaboration called STRIDA (Collaborative 
project concerning toxicity assessment and risk assessment 
of Internet drugs based on laboratory analysis). The Swedish 
Customs laboratory, the National Board of Forensic 
Medicine, the National Laboratory of Forensic Science and 
the MPA are the members of the network. This is a national 
activity focused on Internet drugs which aims to provide 
current information on the drugs in use, addiction potential, 
how they are metabolised in the body and how to develop 
new analysis techniques. STRIDA also interacts with, and 
distributes information to the healthcare sector and relevant 
authorities. STRIDA is partly financed by SNIPH.
The Network for the Current Situation of Drugs (NADiS) 
was formed in Sweden when the Act on the Prohibition of 
Certain Goods Dangerous to Health (SFS 1999:42) entered 
into effect. The law applies to goods that, due to their 
inherent characteristics, entail a danger to human life or 
health and are used or can be assumed to be used with the 
aim of achieving intoxication or other effects. The NADiS 
was founded by the SNIPH in 2000. Contributing bodies are 
the MPA, Swedish Customs, National Criminal Investigation 
Department of the National Police Board, the Department of 
Forensic Chemistry, the National Board of Forensic Medicine, 
the National Laboratory of Forensic Science, the Swedish 
Poisons Information Centre, CAN, the Swedish Prosecution 
Authority, Karolinska Institutet and representatives from the 
social services and healthcare services. 
In 2003/2004, the Danish National Board of Health and the 
Norwegian Institute for Alcohol and Drug Research (SIRUS) 
joined in the network. After a couple of years, Finland de-
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cided to follow suit in 2006. Iceland joined this year. 
The purpose of the network is to increase knowledge and 
gather information about new substances with the aim of 
possible regulation at the national level. This extended 
network is known as the Network for the Current Situation 
of Drugs in Nordic countries (Nordic-NADiS).
These networks are the providers of the EWS, which makes 
it possible to identify new synthetic drugs as they appear 
on the European and Nordic market and incorporates a 
mechanism for assessing the risks of these drugs. The EWS 
also comprises a decision-making process through which 
these products may be placed under control in Sweden and 
the other Nordic countries.
Organisational issues
The Swedish National Institute of Public Health was 
established by the Swedish Government.
The goal of drug policy work is a drug-free society. SNIPH 
has three specific duties related to this goal:
•	 monitor and investigate the need for drug classification 
and the need for inspection of goods under the Act on 
the Prohibition of Certain Goods Dangerous to Health 
(1999:42); 
•	 promote access to quality statistics;
•	 serve as the national unit in the cooperation with  
EMCDDA.
A Government decision regarding proposed classifications 
led to regulation according to the Act on Penal Law on 
Narcotics (1968:64), the Act on the Control of Narcotic 
Drugs (1992:860) or to the Act on the Control of Narcotic 
Drugs (1999:42). In Sweden, a control system is applied 
which classifies substances individually, i.e. substance by 
substance. On 1 April 2011, The Destruction of Certain 
Hazardous Abuse Substances Act (2011:111) entered into 
force. According to this Act, it is possible to seize and 
destroy a substance that is likely to be regulated at the 
national level, following a decision by a public prosecutor. 
From April to December 2011, approximately 100 decisions 
to destroy a psychotropic substance from a seizure were 
taken due to the new legislation.
Objectives 
The National early warning system (N-EWS) does not only 
serve the Council Decision. It has a wider role as its 
objective is to stay alert and aware of the current situation of 
drug use and create conditions under which a more scientific 
approach to classifications can develop. The collaboration 
within NADiS and Nordic-NADiS is an important tool to 
increase knowledge on new drugs and the way they are 
used/misused and their interaction with pharmaceuticals. 
At the same time, the collaboration also minimises the risk 
of countries doing the same work when experiences can be 
used across borders. Finally, Nordic-NADiS facilitates the 
Nordic countries’ obligation as a focal point in the EWS.
Institutional basis 
The SNIPH is the responsible institution, the national focal 
point for EMCDDA and an agency under the Ministry of 
Social Affairs.
Link to EU institutions 
The SNIPH is obliged to report to the EMCDDA on the drug 
situation. The National Criminal Investigation Department of 
the National Police Board collaborates with Europol.
Coverage
The N-EWS operates on a national level, but collaboration 
with the other Nordic countries takes place on a regular 
basis.
Staff 
Currently, two persons at the SNIPH are working with the 
N-EWS and classifications and their scientific backgrounds 
are within pharmacology (PhD) and biology (Master of 
Science). 
Approximately 25 people in Sweden are active within 
NADiS. The SNIPH, MPA, Swedish Customs, the National 
Criminal Investigation Department of the National Police 
Board, the Department of Forensic Chemistry, the National 
Board of Forensic Medicine, the National Laboratory of 
Forensic Science, the Swedish Poisons Information Centre, 
CAN, the Swedish Prosecution Authority, the social services 
and the healthcare services have representatives in this 
group. Nordic-NADiS has approximately 100 members, but 
not everyone is active. 
Communication tools 
As a base for the EWS work, the European database on new 
drugs (EDND) is used. A Nordic website called the NADiS 
web, where information can be exchanged between the 
Nordic countries and their various participant areas, i.e. 
police, medical care, health institutes etc., is also available. 
This is a fast and simple tool for information exchange. 
The website is encrypted. There are one or two persons from 
each country who have the ability to do editorial work on 
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the website, such as writing on the information page, adding 
fact sheets and issuing members’ passwords. In the forum, 
all Nordic-NADiS members can read and write posts. Each 
national administrator is responsible for the website in their 
country. The SNIPH in Sweden has the overall responsibility 
and the right to the website tool. The administrators of the 
system are regularly in contact with each other. The thought 
behind the web page is that it will be self-serving with a 
minimal contribution from the administrators. Information and 
data that is posted in forums and fact sheets is used in the 
daily work on classifications.
The information posted on fact sheets for a specific 
substance should be as scientific as possible with references 
to the source. 
Within the Swedish group meetings are held three to four 
times a year. The meetings are held by the SNIPH who 
convene the meetings, serve as the meeting chair and takes 
notes. The meeting is hosted each time by one of the bodies 
that participate in the group. Discussion around new 
substances and possible classifications is on the agenda and 
a summary of latest news by each of the members.
Within the Nordic-NADiS group, an administrator meeting 
is held at least once a year. Practical questions regarding 
the national groups, Internet functions and theoretical 
questions are reviewed. The current situation in each country 
is discussed and information is exchanged.
Language 
The spoken language within the Nordic-NADiS is Swedish, 
Norwegian and Danish.
Scientific/political independence
The mission for the SNIPH is controlled by the Government. 
But the SNIPH is scientifically independent.
Reports, statistics and other
information from NADiS
Nordic-NADiS
Denmark, Norway 
and Finland, 
Iceland
Information and
decisions from the
EMCDDA and other
international
sources
Forum discussions,
fact sheets
Internet scouting NIPH and MPA
Investigation
Classification
(suggestion)
Government
decision
Figure 24 — Information flow in the framework of the Swedish EWS
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Core functions and information flow
Data and information from different authorities’ own 
observations are reported on the common web page. 
This is followed by discussions and guidance towards a 
classification. The SNIPH or MPA prepares a classification 
based on the discussions by the group, scientific date, 
statistics, the EDND and other web information. 
The classification is executed by a Government decision.
Data collection tools — Other methods and information 
collection used in the classification work are:
•	 surveys
•	 seizures 
•	 drug analyses
•	 controlled purchases 
•	 Internet scouting
•	 official reports from international organisations and 
governmental institutions.
Data appraisal and analysis
The National Laboratory of Forensic Science carries out 
analyses on seizures made by the Swedish Police. For the 
seizures made by Customs, the majority is analysed by the 
Customs’ own laboratory, some exceptional cases are 
analysed with help from the National Laboratory of 
Forensic Science. The Department of Forensic Chemistry 
of the National Board of Forensic Medicine provides 
information about drugs detected in bodily fluid/specimens. 
The Department of Forensic Chemistry performs toxicological 
analyses of specimens from deceased persons and analyses 
blood and urine samples from individuals suspected of 
driving under the influence of drugs. They also analysed 
samples from the correctional care, the police, healthcare 
and social services to verify suspected use of narcotics. 
This statistical report is to be turned in every half year.
Outputs, reporting, publications and distribution — alerts, 
databases, confidentiality levels
Regular meetings with expert groups, information exchange 
within the NADiS-website, where an e-mail is sent to the 
entire group each time someone adds a fact sheet or 
comment on something in the forum. Presentations at
conferences and scientific publications are also information 
tools.
Risk assessment at national level
In principle, the operating guidelines of risk assessment are 
followed.
Case study
Mephedrone
•	 1 January 2008, first police seizure in Sweden
•	 25 April 2008, analysis and identification by the  
Department of Forensic Chemistry
•	 Spring 2008, discussion at the Network for the Current 
Situation of Drugs in Sweden 
•	 17 October 2008, first application for regulation under 
the Act on Prohibition of Certain Goods Dangerous to 
Health (1999:42)
•	 15 December 2008, regulated according to 1999:42
•	 March 2009, application for the substance to be  
regulated under the Penal Law on Narcotics
•	 23 April 2009, Government decision, regulated under 
the Penal Law on Narcotics
•	 25 May 2009, officially regulated under the Penal Law 
on Narcotics.
Strengths, limitations and way forward
Strengths: Broad network, collaboration
Limitations: Software, resources
Way forward: 
•	 increase knowledge and commitment
•	 use of sewage epidemiology and information
•	 Nordic collaboration also includes Iceland
•	 continue to develop the NADiS website for a wider 
range of use
•	 purchase of legal drugs for forensic and chemical  
laboratories to accelerate the possibility for forensic data 
regarding new drugs
•	 Swedish Chemicals Agency should be assigned to  
apply Regulation (EC) No 1272/2008 more extensively 
with the purpose of reducing Internet sales
•	 clarify the role of SNIPH regarding risk assessment
•	 use of techniques such as Quantitative Structure-Activity 
Relationships (QSAR)
•	 biological mechanism/investigations.
Links and references
Links 
Swedish National Institute of Public Health (SNIPH) — 
http://www.fhi.se
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Medical Product Agency (MPA) — 
http://www.lakemedelsverket.se
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Introduction
The early warning system (EWS) Working Group in Turkey 
was established in 2006 as one of the national working 
groups within the framework of the PHARE project launched 
between the EMCDDA (European Monitoring Centre for 
Drugs and Drug Addiction) and TUBIM (Turkish Monitoring 
Centre for Drugs and Drug Addiction) and has been carrying 
out its activities since then.
Organisational issues
In the Turkish National action plan, it is stated that the EWS 
Working Group established within TUBİM convenes at least 
twice annually under the chairmanship of a national expert. 
The EWS Working Group can be convened under the 
coordination of TUBİM whenever deemed necessary.
There is extensive communication between the EWS Working 
Group in Turkey and the EMCDDA. The information about 
the new substances encountered in the Member States is 
shared with all Member States and other information about 
the substance is demanded by the EMCDDA. Likewise, a 
new psychoactive substance found in Turkey is reported to 
the MCDDA by TUBİM. Turkey also reports to the EMCDDA 
about the new substances recently taken under legal control.
The EWS Working Group was established on a national 
basis. There are 20 officials chosen from different 
institutions dealing with drugs and drug addiction in the 
Working Group. The Working Group comprises the 
representatives of the institutions below:
1) Ministry of Justice:
•	 Council of Forensic Medicine
2) Ministry of Health:
•	 General Directorate of Pharmaceuticals and Pharmacies
•	 Refik Saydam National Public Health Agency
•	 General Directorate of Curative Services
3) Ministry of Customs and Trade:
•	 General Directorate of Customs Enforcement
 — Counter–Narcotics Trafficking Department
4) Turkish National Police:
•	 Department of Anti–smuggling and Organised Crime
 — Division of Counteracting Narcotic Crimes
 — TUBİM (Turkish Monitoring Centre for Drugs and  
 Drug Addiction)
•	 Department of Police Criminal Laboratories:
 — Ankara Criminal Police Laboratory
 — İstanbul Criminal Police Laboratory
5) General Command of Gendarmerie:
•	 Department of Anti-smuggling and Organised Crime 
•	 Department of Criminal Laboratory
6) Turkish Coast Guard Command:
•	 Intelligence Department
 — Intelligence Division — Anti–Smuggling Office
7) Marmara University:
•	 School of Medicine — Department of Medical  
Pharmacology.
The group communicates via e-mails, official letters and 
meetings. A new report, information and meeting reports 
submitted via the EWS system are shared with all the group 
members.
Turkey believes that the EWS works concerning the new 
psychoactive substances should be conducted on an 
effective, fast-paced and scientific basis. There are both 
scientists and people from the field in the EWS Working 
Group. The new substances in the EWS are evaluated 
scientifically and the necessary decisions are taken.
Core functions and information flow
Narcotic units affiliated with the Turkish National Police, 
General Command of Gendarmerie, General Directorate of 
Customs Enforcement and Turkish Coast Guard Command 
send the substances they seize to police and Gendarmerie 
Criminal Laboratories and the Council of Forensic Medicine. 
If a new psychoactive substance is identified at the 
laboratory analysis, the ‘EMCDDA–Europol Reporting Form 
on New Psychoactive Drugs’ developed by the EMCDDA 
and Europol is filled in by those institutions and then sent to 
TUBİM. The new substance reported is then e-mailed to the 
EMCDDA and information about the substance is demanded 
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while other related information, such as the seizure data 
throughout the country, is gathered by TUBİM.
The information gathered is reported to the EWS Working 
Group and their knowledge, ideas and suggestions are 
received. The TUBIM EWS Working Group convenes in 
accordance with the data. In the meetings concerning those 
substances, the following are assessed:
•	 the new substances’ chemical composition and effects;
•	 the possibility of addiction and the gravity of the  
possible addiction;
•	 the social risks for the drug user;
•	 the harm it may cause in the society and its relation to 
violence. 
If the psychoactive substance(s) are considered by 
the experts at the meetings to be a risk to society, a 
recommendation is prepared to legally control the substance. 
The recommendation is sent to the Ministry of Health as an 
official letter by TUBİM.
The necessary processes to include a new psychoactive 
substance in the banned substances list is defined in the 
19th article of Law No 2313 ‘Law on Controlling Drugs’. 
According to this article, substances not listed in the Law as 
illicit drugs and identified as having the effects of a drug, 
are brought under legal control with the recommendation of 
the Ministry of Health and with the decision of the Council 
of Ministers. The Ministry of Health evaluates the substance’s 
chemical structure, its psychoactive effects, its health 
consequences like death and disease and possible social 
risks about its use and trade, by taking into account the views 
of the scientists and commissions, when necessary.
The substances published in the official gazette and included 
in the legal restrictions are reported to the EMCDDA and all 
the relevant authorities by TUBİM.
Case study
The Officials of Antalya Security Directorate Anti-Smuggling 
and Organised Crime (KOM) Division informed TUBİM of the 
recent appearance of a new substance consisting of herbal 
mixtures in Antalya. TUBİM demanded that a sample of the 
said substance be procured and sent to Antalya Criminal 
Police Laboratory and the resulting analysis report to TUBİM. 
EMCDDA
TUBIM
Meeting of TUBIM
EWS working 
group
TUBIM Official Gazette
Ministry of Health Council of Ministers
— Turkish National 
    Police
— Police Criminal 
    Laboratories
— General Command
    of Gendarmerie
— Gendarmerie
    Criminal Laboratory
— General Directorate
    of Customs Enforcement
— Council of Forensic
    Medicine
— Turkish Coast Guard
    Command
Figure 25 — Functioning of the early warning system in Turkey and information flow
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In the meantime, TUBİM was informed of a substance named 
‘bonsai’ consisting of herbal mixtures by Isparta and 
Eskisehir KOM Divisions. As a result of the analysis of these 
plant mixtures in the Criminal Police Laboratories, a new 
psychoactive synthetic cannabinoid substance called 
JWH-018 was identified in it. It was understood to be the 
same substance which had been identified in Antalya.
On the other hand, the General Directorate of Customs 
Enforcement reported to TUBİM a new substance seized by 
İstanbul Customs Enforcement Office of the General 
Director Units. It was Catha Edulis (khat) which involves the 
active ingredients of cathinone and cathine.
The Council of Forensic Medicine and Police Criminal 
Laboratories notified TUBİM of the increasing seizures of 2C-B 
and 2C-P substances of the phenethylamine group. 
In the meantime, ‘Reporting form on new psychoactive drugs’ 
was filled out about the substances identified for the first time 
in Turkey and sent to the EMCDDA. The EMCDDA was 
notified of this development and the present information about 
the said substances has been demanded by Turkey.
By means of the information received from the relevant 
institutions, TUBİM collected data about the substances’ 
chemical properties, nationwide seizure data, whether it was 
previously seen in any European country and its legal status in 
those countries. The resulting data of these researches and the 
data from the EMCDDA were first shared with TUBİM EWS 
Working Group Members and then the group was convened 
outside of its meeting routine.
In this context, as a result of the TUBİM early warning 
System (EWS) Risk Assessment Committee, a decision of 
recommendation concerning the above-mentioned 
substances was taken to include them under the Law No 
2313, Article 19. 
This decision was officially written to the Ministry of Health 
to start the legislation process. These articles also sent to the 
Council of Ministers by the Ministry of Health were subjected 
to the provisions of Law on Drug Control No 2313.
Strengths, limitations and way forward
Thanks to TUBİM’s structuring, called ‘provincial focal 
points’ operating within KOM (Anti-Smuggling and 
Organised Crime) divisions in 81 provinces, new 
psychoactive substances and related information reaches 
TUBİM in a very short time.
The fact that there are officials in the EWS Working Group 
both from the field and scientific community makes it strong. 
The group can get reliable and up-to-date information about 
the substances it examines and evaluates thus, taking 
independent decisions on a scientific basis.
All the relevant institutions have a high level of awareness 
about reporting the new psychoactive substances to TUBİM so 
TUBİM can smoothly get the information as stated above.
In Turkey, one of the most important problems faced in the 
operation of the EWS system is the Forensic laboratories’ 
difficulty in obtaining the ‘reference substances’ to carry out 
the analysis of the new substance. This difficulty may be due 
to the commercial unavailability of the reference substance 
yet, or it may be due to the long amount of time needed for 
the procurement to be completed for those substances that 
are commercially available. Moreover, even though the 
reference substance is obtained, since the analysis cannot 
be conducted outside the Forensic laboratories, there is the 
difficulty of processing the biological samples taken from the 
user.
Another problem is the possible delays in getting such 
substances under the scope of the law due to bureaucratic 
processes. Although the fact that implementation can be 
carried out directly by the Decree of Council of Ministers 
without any requirement for a parliamentary decision in 
Turkey may seem to be a facilitating factor, the lapse of 
approximately 1.5 to 2.5 years for the relevant items in the 
last two Decree of Council of Ministers to be adopted after 
their notification to the Ministry of Health indicates the need 
for remedial measures.
In conclusion, the EWS is one of the most important fields for 
Turkey in the fight against drugs and drug addiction. Turkey 
believes that this fight will be more successful with 
international information/expertise sharing.
Links and references
Turkish Drug Report (2009).
Turkish Drug Report (2010).
Turkish Drug Report (2011).
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Introduction
In the UK, an informal early warning system (EWS) had been 
in operation during the mid-1990s and was managed from 
a base in the Forensic Science Service (FSS). The network 
consisted of representatives from forensic science laboratories 
in Europe. The primary function was to circulate information 
and analytical data on the many new synthetic substances 
that had started to appear in drug seizures in the early 
1990s. This network was superseded by the introduction of 
the Joint Action on New Synthetic Drugs in the EU in 1997 
with national focal points taking responsibility at Member 
State level. From 1997 to 2002, the UK national focal point 
(NFP) was managed by DrugScope, but from 2003, it has 
been based within the Department of Health, London. In 
2005, the Joint Action was superseded by Council Decision 
2005/387/JHA on the information exchange, risk-
assessment and control of new psychoactive substances.
Organisational issues
Apart from agreements with the European Monitoring Centre 
for Drugs and Drug Addiction (EMCDDA), the EWS has no 
other statutory basis. Its primary role since 1997 has been to 
provide information to the EMCDDA, which in recent years 
has been carried out under Council Decision 2005/387/
JHA (above). The EWS is also occasionally used at EU level 
as a convenient mechanism for the distribution of information 
on certain related topics (e.g. contaminants in drugs, health 
alerts, and unusual cases). At national level, a number of 
systems are used for collecting and distributing information 
on a wider range of substances and drug-related activities 
including established drugs of misuse; these include the 
National Programme on Substance Abuse Deaths (np-SAD), 
alerts from the Health Protection Agency (HPA), amnesty bin 
analyses and law enforcement intelligence initiatives. In the 
context of concerns about so-called ‘legal highs’ and the 
Government’s introduction of temporary class drug orders 
(TCDOs), the new Drug Strategy published in December 
2010 included a commitment to improve analytical 
capabilities for new psychoactive substances and to 
establish an effective Forensic early warning system (FEWS). 
Consideration is currently being given to the UK focal point 
assuming a more central role as a de facto ‘information hub’ 
in providing information to support the assessment of new 
psychoactive substances that may be subject to a TCDO.
The membership of the EWS was originally limited to 
government departments, police, Customs, the Europol 
national unit and forensic science laboratories, but it has 
expanded greatly in recent years. This is a reflection of the 
increased public and official interest in what are often 
informally known as ‘legal highs’. From the outset, the EWS 
represented all four countries of the UK. There are currently 
around 50 members of the EWS. In addition to research 
workers in academic establishments, the organisations 
represented include: Department of Health (in which the UK 
focal point on drugs is based); Medicines and Healthcare 
products Regulatory Agency (MHRA); Scottish Crime and 
Drug Enforcement Agency (SCDEA); Serious and Organised 
Crime Agency (SOCA); Forensic Science Service, (FSS); 
LGC Forensics; Forensic Science Agency of Northern Ireland 
(FSNI); Guy’s and St Thomas’ NHS Foundation Trust; ROAR 
Forensics; Key Forensics; Environmental Scientifics Group; 
National Poisons Information Service; Home Office (Drugs 
Policy); Advisory Council on the Misuse of Drugs (ACMD); 
Public Health Wales; International Centre for Drug Policy at 
St. George’s Hospital Medical School, London; TICTAC 
Communications, St. George’s Hospital Medical School, 
London. Although not formally part of the UK, the network 
also includes members from the Channel Islands (Official 
Analyst’s Laboratory, Guernsey; Customs and Excise, 
Guernsey; Official Analyst’s Laboratory, Jersey).
From mid-2011, the EWS has been coordinated by two staff 
(around 0.2 FTE), one of whom specialises in substance use 
epidemiology and emerging drug issues, while the other is 
an analytical chemist specialising in psychoactive substances 
(previously, it was supported by a chemist with a background 
in forensic science and drug analysis). They are assisted by 
other staff in the NFP when organising the annual meeting. 
Apart from the annual meeting, members of the EWS 
maintain regular contact by e-mail and telephone and 
occasional ad hoc meetings. The working language is 
English. The EWS operates as an independent information 
provider and is not directly involved in policy matters.
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Core functions and information flow
Apart from the EMCDDA, outputs of the EWS are available 
for use by all members of the network including those 
developing policy, but almost all input comes from forensic 
science laboratories and to a lesser extent, forensic and 
clinical toxicology laboratories. Formal data collection is 
carried out twice-yearly to produce the Progress and Final 
reports for the EMCDDA, and on those occasions when 
information is required by the EMCDDA for other purposes 
such as compilation of Joint reports and EU-wide risk 
assessments under the Council Decision. No national 
database of new substances is maintained, since this 
function is well-provided at EU level by the European 
Information system and European database on new drugs 
(EDND). 
The EWS acts as the national (UK) contact for the EMCDDA, 
receiving information from it and disseminating this within the 
UK as appropriate. Its staff maintain an overview of the 
scientific and grey literature, including Internet sources, as 
well as legislative developments in the UK and elsewhere, 
primarily to keep abreast of developments with new 
substances. They also engage in other academic and 
professional activities relevant to these substances. 
Risk assessment at UK level is not the function of the EWS. 
However, the ACMD assess the harms of drugs, as 
appropriate in the context of the Misuse of Drugs Act 1971.
Case study
The main strength of the EWS from a UK perspective has 
been the information-sharing phase. The EU-wide control 
decisions taken before 2008 were of limited value to the UK 
since the various phenethylamines examined by earlier 
risk-assessments (i.e. MBDB, 4-MTA, PMMA, 2C-T-2, 2C-T-7 
and TMA-2) were already controlled in the UK, mostly by 
generic legislation. It was also the case that mephedrone 
(4-methylmethcathinone) had already been brought under 
control in the UK in early 2010 before a risk assessment was 
carried out by the scientific committee of the EMCDDA in 
mid-2010.
In the case of 1-benzylpiperazine (BZP), the EMCDDA risk 
assessment was of special benefit to the UK. Although the 
question of controlling BZP first arose in discussions in 
the ACMD in late 2006, it was clear at that time that the 
substance was being considered by the EMCDDA. It was 
therefore agreed that the ACMD process would wait for a 
decision to be made at EU-level. Following a risk assessment 
carried out in mid-2007, a decision was subsequently made 
to recommend control of BZP in all Member States. Although 
the exact classification of BZP under the Misuse of Drugs 
Act 1971 still had to be determined, the need for a detailed 
domestic assessment of the harms posed by the drug was 
avoided.
Strengths, limitations and way forward
The major strength of the EWS is that forensic drug analysis 
in the UK is well-managed and well-equipped, and staffed by 
individuals with great enthusiasm for reporting new 
substances. In late 2010, the UK Government announced 
that the Forensic Science Service (FSS) would be winding 
down its services. Robust arrangements have been put in 
place to ensure continuity of service once the FSS has ceased 
operational business.
Although the collection of information on new substances for 
the purposes of the 2005 Council Decision is not intended 
to be an exercise in precise epidemiology, a further difficulty 
arises because of the way in which some drug types 
(especially piperazine derivatives such as BZP, CPP, TFMPP 
mCPP and DBZP) are normally found as mixtures with one 
another and with established drugs such as amphetamine, 
cocaine, heroin, ketamine and MDMA. Another limitation 
on information about new substances arises from the fact 
that, at least initially, they are not controlled by drug 
legislation. Since the primary role of forensic science 
laboratories is to provide a service to law enforcement 
and prosecution agencies, the analysis of non-controlled 
substances may be treated as a low priority.
Some information is received from clinical and forensic 
toxicology laboratories, but this is more ad hoc and partly 
reflects the wider variations of such analyses between 
different hospital trusts, as well as the limited chemical 
analysis that is justified in non-fatal cases. Scope exists for 
obtaining far more clinical information from poisoned 
patients that would benefit the EWS. The UK focal point, part 
of which is the EWS, is currently working with a number of 
national stakeholders including the National Poisons 
Information Service, a service commissioned by the Health 
Protection Agency on behalf of the Department of Health 
across the UK to obtain such information directly and on 
regular basis. 
Although the UK is fortunate in that some laboratories have 
access to analytical techniques such as nuclear magnetic 
resonance spectroscopy (NMR), which provides absolute 
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chemical-structural information, the limited availability of pure 
reference materials remains a problem in the identification 
of new substances. In early 2011, the Home Office started 
a project to test-purchase ‘legal highs’ and to commission 
syntheses of selected substances as reference materials. 
This is largely intended to support the TCDOs on certain 
substances, but should be of general assistance to the EWS. 
It should also be mentioned that the rapid proliferation of 
new substances and their chemical complexity in the past 
three years has placed increased demands on all of those 
involved in the EWS. 
Some of the EWS members are part of academic 
establishments, which host a variety of activities dedicated 
to researching new psychoactive substances. The resulting 
output informs a variety of stakeholders operating on both 
national and international levels. For example, the two 
current coordinators maintain an interdisciplinary research 
programme designed to address the issues of psychoactive 
drugs in the context of chemistry, pharmacology and public 
health. Examples included the implementation of test 
purchases, development of improved organic synthesis 
procedures and increasing involvement in the determination 
of pharmacological investigations. 
Apart from laboratory data, currently little useful 
information on new substances is derived from other sources. 
It has remained the case that, in the absence of precise 
laboratory analysis, qualitative data from users or drug 
agencies is of limited value in assessing trends with new 
substances.
Links and references
Links 
Forensic Science Service (FSS) — 
http://www.forensic.gov.uk
Forensic Science Agency of Northern Ireland (FSNI) — 
http://www.fsni.gov.uk
Guy’s and St Thomas’ NHS Foundation Trust — http://www.
guysandstthomas.nhs.uk
Home Office — http://www.homeoffice.gov.uk
International Centre for Drug Policy — 
http://www.sgul.ac.uk/research/projects/icdp
National Programme on Substance Abuse Deaths (np-SAD) 
— http://www.sgul.ac.uk/research/projects/icdp/our-work-
programmes/substance-abuse-deaths%20/?searchterm=np-
sad
Key Forensics — http://www.keyforensic.co.uk
LGC Forensics — http://www.lgc.co.uk/divisions/lgc_foren-
sics.aspx
Medicines and Healthcare products Regulatory Agency 
(MHRA) — http://www.mhra.gov.uk/index.htm
ROAR Forensics — http://www.roarforensics.com
Scottish Crime and Drug Enforcement Agency (SCDEA) — 
http://www.sdea.police.uk/mission.htm
Environmental Scientifics Group — http://www.esg.co.uk/
Serious and Organised Crime Agency (SOCA) — 
http://www.soca.gov.uk
TICTAC — http://www.tictac.org.uk/Introduction
UK Focal Point — http://www.ukfocalpoint.org.uk
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About the EMCDDA
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
is one of the European Union’s decentralised agencies. Established in 1993 
and based in Lisbon, it is the central source of comprehensive information on 
drugs and drug addiction in Europe.
The EMCDDA collects, analyses and disseminates factual, objective, 
reliable and comparable information on drugs and drug addiction. In doing 
so, it provides its audiences with an evidence-based picture of the drug 
phenomenon at European level.
The Centre’s publications are a prime source of information for a wide range 
of audiences including policymakers and their advisers, professionals and 
researchers working in the field of drugs, and, more broadly, the media and 
general public.
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